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CHAPTER 1 
INTRODUCTION AND OUTLINE OF THE THESIS 
THE PATHOGENESIS OF THE HEMOLYTIC UREMIC SYNDROME: 
The role of the granulocyte 
Clinical features 
The hemolytic uremic syndrome (HUS) was for the first time described in 1955 by Gasser et al 
(1) and is defined by a triad of clinical features that include hemolytic anemia, 
thrombocytopenia, and acute renal failure HUS is mostly seen in children, especially below the 
age of five years although the syndrome is increasingly recognized in adults (2-4) Children 
that present with HUS are pale and restless Petechiae and bruises can be found due the 
presence of thrombocytopenia Fragmented erythrocytes or so-called 'Burr cells' can be found 
in the peripheral blood smear of HUS patients Oliguria or even anuria is often present at the 
time of admission to the hospital (5) Hyperglycemia and the development of insulin-dependent 
diabetes mellitus as a consequence of pancreas dysfunction belong to the rare, but severe 
complication of HUS (6-8) HUS is the leading cause of acute renal failure in childhood, at 
least in developing countnes (9) HUS can be broadly divided in two subtypes, the typical or 
epidemical form that in most cases is preceded by a prodromal phase of acute, often bloody 
diarrhea and has therefore been termed D+ HUS It is believed that D+ HUS is caused by an 
infection with a verocytotoxin producing Escherichia coli (10) Seventy of D+ HUS is 
associated with young age, anuna during the prodromal phase and a white blood cell count 
greater than 20x 109 cells/L (11,12) The second form of HUS we know is the atypical or 
sporadic form and resembles in most cases a disease more common in adults namely 
thrombotic thrombocytopenic purpera (TTP) The atypical form of HUS is not preceded by a 
prodromal phase and has been termed D- HUS Several causes for the atypical form of HUS 
have been described like factor H deficiency and recently the involvement of a vWF-cleaving 
protease deficiency in some cases with atypical HUS has been suggested This thesis focuses 
on the typical form of HUS 
Epidemiology 
Several studies in the past had noted that the majonty of HUS cases were preceded by diarrhea 
and an infectious cause was suspected In 1983, Karmah and colleagues demonstrated for the 
first time a linkage between the presence of infection with VTEC serotype 0157 H7 and the 
occurrence of sporadic D+ HUS (10) In the beginning of the same year, a study was published 
describing a relationship between the presence of VTEC 0157 H7 infection and hemorrhagic 
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colitis (13). The designation "O" represents a specific lipopolysaccharide or O-antigen and the 
designation "H" represents a specific flagellar antigen. In the years that followed it became 
clear that in 90% of the cases of D+ HUS evidence of VTEC infection could be found. It has 
been suggested that only 6-8% of the population infected with VTEC will develop HUS (14). 
However, it is difficult to estimate the true incidence of VTEC infection and in this way the 
occurrence of D+ HUS, since many persons with only mild clinical symptoms will not need or 
search medical care. The incidence rate of D+ HUS varies among different countries. For 
example, the incidence in Argentina is about 20 cases per 100 000 children a year whereas in 
the Netherlands 2-3 cases pr 100 000 children below the age of five years are seen (15-17). 
Serotype 0157: H7 can be found in Western Europe in 70% of the cases. In addition, some 
other non-0157 serotypes can also be important in causing disease, in particular serotypes 026, 
O103, and Ol l i (18-21). The majority of outbreaks with VTEC are linked with the 
consumption of improperly cooked contaminated ground beef (22,23) although infections as a 
consequence of contaminated water or other food products, like apple cider, potatoes and 
yogurt have been described (24). Another route of transmission of the infection is from person-
to-person (25,26). Although D+ HUS is mostly seen in early childhood, it can occur in all age 
groups. (27). Outbreaks have occurred in nursing homes and day care centers (28,29). Besides, 
it seems that there is a seasonal variation considering the occurrence of D+ HUS and VTEC 
infection, with most cases seen during the summer and autumn. The cause for this is not clear, 
but it has been suggested that the ecology (relationship with environment and life 
circumstances) of the animals that are a source for VTEC infection might play a role. Another 
explanation might be that during the summer months more products are incompletely cooked. 
In this way the bacteria can survive and be ingested. 
Passage of the intestinal barrier 
As mentioned before, infection with VTEC mostly occurs through consumption of 
contaminated food. After ingestion, the bacteria can survive the acidity of the stomach and can 
colonize in the distal small bowel and the large bowel. The adhesion of VTEC to intestinal 
epithelial cells demonstrates a pattern of attaching and effacing (A/E) lesions that have been 
previously described in enteropathogenic E. coli strains (30-32). For the interaction and 
adhesion to the enterocytes a variety of genes is necessary, some of them encoded on a 
pathogenecity island known as the locus of enterocyte effacement (LEE) region (33,34). One of 
the genes found in this locus is the eae gene, encoding intimin, an outer membrane protein that 
plays an important role in the adherence process (35). Another gene that can be found in the 
LEE region is the tir gene, encoding a receptor for intimin. The exact function of tir is not 
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known but it has been suggested that tir functions as a receptor for intimin on the surface of 
cells (33). The LEE region is not present in normal E. coli flora, but can be found in strains that 
are capable of producing A/E lesions like VTEC. The A/E lesions are characterized by intimate 
adherence between the bacterium and the epithelial cell membrane associated with effacement 
of the epithelial microvilli (34). Cytoskeletal changes are seen just below the adherent 
bacterium, including the accumulation of polymerized actin resulting in the formation of 
adhesion pedestals (Figure 1). It is still not clear, how VT moves across the intestinal mucosa 
after adherence to the intestinal epithelial wall. The fact that VTEC is not invasive and human 
intestinal epithelial cells do not possess the classical receptor for VT, the Gb3, makes it even 
more difficult (36,37). However, several possible routes by which the toxin may gain access to 
the circulation have been suggested (38,39). In vitro studies have shown that SLT-1 is able to 
translocate via an energy requiring process from the apical to the basolateral surface of 
intestinal epithelial cell lines without loss of monolayer integrity. Toxin that moved across the 
barrier retained its biological activity. 
TEC 
Π 
II III 
Figure I : Schematic representation of the adherence of the E. coli bacteria and formation of pedestals. 
The bacteria can connect with the host cell (Ι+Π) and forms attaching and effacing lesions (III). There 
are cytoskeletal changes just below the bacterium resulting in the formation of pedestrals (III). 
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Nomenclature 
In 1977, Konowalchuk and colleagues reported that certain diarrheagemc E coli strains make a 
cytotoxin that was able to kill cultured Vero-cells, a epithelial cell line isolated from African 
green monkey kidneys, hence these cytotoxins were called verocytotoxms (40) The striking 
similarity in structure and biological activity of verocytotoxms (VT) with Shiga toxin, a 
cytotoxin produced by Shigella dysenteria type I and the fact that VT could be neutralized by 
anti-Shiga toxin was the reason that VT have also been called Shiga-hke toxin or Shiga toxin 
(41,42) In this thesis, the original nomenclature, verocytotoxin or VT will be used 
Characteristics of VT 
The structural genes that encode for VT are incorporated in bactenophage DNA of VTEC in 
contrast to Shiga toxin that is encoded by the chromosomes of the Shigella bactena It's 
important to realize that the pathogenic property can be transferred between E coli strains, with 
potentially senous clinical and epidemiological consequences (43,44) Several forms of toxins 
are currently purified and cloned, VT-1, VT-2, VT-2c, VT-2d, VT-2e and the just recently 
discovered VT-2f (45-47) Three of them, VT-1, VT-2, and VT2c, are mostly associated with 
pathogenic diseases in humans although infections with VT2d and VT2e have been described 
(45,48) VT-2e is associated with edema disease in pigs, that is charactenzed by vascular 
necrosis, neurological signs and edema in the central nervous system and gastrointestinal tract 
(49) VT-1 differs only one amino acid at position 45 with Shiga toxin that is produced by 
Shigella Dysenteria type 1 On the contrary, the structural genes of VT-1 and VT-2 share only 
58% overall nucleotide and 56% amino acid sequence homologies Human pathogemc VTEC 
can produce more than one type of toxm Infections with strains that produce VT-2 increase the 
likelihood of developing D+ HUS (50) Although the variants of VT might differ in amino acid 
sequence, they are structurally the same They consist of two parts, one part that is responsible 
for the binding of the toxin (B-subunits) and an enzymatic active part (A-subumt) The bmding 
part of the toxin consists of five small B-subunits (7 kDa) that are noncovalently bound to the 
A-subumt (32 -kDa)(51,52) 
Cellular internalization and cytotoxicity 
In vitro and m vivo studies have shown that VT binds to specific glycosphingohpids in order to 
exert its cytotoxic effect The general structure of glycosphingohpids consists of a polar head 
with one or more sugars and a non-polar ceramide group VT can bind through his B-subumts 
to specific neutral sphmgoglycohpids 
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The classical receptor known for VT, globotnaosylceramide (Gb3), has a terminal Galal-4Gal 
residue, and can be found in human renal tissue, human lymphocytes, human erythrocytes (Pk-
antigen) and human endothelial cells (53-55) In this regard, it is important to realize that 
cultured confluent endothelial cells expose this receptor only in very small amounts on their 
surface Stimulation of these cells with inflammatory cytokines such as tumor necrosis factor 
alpha induces the expression of the VT receptor Gb3 (55,56) Not only the sugar residues 
determine the binding affinity of VT but also the ceramide part plays an important role. Fatty 
acid chain length and degree of saturation have been shown to markedly affect the ability of the 
toxin to bind to glycosphingohpids (57,58) After binding of the holotoxin to the classical 
receptor Gb3, the toxin can be internalized by clatnn-endocytotic mechanism (59) 
Endosomes 
O 
DSOÌ 
1 
Lysosomes 
VT 
i. ~<^ 
jRecyclmg I Clatnn-dependent 
endocytosis 
Furiti 
Golgi 
Cttlpam <h^ 
η 
Figure 2 Schematic representation of the internalization ofverocytotoxin Somewhere 
during the routing of the toxin, the A-subumt of the toxin is cleaved into two fragments 
(A1+A2) by either funn or calpain leading to activation 
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The toxin, once endocytosed is either delivered to the endosomal compartment and from there 
transported to the trans-Golgi network or recycled back to the cell surface, and delivered to the 
lysosomes for degradation or transcytosed to the opposite surface (Figure 2). 
Retrograde transport of the toxin via the Golgi apparatus to the rough endoplasmic reticulum 
occurs and even proceeds to the nuclear envelopes (60,61). It is interesting to notice that the B-
subunits of the toxin alone also can be transported retrogradely indicating that the A-subunit is 
not required for this process. The retrograde transport through the endoplasmic reticulum seems 
to be very important for the cytotoxic effect of the toxin because when the toxin is inhibited 
from entry of the Golgi apparatus, cells are protected against the toxin actions (59,62). Sandvig 
and colleagues were able to demonstrate that this transport was calcium, temperature and pH 
dependent (63-65). Somewhere during the routing of the toxin, the A-subunit of the toxin is 
cleaved into two fragments, one of 27- kDa (Al) and one of 4-kDa (A2). The B-subunits of the 
toxin remains associated with the smaller fragment. The Al subunit forms an active 
intracellular enzyme N-glycosidase and can cleave the N-glycoside bound of adenine at 
position 4324 from the 5' end of 28S ribosomal RNA. This prevents ribosomal elongation 
factor dependent binding of aminoacyl-transfer RNA molecules to the 60 S ribosomal unit 
(59,62,66). If protein synthesis is completely inhibited, cell death occurs. Recent observations 
have shown that besides inhibition of protein synthesis, programmed cell death or apoptosis 
may play a role in the VT mediated cell cytotoxity (67-69). 
It is believed that the presence of Gb3 is necessary to mediate cytotoxicity. In concert with this 
theory is a study performed with rabbits. These animals were challenged with 125I- VT-1. 
Highest uptake of I- VT-1 was correlated with those areas (spinal cord, brain, cecum, colon 
and small bowel) that had the highest amount of the classical Gb3 receptor and corresponded 
with the thrombotic microangiopathy observed (70). Interestingly, the rabbit lacks VT receptors 
in the kidney and can therefore not be used as an animal model for the renal failure as seen in 
HUS. Interesting in regard to this receptor related cytotoxicity, is the observation of Lingwood 
that Gb3 is more pronouncedly present in the glomeruli of the kidney of children under 2 years 
old but not in adults (53). However, van Selten et al. was not able to confirm these results and 
suggested that inflammatory mediators are necessary for the induction of VT susceptibility in 
glomerular endothelial cells. The finding of strong VT binding in renal tissue of an adult patient 
with sepsis in her study strengthens this hypothesis (71). 
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Target cells 
The systemic circulation 
After passage of the intestine VT is transported through the systemic circulation to the target 
organs It is thought, that once VT has entered the circulation, it rapidly binds to Gb3 receptors 
on endothelial cells in the target organs The way of transport of the toxin through the 
circulation was not known at the start of our studies Three candidates for binding VT in the 
blood had been suggested Ρ blood group antigens on erythrocytes, platelets and lipoproteins 
On the basis of in vitro studies, binding of VT to erythrocytes as function of their Ρ blood 
group has been suggested (54) The antigens of the Ρ blood group system include the Pk-, P-
and Pi -antigen, representing Gb3, Gb4 and pentaosylceramide, respectively Binding of VT to 
Pk- and Pi -antigen, both having a terminal gal l-4gal residue, have been found. Having the Pk-
and Pi antigen might protect target organs for the effects of the toxin by catching the toxin out 
of the circulation (72,73) Erythrocytes have no nucleus and are therefore not susceptible for 
the protein synthesis inhibitory effect of VT It cannot be excluded that VT affect membrane 
stability of the erythrocyte or maybe sensitize them to mechanical or oxidative stress In theory, 
VT might bind to erythrocytes in the circulation and once bound, is transported through the 
systemic circulation However, VT bound to erythrocytes has never been detected in patients 
with HUS 
Besides the binding of VT to erythrocytes, interaction of VT with platelets has been reported 
Cooling et al (74) showed that human platelets express two different glycohpids that can bind 
VT (= SLT), the first one is Gb3, and the second one galabiosylceramide or PI, a novel 
glycosphingohpid that immunological is different from the Gb3 However, Yagi et al showed 
that leukocyte-depleted normal platelets lack the Gb3 receptor and VT not directly induced 
platelet aggregation Furthermore, he demonstrated that under low shear stress VT was capable 
of inducing platelet aggregation presumable by the release of cytokines or chemical compounds 
from target cells (75) Plasma from six out of seven HUS patients had activity similar to Stx-1 
(75) Further investigation is needed to determine which source produces the cytokines or other 
chemical compounds that might play a role in this One of the sources of these cytokines might 
be monocytes In vitro studies have shown that LPS-stimulated monocytes are capable of 
binding VT-1 to a receptor that is different from that found on endothelial cells After binding, 
VT-1 can induce the synthesis of cytokines like TNFa, IL-6 and IL-8 (76,77) The induction of 
cytokine release is accompanied by an increase in cellular mRNA concentrations Elevated 
levels of IL-8, IL-6 and TNFa in plasma and serum of HUS patients and elevated 
concentrations of TNFa, IL-6 and IL-8 in unne of HUS patients have been found suggesting 
that the release of inflammatory mediators indeed play a pivotal role in the pathogenesis of 
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HUS. Activation of neutrophils and neutrophil mediated endothelial cell injury plays probably 
an important function in the pathogenesis of HUS. A significant correlation has been found 
between neutrophil count and outcome of the disease. Furthermore, polymorphonuclear 
leukocytes, isolated from patients with HUS adhere more avidly to the endothelium than 
controls and are capable to damage the endothelium (78-81). That neutrophils have an 
important role in the pathogeneses in HUS is supported by the presence of increased numbers 
of neutrophils in the kidney of HUS patients (82). However, it has to be considered that the 
elevated levels of IL-8 found in HUS patients also may just reflect inflammatory response in 
the intestine. Elevated levels of IL-8 have also been reported in patients with Crohn's disease 
and colitis ulcerosa (83). Therefore, a critical evaluation of the role of PMN in HUS is required. 
The Kidney 
The main organ involved in HUS is the kidney, but in severe cases other organs like brain and 
pancreas can become involved (4). The pathogenesis of HUS is characterized by endothelial 
damage of glomeruli and kidney arterioles (2). Histopathological studies of kidney material of 
D+ HUS patients showed swollen and detached endothelial cells and deposits of fibrin all in the 
glomerulus. It is generally believed that VT, after entering the systemic circulation, is 
transported through the systemic circulation until VT attaches to endothelial cells that express 
VT binding receptors. After binding, VT can cause inhibition of protein synthesis finally 
leading to cell death. In vitro studies have shown that VT is only cytotoxic for endothelial cells 
when they have been previously stimulated with inflammatory mediators, such as tumor 
necrosis factor alpha (TNFoc) and interleukin-1. It is thought that the increase of galactosyl 
transferase activity by TNFa in these cells leads to the induction of the Gb3-receptor (55). 
Although it is believed that endothelial damage is one of the primary events in the pathogenesis 
of HUS, damage to other cell types, like tubular epithelial cells and mesangial cells have been 
suggested (84-87). Several in vitro studies performed with tubular epithelial cells have shown 
that VT is cytotoxic for these cells and can induce apoptosis (88,89). The finding of apoptosis 
in the renal epithelium of a HUS patient and the results found in vitro are suggestive for a 
contribution of renal epithelium in the pathogenesis of HUS (89). Another cell type that might 
play an important role in the pathogenesis of HUS is the mesangium. Mesangial cells, under 
normal conditions, regulate glomerular hemodynamics (90). The mesangium has a central 
anatomical position within the glomerulus and only a single layer of fenestrated endothelium is 
separating the circulation from these mesangial cells. If this single layer is damaged as in HUS, 
substances like VT can easily reach the mesangium. In vitro studies have shown that mesangial 
cells possess the classical receptor for VT, the neutral glycolipid Gb3. After binding VT was 
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able to inhibit protein synthesis by 75% but did not cause cell death Furthermore, it was shown 
that proliferation of human mesangial cells was inhibited even more than protein synthesis was 
inhibited (86,87,91) The B-subumt of VT, which did not inhibit protein synthesis, was able to 
inhibit cell proliferation indicating that two different pathways are involved (87) The 
interaction of VT with the mesangium may interfere with normal mesangial function and m this 
way with renal function For this reason, it might be necessary to study the effects of VT on 
mesangial cells further 
Outline of the thesis 
In the last decade, a lot of progress in understanding the pathogenesis of D+ HUS has been 
made The pathogenesis of the syndrome is hallmarked by endothelial damage of 
predominantly glomeruli and kidney arterioles Several in vitro studies have shown that 
verocytotoxin (VT) is able to inhibit protein synthesis leading to cell death in several cell types 
that express the classical receptor for VT, globotnaosylceramide Furthermore, it was 
demonstrated that in vitro stimulation of endothelial cells with inflammatory mediators appears 
to be required for VT cytotoxicity It has been suggested that monocytes might be the source of 
these inflammatory mediators Although all these data give more insight in the pathogenesis of 
HUS, we still do not know exactly how the infection with VTEC leads to D+ HUS in especially 
children Important questions considering the pathogenesis of D+ HUS can be asked For 
example, how is VT passing the intestine wall and gains access to the systemic circulation9 
How is the VT transported through the systemic circulation9 How develop patients renal failure 
and why is the kidney the mam organ involved in this syndrome9 And finally, why are mainly 
children affected and not adults9 
The aim of this thesis was to provide some of the lacking knowledge about the 
pathogenesis of the hemolytic uremic syndrome First of all, the possible route of transport of 
VT through the systemic circulation of D+ HUS patients was evaluated in this study (Chapter 
2, 3,4 and 5) In addition, the role of nitnc oxide and endothehn-l were studied (Chapter 6) 
Nitnc oxide may play a role in the localization of the damaging effects that are mainly seen in 
the kidney These damaging effects could lead to disturbances in the production of endothehn-l 
or may induce apoptosis in the kidney For this reason, the presence of apoptosis in renal 
biopsy material of HUS patients was evaluated (Chapter 8) As mentioned before, not every 
infected child will develop HUS and differences in seventy of the disease are observed It 
might be that genetic variability plays a role in this Therefore, polymorphisms of the TNFct 
and plasminogen activator inhibitor-I (PAI-I) gene were investigated Both play a role in the 
pathogenesis of HUS High levels of TNFa and PAI-I are associated with a more severe form 
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of HUS (Chapter 7). Finally, the role of vascular endothelial growth factor as possible 
regulator of the restoration of damaged glomerular capillaries has been studied (Chapter 9). In 
the last chapter, Chapter 10, the results found in this study are being discussed, summarized 
and put into perspective. 
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CHAPTER 2 
BINDING AND TRANSFER OF VEROCYTOTOXIN BY POLYMORPHONUCLEAR 
LEUKOCYTES IN HEMOLYTIC UREMIC SYNDROME 
D. Maroeska W.M. te Loo, Leo A.H. Monnens, Thea J.A.M. van der Velden, Mario A. 
Vermeer, Frank Preyers, Pierre N.M. Demacker, Lambertus P.W.J, van den Heuvel, Victor 
W.M. van Hinsbergh 
Blood 2000; 95: 3396-3402 
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ABSTRACT 
The hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in 
children The role of a verocytotoxin- (VT-) producing E coli has been strongly implicated in 
the epidemic form of HUS Although direct toxicity of VT on glomerular endothelial cells has 
been demonstrated, it remained still unclear how the VT is transported from the intestine to the 
target organs 
In this study we demonstrate that VT, when incubated in whole blood, binds rapidly 
and completely to human polymorphonuclear leukocytes (PMN) and not to other components 
of blood Binding studies with 125I-VT-1 showed a single class of binding sites on freshly 
isolated, non-stimulated human PMN The Kd of VT-binding to PMN was 108 mol/L, a 100-
fold less than that of the VT-receptor globotnaosylceramide On incubation of VT-preloaded 
PMN with human glomerular microvascular endothelial cells (GMVEC), transfer of VT-1 to 
the endothelial cells occurred Incubation of non-stimulated GMVEC with VT-preloaded PMN, 
but not with PMN or VT-1 alone, caused inhibition of protein synthesis and cell death Our data 
are in concert with a role of PMN in the transfer of VT from the intestine to the kidney 
endothelium This occurs by selective binding to a specific receptor on PMN and subsequent 
passing of the ligand VT to the VT-receptor on GMVEC, which causes cell damage This new 
mechanism further underpins the important role of PMN in HUS 
INTRODUCTION 
The hemolytic uremic syndrome (HUS) is the most frequent cause of acute renal failure in 
children The traditional diagnostic criteria for this syndrome include hemolytic anemia with 
fragmented erythrocytes, thrombocytopenia and renal failure (2) The endothelium of kidney 
arterioles and glomeruli plays a central role in the pathogenesis of HUS Histopathological 
studies of the kidney of HUS patients show characteristic lesions consisting of swelling and 
detachment of the endothelial cells of glomeruli and deposits of fibnn in glomeruli and 
arterioles (3, 92) In severe cases, the cell damage is not limited to the kidney, but other organs 
such as brain and pancreas, are also involved 
The epidemic form of HUS, or (D +) HUS, occurs mostly following a prodromal phase 
of bloody diarrhea In 90% of the cases with (D+) HUS, an infection with a verocytotoxin (VT) 
producing Escherichia coli is strongly implicated (3,4,5,43,92) Strains of the VT producing E 
coli associated with HUS can produce VT-1 or VT-2, or both The structure of the VT is 
formed by a biologically active A subumt and five Β subumts, by which the toxin binds to 
22 
specific glycolipid receptors. The VT producing E. coli is transmitted by contaminated food or 
water or from person-to-person. After ingestion, the E. coli binds to specific receptors to the 
intestinal wall and VT enters the circulation via a still unknown mechanism (3,94,95). VT is 
transported to the target-organs and can bind specifically to its receptor globotriaosylceramide, 
also called Gb3. This receptor has been demonstrated in human renal tissue and in human 
endothelial cells (53,102). After binding to Gb3, the active subunit of the VT enters the cell and 
causes inhibition of protein synthesis (60,61,85,88,89, 96). The route of transport of the VT 
from intestine to the kidney or other target organs is not solved yet. Although epidemiological 
studies have pointed to a role of VT in (D+) HUS, no VT has been encountered thus far in the 
plasma of HUS-patients. In vitro experiments showed that VT can bind to erythrocytes, 
depending on the P-blood group glycolipids, that are structurally related to the known VT 
receptor Gb3. It has been reported that VT can bind to the Pl-phenotype (Pk, PI, P2 antigens) 
and, to a less extent also to the P2 phenotype (Pk and Ρ antigens) but not to the P-phenotype 
(lacking antigens)(93,54,97,98). In vitro experiments also showed binding to activated human 
monocytes (76). Other possible candidates for transporting the VT are platelets and lipoproteins 
(57,74,58). In this study we evaluate which fractions of the blood contribute to VT binding and 
transfer. Our data suggest that polymorphonuclear leukocytes (PMN) are responsible for 
transporting the VT in blood and that the receptor responsible for binding VT to PMN is 
different from that found on endothelial cells. Furthermore, we demonstrate that VT is 
transferred from PMN to human glomerular endothelial cells. 
MATERIALS & METHODS 
Materials. 
Purified VT-1 was kindly provided by Dr. M.A. Karmali (Toronto, ON, Canada). Ficoll was 
purchased from Pharmacia (Uppsula, Sweden). Plastic coated silica gel Fl 500 Thin layer 
chromatography (TLC) plates were obtained from Schleicher and Schuell (Dassel, Germany). 
A standard mixture of pure neutral glycolipids was obtained from Biocarb AB (Lund, Sweden). 
VT-1 labeled with FITC (VT-FITC) was kindly donated by Dr. Lingwood (Hospital for Sick 
Children, Toronto, Ontario, Canada). FACS ™ lysing solution was purchased from Becton 
Dickinson Immunocytometry Systems (San Jose, USA). CD13-PE, CD14-PE and CD45-
TRJTC were purchased from DAKO (Glostrup, Denmark). All other reagents were of 
analytical grade or as described previously (18,56,76). 
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Flow activated cell sorter (FACS) analysis and immunohistological study of whole blood 
VT-FITC was used to determine binding of VT in whole blood. Blood was obtained from 10 
different healthy donors, 8 adults and 2 children (age ten and six) and blood group of the adults 
was determined according to established procedures. Two donors had bloodgroup O, four 
bloodgroup A and two had bloodgroup B. There were two donors with the PI-bloodgroup. 
Blood was immediately put on ice. 100 μΐ of blood was incubated for 20 minutes on ice with 
VT-FITC, followed by addition of FACS™ lysing solution to remove erythrocytes. The 
solution was centrifiiged 200x g for 5 minutes at 40C. The cells were washed twice with 
phosphate buffered saline (PBS) containing 1 % albumin. Cells were resuspended in 500 μΐ of 
a 0.5% paraformaldehyde solution for fixation. Flow cytometry was used to determine binding 
of VT-FITC. Fluorescence was measured in a histogram using a log scale. The different cell 
types were characterized using monoclonal antibodies; CD13-PE and CD16-PE for PMN, 
CD14-PE for monocytes and CD45-TRITC for lymphocytes. To exclude non-specific binding 
whole blood was previously incubated with unlabeled VT for 20 minutes followed by 
incubation with VT-FITC. The same procedure as above was used for direct 
immunofluorescence studies. Briefly, cells were incubated for 20 minutes with VT-FITC and a 
monoclonal antibody to indicate the cell type. Cells were washed twice with PBS and were then 
resuspended in 500 μΐ of 0.5% paraformaldehyde. Cells were centrifiiged by 200x g. 
Subsequently, cells were analyzed by a Zeiss fluorescence microscope (Aksioscope) with 
standard FITC filter (09) and PE-filter (014) (excluding the possibility of interference of FITC 
and PE-staining), for VT-FITC, CD13-PE, CD14-PE and CD45-TRITC staining, respectively. 
Isolation of PMN 
Twenty milliliters of EDTA or heparin blood of eight healthy adult donors and of two children 
was obtained for the isolation of PMN. Blood was directly put on ice. Blood was mixed with 15 
mL of PBS and put into a 50-mL tube. The blood was underlayed using Ficoll 1.077 g/mL. The 
cells were centrifiiged 20 minutes 200x g at 4 "C in a Sorvall centrifuge. The pellet contained 
PMN and erythrocytes. Erythrocytes were lysed using ammoniumchloride or FACS lysing 
solution and PMN were washed twice with PBS containing 1% bovine serum albumin (BSA). 
PMN were resuspended in PBS or RPMI-medium containing 1% of human serum and stored at 
40C till use for < 1 hour until use. The population PMN was over 95% pure as measured by an 
Hs-analyser (Technicon, Bayer). 
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Flow-cytometric analysis after isolation of different cell types 
Pooled PMN as described above were used. Blood was mixed with PBS and cells were 
separated using Ficoll. The interphase was collected for studying binding to lymphocytes and 
monocytes separately. The pellet contained PMN and erythrocytes. The pellet was resuspended 
in 20 ml PBS. Subsequently, Ficoll 1.077 g/mL was used to separate PMN from erythrocytes. 
To make sure that the different cell populations were more than 95% pure, cell populations 
were analyzed by a H3 -analyzer. Different cell types were incubated with 0,5 μΐ, VT-FITC ( 
Img/mL) on ice for twenty minutes. Cells were then washed twice with PBS/1%BSA and 
centrifuged at 200g for 5 minutes. Cells were resuspended in 500 yiL of 0.5% 
paraformaldehyde. Binding of VT-FITC was measured using flow cytometry. Experiments 
were repeated for the different cell types using an incubation time of three hours. 
Results were confirmed by using direct immunofluorescence and incubation of the different 
cell populations separately with 125I-VT-1 (see below). 
Binding of VT-FITC to lipoproteins 
To examine the binding between VT and lipoproteins, lipoproteins were isolated by 
ultracentrifiigation and a precipitation method (99). Very low-density lipoproteins (VLDL), 
high-density lipoproteins (HDL), or low-density lipoproteins (LDL) were incubated with VT-
FITC during three hours on ice. After the incubation lipoprotein-depleted serum was added. 
The solution was mixed thoroughly, and incubated for ten minutes. Subsequently, a 
precipitation solution was added followed by centrifligation. After centrifligation binding of 
VT-FITC was determined by fluorescence spectrometry. Experiments were repeated using an 
incubation time of one hour or twenty minutes to determine whether binding of VT to 
lipoproteins occurred after a similar incubation period as needed for PMN. 
Binding ofl25I-VT-l to human PMN 
VT-1 was labeled with Na- l25I according to the lodogen procedure (53). After isolation of 
PMN from EDTA blood, PMN were washed twice with PBS and were then resuspended in 
Hanks Balanced Salt Solution (HBSS) containing 1% Human Serum Albumin (HSA; Central 
Laboratory of the Red Cross, Amsterdam) at 0 0C. Subsequently, 0.5 χ ΙΟ6 PMN/250 μ ι were 
incubated for three hours with 125I-VT-1 in different concentrations ranging from 0.3 up to 70 
nmol/L. To determine non-specific binding unlabeled VT-1 in 25-fold excess was added 
parallel with 1251-VT-1. After incubation the free fraction of 125I-VT-1 was separated from the 
fraction of 125I-VT-1 bound to the PMN using Ficoll 1.077 g/mL. PMN were then washed with 
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HBSS/1% HSA and centriftiged at 200 χ g for 10 minutes. Cell-associated 1251-VT-1 was 
determined in a gamma-counter. All determinations were done in duplicate. Binding data were 
analyzed, using the method of Scatchard (100). 
Thin layer chromatography of neutral glycolipids extracted from PMN. 
PMN were isolated as described before. They were washed twice with PBS and subsequently 
resuspended in 0.5 ml of PBS. Next, glycolipids of the cells were extracted and separated as 
described by Lingwood et al. (101). For the extraction of neutral glycolipids 1 mol/L NaCl was 
used instead of water to receive maximal yield. After separation of the neutral glycolipids, the 
TLC-plate was coated with polyisobutylmetacrylate, blocked overnight with 1% PBS/Tween 
and incubated with 125I-VT-1 in 1% albumin and 0.05% Tween-20 in PBS (102). After 
washing, the binding of 125I-VT-1 was analyzed using a Fuji BAS 1000 phosphor-imager. 
Human glomerular microvascular endothelial cells 
Human glomerular microvascular endothelial cells (GMVEC) were isolated and cultured on 
gelatin-coated dishes as described by van Seiten et al (56). Cells were characterized by indirect 
immunofluorescence microscopy using antibodies against von Willebrand factor, PEC AM-1 
and VE-cadherin. No immunoreactivity was observed with antigens against α-smooth muscle 
actin or cytokeratin 20, indicating that there was no contamination with mesangial or epithelial 
cells. GMVEC were cultured in 24-well plates to perform experiments and used between 
passages six and ten. They were used five days after reaching confluence and stimulated for 24 
h with 10 ng/mL tumor necrosis factor alpha (TNF-a), if indicated. 
Transfer of VTfrom PMN to endothelium in vitro 
After isolation, PMN were washed twice with PBS and were then resuspended in medium 
M199 containing 20% fetal calf serum. PMN were incubated with a monoclonal antibody, 
CD16-PE, to exclude the possibility that PMN interfere with FACS analysis. Subsequently, 
different amounts of PMN, varying between 0.5 and 2.0 χ IO6 PMN were incubated with 0.5 μΐ 
VT-FITC on ice during 30 minutes. After that, PMN were washed twice with medium Ml99. 
Non-stimulated GMVEC and TNF-a-stimulated GMVEC were incubated on ice, for four 
hours, with 0.5 - 2.0 χ IO6 PMN loaded with VT-FITC. As control, GMVEC were also 
incubated alone with VT-FITC, PMN or with medium containing 10% fetal calf serum. After 
the incubation period, GMVEC were washed three times with M199. GMVEC were detached 
with trypsin treatment and centriftiged for 5 minutes 200g at 40C. Cells were washed with PBS 
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and then resuspended in 500 μΐ 0 5% paraformaldehyde, and transferred into a tube suitable for 
FACS-analysis 
Measurement of protein synthesis 
GMVEC were cultured in 24-wells plates, and were used five days after reaching confluence 
GMVEC stimulated by TNF-ct (10 ng/ml) and non-stimulated GMVEC were incubated with 
106 PMN at 370C for 24 hours PMN were preloaded with VT m different concentrations, 
ranging from 0 1 nmol/L to 10 nmol/L VT and washed two times before adding to the 
GMVEC PMN not preincubated with VT were used as control Protein synthesis was 
determined by assaying the incorporation of 3H-leucine in newly synthesized protems as 
described previously (18,56,76) 
Statistics 
All results of measuring protein synthesis are expressed as mean ± S Ε M Changes with 
respect to control values were analyzed by using an unpaired Student's t-test Values where Ρ 
was equal or less than 0 05 were regarded as significant 
RESULTS 
Binding of VT in blood 
Incubation of whole blood with VT-FITC showed after 20 minutes almost complete binding of 
VT to PMN (Figure 1C and ID), independent of blood group or age of the donor Binding was 
completely blocked by pre-incubation of blood with unlabeled VT-1 for 20 minutes (data not 
shown) More than 90% of PMN were positive and all other cell types were negative Control 
blood, incubated with an IgG antibody conjugated with FITC, showed no staining (Figure 1A 
and IB) Selective binding of VT-FITC was also demonstrated by direct immunofluorescence 
studies (Figure 2) Only PMN bound VT-FITC 
To substantiate that PMN were the only cells binding VT in blood, VT-FITC binding to 
purified erythrocytes, monocytes and platelets was also studied Erythrocytes were incubated 
and binding was analyzed using FACS-analysis and direct immunofluorescence No binding of 
VT-FITC to erythrocytes was observed independent of the P-bloodgroup (8 donors) No 
significant binding of VT-FITC to non-stimulated monocytes was observed (6 donors) 
Lymphocytes and thrombocytes (3 different donors) also did not bind VT-FITC in our 
conditions Lingwood (57,58) suggested that lipoproteins may bind glycohpids such as Gb3, 
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and that VT may be cotransported by lipoproteins in a piggyback way. LDL and HDL 
preparations were incubated separately with VT-FITC on ice for three hours. No significant 
binding was observed. 
Figure 1. Binding of VT-FITC to PMN in whole blood was demonstrated by flow cytometric 
analysis. A,B: Flow cytometric analysis of control blood (incubated with IgG-FITC alone) 
before addition of VT-FITC. C,D Analysis after 20 minutes incubation with 0,5 μΐ VT-FITC 
(lmg/ml) exclusive binding to PMN was found. L: lymphocytes; M; monocytes; P: PMN. The 
experiment is representative for duplicate determinations in 10 experiments with blood of 
different donors. 
This experiment was repeated with incubation times of 20 minutes and 1 hour. Again no 
binding was found (data not shown). Similarly, no binding of12SI-VT to these preparations was 
found. From these data we conclude that VT only significantly binds to PMN in whole blood 
and not to other components such as erythrocytes, lymphocytes, monocytes and lipoproteins. 
Analysis VT-binding to PMN 
To evaluate whether high-affinity binding sites were involved in the binding of VT to PMN, the 
binding of ,25I-VT-1 to PMN was determined. Figure 3A shows that the binding of 125I-VT-I 
is saturable and specific. After incubation with a 25-fold excess of unlabeled VT-1, binding 
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with I-VT-1 decreased more than 95%. Scatchard plot analysis (Figure 3B) showed that 
non-stimulated PMN have 2.1 χ 105 binding sites with a high affinity for VT (Kd = 10'8 mol/L). 
This affinity is 100-fold less than those others and we consistently found for VT-1 binding to 
Gb3 in human vein and GMVEC (56,102). To confirm that VT remained exposed on the 
surface, 125I-VT-1 was bound to PMN (30 minutes, 370C), and after 3 washings, the VT-loaded 
PMN were incubated for 2.5 h at 37 0C in medium supplemented with 10% fetal calf serum and 
100 U/mL aprotinin. After removal of the serum-containing medium, treatment of these PMN 
for 10 min by trypsin/EDTA released 95% of the 125I-VT-1 associated with the cells. This 
indicates that the VT-1 remained available at the cell surface. 
Figure 2: Direct immunofluorescence of binding of VT-FITC to PMN. Whole blood was incubated 
with CD13-PE (A), a specific marker for PMN, and with VT-FITC (B) on ice for twenty minutes. PMN 
were the cells that had bound VT-FITC. No other components of blood were positive for binding VT-
FITC. 
To investigate whether Gb3 or a different neutral glycolipid was responsible for binding of VT, 
thin layer chromatography (TLC) of neutral glycolipids extracted from non-stimulated PMN 
was performed and compared with those of TNF-a-stimulated GMVEC and LPS-stimulated 
monocytes. 
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Figure 3: PMN of two different donors were used to determine binding of I-VT-1 to PMN. Figure A: 
PMN were incubated with increasing concentrations of 125I-VT-1 (0.3 to 70 nmol/1) at 4° C for three 
hours ( ). Non-specific binding ( ) was determined in the presence of 25-fold excess of unlabeled VT-
1. Figure Β shows the result of Scatchard plot analysis. 
Thin layer chromatograms were incubated with radiolabeled VT-1 and washed thoroughly. The 
bound '25I-VT-1 was detected with the use of a phosphor imager (Figure 4). 1 2 5 I-VT-1 strongly 
bound to the Gb3 in the standard neutral glycolipid preparation (lane D) and the TNF-a-treated 
neutral glycolipid extract of GMVEC (lane B). Two other bands binding 125I-VT-1 just below 
the globotetraosylceramide (Gb4) were found in glycolipid extractions of monocytes (lane C) 
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and in smaller amounts in those of GMVEC. Non-stimulated PMN showed two small bands 
with an Rf value just below the Gb4 but distinct from that observed for monocytes. This pattern 
was consistently found with 4 different neutral glycolipid extracts of PMN obtained from four 
different donors. 
Figure 4: n!I-VT-l binding to neutral glycolipid extracts from human PMN, GMVEC and monocytes. 
Glycolipids were extracted and separated as described in Materials and Methods. Binding of 125I-VT-1 
was visualized using a phosphor imager. Lane A: Glycolipid extract of 30 million PMN of one 
representative donor. Lane B: Neutral glycolipid extraction of TNFa-treated GMVEC. Lane C: 
glycolipid extract of monocytes stimulated with LPS (1 ng/ml). Lane D: Standard mixture of neutral 
glycolipids, 2 μg of each glycolipid. Standard of neutral glycolipids was stained with orcinol. (Gb3, 
globotriaosylceramide: Gb4, globotetraosylceramide and Gb5, Forssman pentasaccharide). 
Transfer of VTfrom PMN to GMVEC 
In order to investigate if VT-1 could be transferred from PMN to GMVEC, we incubated non-
stimulated and TNEct-stimulated GMVEC with PMN that had bound VT-FITC at 0oC. 
PMN were previously incubated on ice with CD16-PE, a specific monoclonal antibody for 
PMN, to prevent interference of PMN by FACS-analysis. After an incubation time of three 
hours on ice, GMVEC were washed carefully three times with PBS. Subsequently, GMVEC 
were detached and analyzed by flow cytometry. No PMN were retained by non-stimulated 
GMVEC (as revealed, by FACS-analysis after staining with CD16-PE) (Figure 5A and C). 
GMVEC were negative for CD16-PE staining (Figure 5C). However, TNF-cc stimulated 
GMVEC retained a small percentage of the PMN added (ranging between 2.8% and 3.6%) 
(Figure 5B). 
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Figure 5: The transfer of VT-1-FITC bound to PMN to human GMVEC was studied by flow 
cytometry. Panels A ,C and F: FACS analysis of non-stimulated GMVEC incubated for 4 h with PMN 
loaded with VT-FITC on ice. (A) Forward scatter and side scatter of non-stimulated GMVEC are 
shown. (C) No positive staining for CD16-PE was observed, indicating that all PMN were removed by 
washing the monolayers. (F) Non-stimulated GMVEC did not bind any VT-FITC after incubation with 
VT-FITC-loaded PMN. Panels B, D, E, G, H: TNFa-stimulated GMVEC retained 2.8-3.6% of PMN 
(present in the gated area Ρ in panel B) after 4 h incubation and washing of the monolayers. (D, E) PMN 
were distinguished from GMVEC using CD16-PE; panel D represents all cells, while panel E reflects 
the gated area. (G) TNFa-treated GMVEC incubated with VT-FITC-loaded PMN were able to bind 30-
50% of VT-FITC after the incubation period of 4 hours (all cells minus the gated area Ρ). (H) PMN 
showed no positive staining for VT-FITC indicating that ligand passing of VT-FITC from PMN to 
GMVEC had occurred. 
The population of PMN was gated (indicated by the area Ρ in Figure 5B), which_allowed 
simultaneous analysis of PMN and GMVEC. The population of gated PMN was positive for 
CD-16-PE (Figure 5E) and distinct from the CD-16-PE-negative GMVEC (Figure 5D). The 
differentiation between PMN and GMVEC by gating permitted us to investigate if a transfer of 
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VT-FITC from PMN to GMVEC had occurred. After the 3 hours incubation period 30% of the 
stimulated GMVEC had bound VT-FITC (figure 5G). Non-stimulated GMVEC did not bind 
any VT-FITC (Figure 5F). When IgG-FITC was incubated with GMVEC, no binding occurred. 
This excludes nonspecific binding of FITC to these cells. Ligand passing of VT-FITC from 
PMN to GMVEC was further confirmed by the fact that no VT-FITC could be demonstrated on 
PMN that were removed after the 3h incubation period on GMVEC on ice. Furthermore, PMN 
that were CD16-PE positive and still adhering to endothelial cells (2.8-3.6% of total PMN 
added) were negative for VT-FITC binding (Figure 5H). No uptake of VT-FITC by PMN 
occurred during the incubation period. 
GMVEC damage by ligand passing of VTfrom PMN 
Similar experiments were performed at 37 0C. Unlabeled VT-1 bound to PMN was used to 
study whether the transfer of VT-1 from PMN to GMVEC caused a biological effect. In TNF-
α-stimulated GMVEC both VT-binding PMN and VT alone caused severe cytotoxity during a 
24h period, while PMN alone had no effect (Figure 6). The exposure of non-stimulated 
GMVEC to VT-binding PMN also caused considerable cell death (30-40%), while exposure of 
VT-1 or PMN alone had no effect. Comparable toxicities were observed when the VT-binding 
PMN were washed 3 times and first incubated for 2.5 h at 37 0C (to mimic a circulation time 
before reaching the target tissue), before they were washed again and transferred to the 
endothelial cells (data not shown). 
Because VT exerts its cytotoxic effects by inhibiting protein synthesis, we quantified 
the effect of VT-preloaded PMN on the viability of GMVEC by determining the overall protein 
synthesis (from the incorporation of 3H-leucine in newly synthesized proteins). 
No effect on protein synthesis was observed when stimulated or non-stimulated GMVEC were 
incubated with PMN. However, when non-stimulated and TNFa-stimulated GMVEC were 
incubated with VT-preloaded PMN inhibition of protein synthesis (30 ±15 % and 60 ± 25 %, 
respectively) was observed (Figure 7). 
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Figure 6: Phase-contrast microscopy of human GMVEC. Magnification used χ 50, except for figure Β 
(Magnification χ 100). (A) Represents control GMVEC. (B) Shows the result of GMVEC incubated 
with PMN for 24h. No change of morphology was observed. When cells were incubated with PMN 
loaded with VT-1 cell death was observed after 24h incubation (C). (D) Represents control TNF-a-
treated GMVEC. The effect of PMN loaded with VT-1 was also studied on TNF-a-treated GMVEC (E) 
and compared to the effect of VT-1 on TNF-a-treated GMVEC (F). In both conditions equal amounts of 
cell death were observed. 
DISCUSSION 
In this study, we demonstrate that VT-I binds almost exclusively to non-stimulated PMN in 
whole blood. Only 20 minutes of incubation was sufficient to bind VT-1 to PMN for more than 
90%. No binding to other components of blood was observed, not even when incubation time 
was prolonged to 3 hours. The K^  of the high affinity receptor for VT on PMN is a 100-fold 
less than that found for the functional receptor for VT, Gb3 on GMVEC. In line with this 
difference in affinity of VT, we found transfer of VT from PMN to GMVEC, and subsequent 
inhibition of protein synthesis and cell death. Several suggestions have been made to explain 
the transfer of VT from the intestine to the kidney. Bitzan et al. (54) described that erythrocytes 
could bind VT depending on their P-blood group phenotype. 
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Figure 7: Measurement of protein synthesis by incorporation of 3H-leucine in newly synthesized 
proteins. (A) Non-stimulated GMVEC incubated with VT-1 loaded PMN showed during 24h incubation 
a reduction of protein synthesis. (B) GMVEC pre-stimulated for 24h with TNF-ot (10ng/mL) showed 
strong inhibition during incubation with VT-1 alone or after incubation with VT-1 preloaded PMN. 
Similar results were obtained from five different donors for GMVEC. Results are expressed as ± S.E.M. 
Statistical analysis was performed using unpaired Student's t-test. P-values smaller than 0.05 were 
considered to be significant. * Ρ < 0.05 as compared to non-stimulated GMVEC (A) and TNFa-
prestimulated GMVEC ( B). 
Robson et al as well as Taylor et al suggested even that there was an association between the 
outcome of the epidemic form of HUS and Ρ blood group (97,98). However, others 
investigators could not demonstrate a protective effect of the PI blood group in HUS. We also 
could not find VT binding to erythrocytes in whole blood of the two donors with PI blood 
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group in our study. However, we cannot exclude yet that local variations exist in PI-blood 
group-binding proteins causing VT-binding in some people. Cooling et al. (74) indicated that in 
particular small and older platelets, obtained by apheresis, contain small amounts of Gb3 and 
can bind VT. In a whole blood environment we did not observe any significant binding of ' 51-
VT-1 and VT-FITC to platelets (8 subjects were studied). Therefore, the relative contribution 
of platelets to the transport of VT in plasma appears insignificant as compared to PMN. 
Lingwood suggested that lipoproteins might be responsible for transporting VT (57,58). 
However, in the present study we could not find binding of VT to human LDL, VLDL or HDL, 
thus excluding this possibility. In line with our previous observation that purified human 
monocytes only bind VT significantly after activation by LPS (76), we found no VT binding to 
monocytes in whole blood. On the contrary, VT binding occurred exclusively to PMN, 
independent of blood groups or age of the donor. These data leads to the conclusion that PMN 
are a good candidate for transporting VT in the systemic circulation to target organs in adults as 
well as in children. 
The rapid binding of VT to PMN can explain why VT is usually not detectable in blood 
plasma (103). After binding the VT, PMN are able to transport the VT to target organs and 
transfer the VT to endothelial cells in vitro. Stimulating the GMVEC with inflammatory 
mediators, such as TNF-a or LPS, induces the VT receptor Gb3 on the cell surface (55,56). As 
expected transmission of VT-1 from PMN to endothelium increased when GMVEC were 
previous stimulated with TNF-a. We demonstrated in this study that one type of binding sites 
is involved in VT-1 binding on PMN, and that this binding site is different from the Gb3 
receptor found on endothelial cells. It is uncertain whether the VT receptor on PMN represents 
a glycolipid, because VT-1 binding to PMN was highly sensitive to trypsin treatment. In 
contrast to the classical VT receptor, Gb3, the VT receptor found on PMN does not result in 
VT internalization. The lower Kd for the receptor on PMN than for Gb3 allows transfer of VT 
from PMN to endothelial cells. Within 24 h this transfer was accompanied by biological 
effects, especially inhibition of protein synthesis and cell death. Interestingly, we observed that 
such biological effects not only affected cells that were prestimulated with TNFa but also in 
non-stimulated GMVEC that were incubated with VT-binding PMN. These data indicate that 
PMN not only can bind VT in the circulation, but also can transfer it to target cells that express 
the VT-receptor Gb3. 
That PMN may play a seminal role in pathogenesis of HUS has been suggested many 
times. Firstly, the number of PMN is elevated in HUS. It has been suggested that the number of 
PMN is a predictive factor for the outcome of the disease (11,105,106). In addition, Taylor and 
colleagues showed that there was an increased number of PMN in autopsy material of diarrhea 
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associated HUS patients (82,107). Furthermore, Fitzpatrick et al. described that PMN of HUS 
patients were activated and that, in HUS patients, levels of elastase and IL-8 were elevated 
(79,80) These results were confirmed by other investigators (108), and suggested that PMN may 
damage the endothelium through release of the intracellular components, such as elastase (79-
81). Finally, Morigi and colleagues described that VT-1 increased PMN adhesion to the 
endothelium under flow conditions by up-regulating adhesive proteins (78). The binding of 
PMN to the endothelium was reduced by blocking of E-selectin, ICAM-1 and VCAM-1 with 
respective antibodies. The adhesion of PMN to the endothelium was enhanced by pre-exposure 
of the endothelial cells by TNF-a. These investigators found that VT-1 was able to inhibit the 
process of rolling that normally proceeds adhesion of cells to the endothelium. In line with 
these findings is that PMN of HUS patients adhere more avidly to endothelial cells than PMN 
of healthy control subjects (81). All these results together indicate that PMN play an important 
role in pathogenesis of hemolytic uremic syndrome. Our data show a new and crucial aspect of 
the involvement of PMN in the epidemic form of HUS, namely the specific binding and 
transport of VT to PMN in whole blood. Additional studies are needed to evaluate whether the 
binding of VT to PMN causes a metabolic effect in PMN themselves. In this respect, it is of 
interest to note that in a recent study, the induction of superoxide production in PMN by Shiga 
toxin-1 was described (110). 
In conclusion, our study demonstrates an additional role of PMN in the pathogenesis of 
HUS and strongly suggests that PMN are the cells that transport the verocytotoxin form 
intestine to endothelium. This transport is facilitated by a receptor that has a 100-fold lower 
affinity than the high-affinity receptor (Gb3) that is expressed on glomerular microvascular 
endothelial cells after exposure to TNF-a. PMN loaded with VT display a direct cytotoxic 
effect to the endothelium of the kidney in vitro by inhibition of protein synthesis. The 
occurrence of VT-1 binding to PMN in vivo and ligand passing of VT and PMN has to be 
demonstrated in future studies. We believe that this observation is important in understanding 
the pathogenesis of (D+) HUS and opens perspectives for future treatment. 
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CHAPTER 3 
DETECTION OF VEROCYTOTOXIN BOUND TO CIRCULATING 
POLYMORPHONUCLEAR LEUKOCYTES OF PATIENTS WITH HEMOLYTIC 
UREMIC SYNDROME 
D. Maroeska W.M. te Loo, Victor W.M. van Hinsbergh, Lambertus P.W.J, van den Heuvel, 
Leo A.H. Monnens 
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ABSTRACT 
The epidemie form of hemolytic uremic syndrome is the most common cause of acute renal 
failure in children and is characterized by a prodromal phase of some times bloody diarrhea. 
The role of verocytotoxin (VT)-producing Escherichae coli has been strongly implicated. 
Although antibodies against VT have been found in serum of HUS patients, VT itself has never 
been detected in circulating blood. In this study, VT-2 was detected in the systemic circulation 
in 9 out of 10 patients with the epidemic form of HUS. In those cases, VT-2 was bound 
exclusively to polymorphonuclear leukocytes (PMN). The detection of VT-2 bound to PMN 
was associated with the presence of (bloody) diarrhea at the time the blood samples were 
obtained. The one patient, for whom VT was not detected, presented with atypical HUS. For 5 
of the 10 patients with HUS who were studied, the time course of VT binding was analyzed and 
decreased in four patients. The finding of VT bound to PMN in the systemic circulation of 
HUS patients is important for a clearer understanding of the pathogenesis of HUS and suggests 
new approaches for treatment in the future. 
INTRODUCTION 
The epidemic form of hemolytic uremic syndrome (HUS) is the most common cause of acute 
renal failure in children (2,3). Endothelial damage of predominantly glomeruli and to lesser 
extent arterioles of the kidney appears to play an important role in pathogenesis of HUS. In 
severe cases, however, endothelial cell damage is not limited to the kidney, but extends to other 
organs such as the brain and pancreas (4). In 90% of HUS cases, infection with a verocytotoxin 
(also termed "Shiga" or "Shiga-like toxin") producing Escherichae coli (E. coli) has been 
strongly implicated, especially serotype 0157: H7. E. coli can produce verocytotoxin-1 (VT-1), 
verocytotoxin-2 (VT-2) or both. Most common among patients with HUS are infections caused 
by a VT-2 producing E. coli (10,92). VT can cause inhibition of overall protein synthesis after 
binding to globotnaosylceramide (Gb3) receptor, which is found on endothelial cells after 
stimulation with inflammatory mediators (55,56). Serological testing of HUS patients for 
antibodies to the lipopolysaccharide of E. coli 0157: H7 is often used to detect infection by 
VT-producing E. coli 0157 (18,111,112). However, VT itself has never been detected in blood 
of patients with HUS. Recently, we investigated the binding of VT-1 and VT-2 in whole blood 
(113). In that study, we demonstrated that VT binds rapidly and exclusively to 
polymorphonuclear leukocytes (PMN) when incubated in whole blood in vitro. The binding 
occurs via selective binding to a specific receptor on PMN. Thin layer chromatography 
demonstrated that the receptor exhibited an Rf value between Gb4 and Gb5. In addition, the 
receptor on PMN exhibited a 100-fold lower affinity compared with that of the Gb3-receptor, 
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which can be found on endothelial cells. PMN previously loaded with VT were able to pass the 
ligand VT to tumor necrosis factor alpha (TNF-cc) -stimulated glomerular microvascular 
endothelial cells m vitro (GMVEC) which then causes inhibition of protein synthesis (113). In 
this study, we demonstrate for the first time, to our knowledge, the presence of VT-2 in the 
systemic circulation of patients in the acute phase HUS. Here we confirm that VT binds to 
PMN, as suggested by our in vitro studies, supporting our theory that PMN are responsible for 
transferring the ligand VT from the intestine to target organs. 
MATERIALS & METHODS 
Patients and controls 
Ethylenediaminetetraacetate-treated blood was collected from 11 patients with HUS, during the 
acute phase of the disease. Ten of eleven patients exhibited a prodromal phase of sometimes 
bloody diarrhea, and antibodies against the E. coli 0157: H7 were detected for seven patients 
(Table 1: patients 2 to 11). The patient without a prodromal phase had an atypical form of 
HUS. No E. coli (0157 or other types) was present in stool, and no antibodies against 
lipopolysaccharide could be detected. All patients exhibited thrombocytopenia, hemolytic 
anemia with fragmented erythrocytes, and renal failure. 
Clinical characteristics of the patients are presented in Table 1. Blood samples were analyzed 
for the presence of VT-2 within two hours after withdrawal. Ethylenediaminetetraacetate-
treated blood of 11 healthy volunteers and six patients with infectious disease (one with 
peritonitis, two with influenza virus, one with otitis media, one with toxic shock syndrome and 
one patient with an upper respiratory tract infection) were used as a negative control for the 
presence of VT. 
Detection of verocytotoxin by indirect immunofluorescence and flow cytometry 
PMN were isolated as described previously (113). Briefly, whole blood of patients with HUS 
and control subjects was underlayed with an aliquot of Ficoll 1.077 g/mL (Pharmacia, Uppsula 
Sweden) and centrifuged at 200-x g for 20 minutes at 4 0C in a Sorvall centrifuge (Meyvis and 
Co., Bergen op Zoom, the Netherlands). The interphase, containing lymphocytes, monocytes 
and a few PMN, was collected and washed with phosphate-buffered saline (PBS). The pellet 
contained PMN and erythrocytes. The pellet was resuspended and erythrocytes were lysed in 
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Patient 
Nr: 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Prodromal 
phase 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Anti-0157 
Neg. 
Neg. 
ND 
Neg. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos. 
Pos 
Hb 
mmol/L 
4.6 
7 
6.1 
5.2 
5.1 
6.5 
4.8 
5.6 
6.8 
4.5 
3.9 
2,2 
4.2 
4.4 
Platelets 
Xl(f/L 
31 
68 
23 
169 
21 
169 
97 
45 
36 
60 
32 
52 
56 
252 
WBC 
xl(f/L 
9.2 
13.8 
50 
21.2 
28 
18.1 
15.8 
10 
40 
42 
42.5 
N.D. 
18 
9.5 
Creatinin 
e 
μτηοΙ/Ι 
118 
452 
108 
355 
94 
206 
423 
859 
360 
340 
157 
600 
306 
93 
P.D. 
No 
No 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
No 
Days (*) 
1,3,5,10 
10 
14 
10 
6 
11 
5 
9 
3 
8 
5 
10 
8 
13 
9 
14 
%PMN 
positive 
0 
1% 
1-5% 
0% 
40-50% 
5-10% 
20% 
22% 
90% 
15% 
96% 
92% (t) 
14% 
0% 
80% 
20% 
Table 1 : Clinical characteristics of HUS patients and percentage of PMN positive for VT-2 binding. 
(*) = Number of days after start of the diarrhea that had passed before receiving the blood sample. 
Patients 1,2,3 and 4 had no (bloody) diarrhea at the time the blood sample was collected. Patient 5 and 8 
and 10 had no diarrhea anymore at the time the second sample was taken. Patient 1 was diagnosed 
having atypical HUS. Results of Hb, platelet count, and white blood cell count (WBC) and serum 
creatinine presented here, are the values measured at the time of blood sampling for the detection of 
verocytotoxin on PMN. Patient nine died on the same day the second sample was taken and patient 10 
was dismissed on the day the second sample was taken and for this reason no values indicating WBC, 
Hb, etc. are present for these patients. N.D.= not determined P.D.= peritoneal dialysis. 
ammoniumchloride or fluorescence activated cell sorting (FACS)-lysing solution. The 
remaining PMN were washed twice with PBS. Total number of cells was counted and IxlO6 
cells were used in each experiment. PMN (IxlO6 cells) and interphase samples (IxlO6 cells) 
from patients and control subjects were incubated for 1 hour, on ice, with a monoclonal 
antibody against VT-2B subunits (concentration 0.1 μΒ/μί; Toxin Technology; Kordia, Leiden, 
The Netherlands) in PBS with 10% fetal calf serum. Subsequently, cells were washed three 
times with PBS and incubated for 30 minutes, on ice, with FITC-goat anti-mouse (1:1000; 
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DAKO, Glostrup, Denmark). Cells were washed again three times with PBS followed by an 
incubation for 1 h on ice with CD13-phycoerythrin, CD 14- phycoerythrin, or CD45-
tetrarhodamine isothiocyanate (DAKO) to differentiate PMN, monocytes, and lymphocytes, 
respectively. Subsequently, cells were washed three times with PBS and resuspended in 0.5% 
paraformaldehyde for fixation. Cells were analyzed either by using a Zeiss microscope 
(Aksioscope; Bakker and Co., Zwijndrecht, the Netherlands) with standard equipment or by 
FACS. FACS analysis made it possible to quantify the percentage of positive cells. 
RESULTS 
On the basis of the results of our in vitro work (113) we focused in this study on the binding of 
VT-2 to PMN. Indirect immunofluorescence assays demonstrated positive staining for VT-2 on 
PMN in nine of 10 patients in the acute phase of HUS (Table 1). The result of an indirect 
immunofluorescence assay for one representative patient are presented in Figure 1. VT-2 
binding was observed only to PMN. To confirm that PMN were the only cells binding VT in 
blood, VT-binding to purified blood cells of patients with HUS was studied. As suggested by 
our previous findings from healthy donors (113), VT-2 bound only to PMN and not to 
lymphocytes, monocytes or erythrocytes from patients with diarrhea associated (D+) HUS in 
the acute phase of the disease. 
Figure 1: Indirect immunofluorescence of VT-2 bound to PMN in one representative patient (patient 9, 
respectively) in the acute phase of HUS. Magnification used lOOOx. 
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FACS-analysis was used to quantify the indirect immunofluorescence results. No VT-2 binding 
was detected in control blood from any of the healthy volunteers (Figure 2, A,C and E). In 
addition, no binding of VT-2 was observed for six patients with infectious diseases (see above). 
Figure 2: Flow cytometric analysis for detection of VT-2 bound to PMN. (A and C) PMN isolated form 
control blood and incubated with a monoclonal antibody against VT-2, followed by incubation with 
FITC-conjugated goat anti-mouse IgG. No positive binding was observed. (E) Interphase sample 
from the same control subject, containing lymphocytes (L), monocytes (M) and PMN (P), incubated 
with a monoclonal antibody against VT-2. No binding of VT-2 was observed. (B) results of the first 
sample of blood from a patient with HUS (patient 8), using the same incubation steps as used for the 
control sample. Of all PMN, 90% were positive for VT-2 binding. (D) Results showing that, five days 
later, VT-2 binding to PMN was reduced to 15%. (F) Results showing that, interestingly, monocytes 
were positive for VT-2 binding on day 5, whereas no binding was observed on day 1. 
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Figure 2 Β presents the results of VT binding to PMN from one patient (patient 8) on the first 
day after admission to the hospital. On the first day 90% of the PMN were positive for VT-2 
staining. Five days later only 15% of PMN were still positive (Figure 2D) suggesting that VT 
was transferred to target cells (data not shown). Interestingly, at that time not only PMN but 
also monocytes (Figure 2E) were positive for VT-binding which is highly indicative of 
activated monocytes as described by van Setten et al (76). For patient 9, VT-2 binding to 
monocytes was also observed 5 d after collection of the first sample. No VT-2 binding to 
monocytes was observed in the other patients, and patient 10 exhibited no binding to PMN 
anymore 5 d after collection of the first sample. 
Time course of VT-2 binding to PMN was studied only in five patients with the greatest 
numbers of VT-2 positive cells (patients 5, 8, 9,10 and 11, respectively) (Figure 3). For patients 
5,8, 10 and 11, large decreases in the numbers of PMN positive for VT-2 were observed in the 
5 d after collection of the first sample. The last sample of patient 9 was obtained 5 d after the 
first sample, and no significant decrease of VT-2 was observed. A possible explanation for this 
may be that additional toxin was absorbed from the circulation and transferred to the white 
blood cells as fast as they could transfer the toxin to the Gb3 containing glomerular cells. 
Patient 9 had a very severe form of HUS, with neurological involvement and died on the day 
the last sample was obtained. 
No positive staining for VT-2 was found in patient 1 and in patient 4. All patients who 
exhibited positive results for VT-2 binding to PMN were still experiencing diarrhea at the time 
the blood samples were obtained. Patient 1 exhibited no prodromal phase of (bloody) diarrhea 
and exhibited a relapse of HUS just a few weeks later. He responded to treatment with 
plasmapheresis. Therefore, he was considered to have an atypical form of HUS. 
DISCUSSION 
In this study, we demonstrate for the first time the presence of VT-2 in the systemic circulation 
in nine of ten patients in the acute phase of the epidemic form of HUS. In 85% of all cases of 
D+ HUS in Western Europe, infections with VT-2 producing E. coli are found (21). Therefore, 
we investigated the presence of VT-2 in the systemic circulation of patients with D+ HUS in 
the acute phase of the disease. 
VT-2 bound to PMN and not to erythrocytes, monocytes or lymphocytes during the 
period of diarrhea. There was a strong association between the detection of VT-2 bound to 
PMN and the presence of (bloody) diarrhea at the same time. One patient with atypical HUS 
showed repeatedly exhibited no positive staining in the acute phase of the disease. In the other 
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case were no VT-2 binding was detected (patient 4) the result was probably negative due to the 
late admission to the hospital This patient was without diarrhea for seven days at the time the 
blood sample was taken A reason for this may be that the toxin had already been transferred 
from intestine to the kidney Alternatively, this patient may have had an infection with a VT-1 
producing E coli, which we did not detect with the specific monoclonal antibody against VT-2 
used in this study 
It has often been suggested that PMN may play a critical role in pathogeneses of EH-
HUS PMN levels are elevated in HUS, and it has been suggested that the number of PMN is a 
predictive factor for the outcome of the disease (12,105) In addition, increased numbers of 
PMN were found in glomeruli of kidney autopsy material from patients with D+ HUS (82,107) 
Furthermore, PMN m patients with HUS are activated and elevated levels of IL-8 and elastase 
are found (80) It has been suggested that PMN of HUS patients may damage the endothelium 
through release of intracellular components such as elastase, or formation of superoxide 
(81,110) In our in vitro experiments, we indeed demonstrated that PMN loaded with VT-1 
were able to induce endothelial cell death whereas VT-1 or PMN alone had no effect (113) In 
addition, a recently published study showed that apoptosis of PMN was inhibited by VT, those 
authors concluded that longer survival of neutrophils might aggravate neutrophil-mediated 
tissue damage (114) Finally, Zoja and colleagues (78) reported that VT-1 can cause an 
increased adhesion of PMN to the endothelium under flow conditions, by up-regulating 
adhesive proteins Administration of antibodies against E-selectin, ICAM-1 and VCAM-1 
reduced the adhesion of PMN to the endothelium 
Karmali and colleagues investigated the distribution of VT-1 in serum of rabbits (70) 
and demonstrated a short serum half-life (2 minutes) for VT-1 From those results, the authors 
concluded that VT is probably rapidly cleared from the systemic circulation and for thus is not 
detectable in the circulation of patients with HUS They did not consider a role for PMN in 
transporting VT, however In our in vitro expenments, we demonstrated that VT binds rapidly 
and exclusively to PMN (113) No binding to other components of blood was observed 
Interestingly, it has been suggested that PMN play also a very important role in the 
pathogenesis of Kawasaki disease, and it has been reported that lipopolysacchande is bound 
and transported by PMN (115) 
In line with our in vitro data is the finding of VT-2 bound to PMN in vivo in nine often 
HUS patients with the epidemic form of HUS We think that VT has never been detected in 
serum of HUS-patients, because VT binds rapidly to PMN after entering the systemic 
circulation and thus is absent in plasma or serum of patients with HUS 
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The finding of VT-2 bound to PMN in D+ HUS patients not only represents the missing 
link between the intestinal infection and damage to the target organs but also provides new 
approaches for therapy. Two patients with severe HUS whom we have studied exhibited high 
percentages of PMN positive for VT-2 binding; in a later phase, binding to monocytes was also 
observed. We think that, during the phase of bloody diarrhea, VT traverses the intestine-blood 
barrier, binds to PMN and thus is transferred to target organs. 
Synsorb Pk, a synthetic analogue of the Gb3 receptor, can bind VT in vitro and can 
neutralize VT when mixed in vitro with VT-positive stools from children with HUS (116,117). 
When Synsorb Pk is administered orally to patients with the epidemic form of HUS while they 
have still diarrhea, it reduces the amount of VT available; this reduction might prevent and/or 
decreases the binding of VT to PMN and the subsequent transfer of VT from the intestine to 
target organs. However, additional therapy is required in severe cases. We think that, on the 
basis of the finding that VT is bound to PMN in D+ HUS patients, leukopheresis would be a 
possible solution in such cases. The presence of VT bound to PMN can be assessed rapidly, 
using a simple, reproducible and quick method, as we have described in this report. PMN 
loaded with VT can be removed using leukopheresis, thus preventing the transfer of VT to 
target organs or protecting target organs from severe damage. 
In conclusion, our data demonstrate a new and crucial aspect in the pathogenesis of 
HUS, namely the specific binding and transfer of VT by PMN in the systemic circulation. We 
think that this observation is important for clarification of the pathogenesis of HUS and for 
treatment of HUS patients. We suggest that in severe cases of D+ HUS an effective therapy 
with leukopheresis should be considered. 
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VEROCYTOTOXIN BINDING TO POLYMORPHONUCLEAR LEUKOCYTES IN 
HOUSEHOLD MEMBERS OF CHILDREN WITH HEMOLYTIC UREMIC 
SYNDROME 
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ABSTRACT 
The hemolytic uremic syndrome (D+ HUS) is the leading cause of acute renal failure in 
childhood and can be caused by different serotypes of verocytotoxin- (= Shiga toxin-) 
producing Escherichia coli (VTEC). Recently we have shown that verocytotoxin (VT) is 
bound to polymorphonuclear leukocytes (PMN) in the systemic circulation of patients with D+ 
HUS. In this study we investigated whether VT bound to PMN can be detected in household 
members of D+ HUS patients. Serum antibodies against Escherichia coli 0157 and when 
available feces from D+ HUS patients and household members were investigated to establish 
the presence of VTEC infection. The circulating PMN of 82% of the household members were 
positive for VT, whereas based on examination of their stool and/or serum only 21% were 
positive. This study shows that with the methods currently used, the total number of infected 
people in the surrounding of D+ HUS patients is underestimated. 
INTRODUCTION 
The hemolytic uremic syndrome (HUS) is clinically characterized by hemolytic anemia, 
thrombocytopenia and acute renal failure (2). The syndrome is preceded in a majority of the 
patients by an episode of diarrhea with or without blood in the stools and has therefore often 
been termed D+ HUS (4). It has been proven that infection with verocytotoxin- (= Shiga toxin-) 
producing Escherichia coli (VTEC) plays a central role in the pathogenesis of disease, finally 
leading to HUS in 10% of the children infected (3,118,119). VTEC strains involved in D+HUS 
may belong to different serological groups but infection with strains belonging to serotype 
0157: H7 is most frequently detected (10). VTEC strains can produce verocytotoxin-1 (VT-1), 
verocytotoxin-2 (VT-2) or both, but in 80% of the human cases in Western Europe VTEC 
strains producing only VT-2 are identified (21,120). Several approaches can be used to 
demonstrate an infection with VTEC, including the examination of patients' stool for free VT 
and/or VTEC organisms and investigating the patients' serum for the presence of antibodies 
binding to lipopolysaccharide (LPS), especially 0157 LPS (70% of the cases is caused by 
VTEC belonging to this serogroup (121). Household members of children with D+ HUS are 
often asymptomatically infected with VTEC. Examination of stool samples showed evidence of 
an infection with VTEC in about 30% of the parents and in 45% siblings (18). To cause its 
systemic effects, the toxin must gain access to the circulation. Acheson et al. showed that VT is 
capable of passing across epithelial cells without any apparent cellular disruption (39,122). 
Other possible routes include the translocation of the toxin through lesions of the mucosal 
barrier. 
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Recently, we have demonstrated that in the acute phase of patients with D+ HUS, VT is 
bound to circulating polymorphonuclear leukocytes (PMN) (123). The binding of VT to PMN 
occurs by selective binding to a specific receptor that is different from the classical VT receptor 
globotriaosylceramide (Gb3) found on endothelial cells (113). The discovery of VT bound to 
PMN not only explains the question of how VT is transported from the intestine to target 
organs but also offers a new detection method to provide evidence for infection with VTEC. 
Furthermore, this detection method enables us to evaluate whether VT is also circulating in the 
blood of the parents and siblings of D+ HUS patients, who did not develop HUS themselves. 
This evaluation provides further insight into the question whether the entry of VT into the 
circulation is the only key factor that determines the development of D+ HUS, or whether 
additional promoting or protective factors also play a role. To provide extra evidence of VTEC 
infection serum samples of D+ HUS patients and their household members were investigated 
for the presence of antibodies to LPS. Additionally, when available fecal samples were 
analyzed for the presence of free VT and VTEC strains causing the infection. Finally, the 
different detection methods were compared and combined to find the true frequency of VTEC 
infection in household members. 
MATERIALS & METHODS 
Patients, household members and controls 
Samples of whole blood (EDTA), serum, and feces were collected from 13 D+ HUS patients as 
well as from one or more of their respective household members (n=28) to find evidence of 
infection with VTEC. Patients represented in this study were collected during the year 2000 
and are non-related individual cases of D+ HUS in the Netherlands and Belgium. All D+ HUS 
patients had thrombocytopenia, hemolytic anemia with fragmented erythrocytes and renal 
failure. In the majority (75 %) of the household members enrolled in this study no symptoms of 
diarrhea did occur at the time of admission or 1 week before admission of the D+ HUS patient 
to the hospital. Whole blood (EDTA) of twelve healthy controls and three patients with atypical 
HUS were studied as negative controls for the presence of VT-1 and/or VT-2. 
Analysis of whole blood 
Within 2 hours after withdrawal, samples of whole blood of the HUS patients, and household 
members (collected in the acute phase of the disease of the child), and controls were tested for 
the presence of VT-1 or VT-2 bound to PMN. PMN were isolated as described previously 
(113). The total number of cells was counted and in each experiment 1x106 cells were used. 
PMN (IxlO6 cells) from patients, household members and controls were incubated with a 
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monoclonal antibody against the Β subunit of VT-1 or VT-2 (concentration 1 μΒ/μΙ.; Toxin 
Technology; Kordia, Leiden, The Netherlands: diluted 1:50) in phosphate buffered saline 
(PBS) with 10% fetal calf serum for 1 h on ice. Subsequently, the cells were washed three 
times with PBS and incubated with phycoerythrin (PE) or fluorescein isothiocyanate isomer 
(FITC)-labeled goat anti-mouse IgG antibody (1:1000; DAKO, Glostrup, Denmark) for 30 
minutes on ice. Subsequently, the cells were washed three times with PBS and then were 
resuspended in 0.5% paraformaldehyde for fixation. Cells were analyzed by flow activated cell 
sorting (FACS, Coulter). FACS-analysis made it possible to quantify the percentage of cells 
positive for VT-binding. 
Serological examination 
Serum samples (collected as soon as possible after admission of the patient to the hospital) 
were tested for the presence of antibodies of the IgM-class binding to the LPS of E. coli 0157 
by ELISA and immunoblotting (120,121). When tested negative, serum samples of HUS-
patients were additionally examined for the presence of antibodies to the LPS of E. coli of 
serogroups: 026, O104, O l l i , 0115 and 0145. 
Stool examination 
Stool samples (collected as soon as possible after admission of the patient to the hospital) of 
D+ HUS patients and household members were streaked onto sorbitol MacConkey (SMAC) 
agar and/or SMAC agar supplemented with Cefixime (0.05 mg/L) and tellurite (2.5 mg/L) to 
isolate VTEC 0157 strains. To detect VTEC strains of other serogroups, stools were enriched 
in modified tryptone soy broth (18-20 h at 370C) and DNA extracts from the enrichment 
cultures were used as templates for a VT-PCR. Furthermore, the cytotoxic activity of both stool 
extracts (free VT) and culture broth filtrates was assayed on Vero cells. 
RESULTS: 
VTEC infection in D+HUS patients 
All D+ HUS patients (100 %) included in this study were found positive for VT binding to 
PMN in the systemic circulation (Table 1). All controls investigated were negative for the 
presence of VT confirming that the detection of VT bound to PMN is specific. Sixty-six 
percent of the patients had IgM-class serum antibodies to 0157 LPS whereas in 50% of the 
patients evidence for infection with VTEC of serogroup 0157 was found based on examination 
of patients' stool. In most hospitals only the presence of E. coli 0157 is investigated (in feces 
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and serum) and therefore patients that are infected with a different strain will be missed. When 
the binding of VT to PMN is determined in the acute phase of the disease it will be possible to 
identify all patients infected with VTEC (Table 1). 
Table 1: Detection of VTEC infection in D+ HUS patients 
Patient 
Nr 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Diarrhea 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Feces (VTEC Ol57, VTEC 
non-0157, free VT) 
Negative (*) 
VTEC 0157 positive (b) 
VTEC 0157 positive (") 
Negative 0 
Negative (a) 
Negative (*) 
VTEC0157Positive(':) 
Negati ve(c) 
VTEC 0157 PositiveO 
VTEC Ol57 Positive (") 
Negative (b) 
Vl'EC Ol57 positive (") 
Negative (a) 
Serum antibodies to LPS 
026 
0157 
0157 
0157 
O l l i 
Negative 
0157 
Negative 
0157 
0157 
0145 and 0115 
0157 (*) 
0157 
%PMNswith VT 
(bound /type ofVT) 
10%/VT-l 
9% / VT-2 
18%/VT-2 
12%/VT-2 
95%/VT-2 
40% / VT-2 
45% / VT-2 
79% / VT-2 
47%/VT-2 
77%/VT-2 
88% /VT-2 
10%/VT-2 
98%/VT-2 
(*) Serum antibodies to 0157 LPS were weak positive in this patient. 
(a) examined only by directly streaking feces onto sorbitol MacConkey (SMAC) agar 
(b) examined by directly streaking feces onto SMAC agar, SMAC agar supplemented with Cefixime and 
tellurite (CT-SMAC) and VT-PCR examined by directly streaking feces onto SMAC agar, CT-SMAC 
agar, VT-PCR and performing verocelcytotoxicity tests 
VTEC infection in household members of D+HUSpatients 
In 82% (n=28) of the household members of the D+ HUS patients VT bound to PMN was 
found (Table 2). The percentage of positive cells ranged between 8 and 90 % similar to the 
percentages found in D+ HUS patients. 
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Table 2: VTEC infection in household members of D+ HUS patients 
Patient 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11 
12 
13 
Household 
members 
Mother 
Mother 
Father 
Mother 
Mother 
Father 
Mother 
Mother 
Father 
Grandfather 
Mother 
Father 
Mother 
Father 
Mother 
Father 
Brother 
Sister 
Mother 
Father 
Brother 
Sister 
Mother 
Grandmother 
Father 
Mother 
Father 
Sister 
Diarrhea 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
No 
No 
No 
No 
Yes 
Yes 
Feces ( VTEC Ol57, VTEC 
non-0157, free VT) 
Negative^ 
Positive 0 1 5 7 ^ 
Negative^ 
ND 
ND 
ND 
ND 
Negative^ 
Negati \tC) 
Negative^ 
Negative^) 
Negative^ 
Negative^ 
NegativeO 
Negative^ 
Negative^ 
Negative 
VlhC 0157 Positive 
Negative^ 
Negative^ 
Negative^ 
VTEC 0157 positive 
ND 
ND 
ND 
Negative 
Negative 
Negative 
Serum antibodies 
toLPS0157 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Positive 
Negative 
Negative 
Weak response 
Positive 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
%PMNswith VT 
bound/ type of 
VT 
Negative 
10%/VT-2 
Negative 
22%/VT-2 
12%/VT-2 
13%/VT-2 
80%/VT-2 
33% / VT-2 
8%/VT-2 
70%/VT-2 
50% /VT-2 
85% / VT-2 
Negative 
22%/VT-2 
24%/VT-2 
49%/VT-2 
Negative 
42% / VT-2 
85%/VT-2 
90% /VT-2 
51%/VT-2 
47%/VT-2 
53% / VT-2 
71%/VT-2 
Negative 
60%/VT-2 
96% / VT-2 
44%/VT-2 
(a) examined only by directly streaking feces onto sorbitol MacConkey (SMAC) agar 
(b) examined by directly streaking feces onto SMAC agar, SMAC agar supplemented with Cefixime and 
tellurite (CT-SMAC) and VT-PCR 
(c) examined by directly streaking feces onto SMAC agar, CT-SMAC agar, VT-PCR and performing 
verocelcytotoxiaty tests 
ND, not done 
The experimental data of FACS-analyses of one HUS patient and the respective household 
members are demonstrated in Figure 1. All were positive for VT-2 binding to PMN except for 
the brother of the HUS patient. The brother had been absent for two weeks, and therefore had 
probably not been exposed to the source of the VTEC infection. VT bound to PMN was 
determined one week later in four household members of patient 8 and patient 9 that were 
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positive on the first day. All four household members were negative one week after admission 
of the HUS patient, whereas the two D+ HUS patients were still positive (37 and 45%, 
respectively) Serum antibodies to LPS were detected in 10% (n=28) of the household members 
examined and 10% (n=19) had positive stool samples for the presence of VTEC. 
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Figure 1. FACS-analysis of a D+ HUS patient (patient 9) and the respective household members. Cells 
are differentiated on the basis of size by a forward scatter (FS) or on the basis of granulation by a side 
scatter (SS). Binding of VT was visualized by a fluorescent signal (FITC). Flow-cytometnc analysis of 
control blood (incubated with IgG-FITC alone) is shown in the first picture (Ai-Ei). The D+ HUS 
patient had 47% positive cells (A2+3). The FACS analysis of the sister of the patient (42%) and brother 
of the patient (0%) are shown in Figure B2+3 and C2+3 respectively. The brother had been absent for two 
weeks and was probably not exposed to the source of the infection. The mother (D2+3) and the father 
(£2+3) had respectively 24% and 49% of PMNs positive for VT-binding. 
DISCUSSION 
VT bound to PMN was found in 82 % of the household members. Based upon the combined 
examination of their stool and serum samples only 21% were positive. No relationship was 
found between the presence of diarrhea and the amount of VT bound to PMN. The finding of 
VT bound to PMN in the circulation of parents and siblings indicated that not only was there 
the entry of the toxin into the circulation of household members of D+ HUS patients, but also 
other additional factors, for example LPS, may play a role in the development of HUS. 
The finding of parents of D+HUS patients being negative for the presence of serum 
antibodies to 0157 LPS is confirmed by earlier reports and serological testing is therefore not a 
useful tool to provide evidence for VTEC infection in household members (18). Occasionally, 
siblings produce antibodies to LPS. Despite the low number of household members detected 
positive, LPS serology is still considered as one of the most applied methods used to provide 
evidence of VTEC infection in D+HUS patients (18,21,120,121). 
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However, we demonstrate in the current study that the detection of VT bound to PMN is more 
sensitive for providing evidence for VTEC infection both in D+HUS patients and in their 
household members. 
In the literature, the percentage of household members found positive for VTEC 
infection based on the examination of their stools can be as high as about 40%, depending on 
the time of collection of the samples and the detection method used (18,25). In this study we 
have shown that 80% of the household members were positive for VT-2 binding to PMN 
indicating that they have been infected with VTEC recently. So it is very likely that at present 
the frequency of VTEC infection in household members is being underestimated using stool 
culture combined with serological analysis. Negative stool samples may be explained by a 
rapid clearance of the VTEC organisms from the gastrointestinal tract of humans and therefore 
the organisms and the toxins they produce are no longer detectable anymore in feces. It has 
been described that the median duration of shedding of VTEC 0157 is 13 days in patients with 
hemorrhagic colitis and 21 days in patients with HUS (124). For household members no data 
are available on the length of shedding. 
Although D+ HUS patients and their household members had similar numbers of PMN 
that had bound VT (one million of PMN being investigated) are found differences in the 
amount of toxin entering the circulation probably occur. In regard to this, it is interesting to 
know that although household members were infected they did not develop symptoms of 
hemolytic uremic syndrome (serum creatinine, blood smear and urine sediment were normal) 
even if more that 50% of PMN were positive for VT-2 binding. The detection of VT bound to 
PMN only provides evidence for the presence of a recent infection. It should be taken in 
account that it is not yet possible to determine the exact amount of VT bound by one individual 
polymorphonuclear leukocyte. Therefore it might be possible that, although high percentages 
of PMN binding VT are found in household members, the true amount of toxin present is much 
less than in D+HUS patients. Furthermore, life span of PMN is normally about 2-3 days, but an 
in vitro study showed that the life span of PMN was prolonged when incubated with VT-2 
(114). As a consequence of the prolonged life span, toxin that entered the circulation can be 
detected for longer than 2-3 days so long as it is not transferred to target cells or eliminated by 
macrophages. In addition, it has to be considered that although equal percentages of positive 
cells are found in D+HUS patients and household members, the number of white blood cells is 
increased in patients with D+ HUS (12,105). Therefore relatively more VT might be present in 
the systemic circulation of HUS patients. To determine the amount of toxin that is present in or 
is entering the circulation, it would be necessary to quantify the toxin present on PMN. 
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The finding of family members positive for VT bound to PMN further underlines the 
importance of measure to prevent further transfer of VTEC infection, especially to children 
because they are more susceptible. Secondary spread of VTEC both during outbreaks and 
sporadic cases have been documented (125-127). It has been estimated that in a large 
hamburger-associated outbreak in the United States in 1993 about 11% of all cases resulted 
from secondary spread (128). The assay of VT binding to PMN provides an adaptive and 
sensitive tool to verify whether people carry a VT producing E. coli infection. 
In conclusion, this study has shown that the number of household members of a 
D+HUS patient infected was much higher than expected before from the examination of feces 
and/or LPS antibodies in their serum alone. Examination of serum and feces remains important 
to determine the origin of the infection and to determine the serotype of the infecting VTEC 
strain. Based on the results of this study one have to assume that almost all household members 
of an HUS patients will be infected. This underlines the importance of advice on the risk of 
person-to-person spread and on necessary hygienic precautions in the home of a D+HUS 
patient to prevent further transmission within families as much as possible. 
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CHAPTER 5 
LIPOPOLYSACCHARIDE IS BOUND TO POLYMORPHONUCLEAR 
LEUKOCYTES IN HEMOLYTIC UREMIC SYNDROME: ACTIVATION OF 
POLYMORPHONUCLEAR LEUKOCYTES 
DMWM te Loo, L.J.H. van Titz, LPWJ van den Heuvel, TJAM van der Velden, NCAJ van de 
Kar, LAH Monnens, VWM van Hinsbergh 
Submitted 
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Abstract 
The hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in 
childhood. The syndrome is in most cases caused by an infection with a verocytotoxin (VT) (= 
Shiga toxin) producing E. coli (VTEC). Recent studies demonstrated that VT is transported by 
polymorphonuclear leukocytes (PMN) through the systemic circulation in D+ HUS patients but 
also in non-symptomatic VTEC infected patients. Therefore, it is reasonable to assume that 
other additional factors are necessary for the development of HUS. Lipopolysaccharide (LPS) 
may be one of these factors. 
In this study we investigated whether LPS could be detected in the systemic circulation 
of patients with HUS and in their household members. Seven out of nine patients with HUS 
were positive for the presence of LPS bound to PMN whereas 5 out of 18 household members 
were also positive. 
In addition, the effects of VT and LPS on PMN were studied in whole blood of healthy 
volunteers. The expression of different activation markers such as CD63, CD66b and 
CD1 lb/CD 18 (= anti-ICAM) increased after incubation with LPS whereas incubation with VT 
alone had no effect. LPS and VT together had similar effects compared to incubation with LPS 
alone. Furthermore, LPS was able to induce the release of elastase by PMN when incubated in 
whole blood. VT was able to induce a slight, although not significant, increase in elastase 
release. Incubation with LPS and VT together induced a release of elastase comparable to 
incubation with LPS alone. 
This study shows for the first time, to our knowledge, the presence of LPS bound to 
PMN in the systemic circulation of patients with HUS. Furthermore, this study demonstrates 
that not VT but the presence of LPS bound to PMN causes activation of PMN in vitro. 
Therefore we postulate that the activation of PMN as observed in patients with D+ HUS is 
caused by the presence of LPS. In addition, we hypothesize that the amount of LPS together 
with the amount of VT entering the systemic circulation is essential for the development of 
HUS. 
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Introduction 
The hemolytic uremic syndrome (HUS) is defined by the triad of hemolytic anemia, 
thrombocytopenia, and acute renal failure and occurs mainly in childhood (2,4). The 
pathogenesis of the syndrome is hallmarked by endothelial damage of mainly glomeruli and 
arterioles within the kidney (92). It is now generally accepted that the development of the 
diarrhea-associated form of HUS (D+ HUS) is caused by an infection with a verocytotoxin (= 
Shiga like toxin or Shiga toxin) producing Escherichia coli (VTEC)(10). Recently, we have 
demonstrated that verocytotoxin (VT) is transported by polymorphonuclear leukocytes (PMN) 
through the systemic circulation of D+ HUS patients (123). In vitro studies performed showed 
that PMN were able to transfer VT to endothelial cells (113). These data are suggestive for the 
conclusion that PMN form the missing link between intestinal infection and organ damage. 
However, VT bound to PMN is also present in household members of D+ HUS patients with 
only VTEC infection (129). Therefore we hypothesized that not only the entry of VT into the 
systemic circulation of D+ HUS patients but also other additional factors are required for the 
development of HUS. 
One of these additional factors might be lipopolysaccharide (LPS). LPS is a major 
component of the outer surface of gram-negative bacteria. Picomolar concentrations of LPS are 
sufficient to elicit inflammatory responses in the host by activating PMN, monocytes, and 
endothelial cells (130). This initiation of cellular response is necessary for the host defense 
against gram negative bacteria. However, if large amounts of LPS enter the circulation an 
excessive response can be seen leading to severe complications like circulatory failure and 
organ damage (130). LPS binding to cells is facilitated by the presence of lipopolysaccharide 
binding protein (LBP) and of CD 14, a glycosylphosphatidyl inositol-anchored species on the 
surface of monocytes and PMN and also present as soluble protein in plasma. It has recently 
been shown that after binding of LPS to the cell, a signal is transferred through Toll-like 
receptors leading to the activation of ΝΡ-κβ (131-133). LBP is a 60-kd serum glycoprotein that 
is synthesized hepatically (134). The concentration of circulating LBP is increased in response 
to LPS and other inflammatory cytokines (135). Levels of LBP in plasma of HUS patients were 
significantly higher when compared to patients with uncomplicated VTEC infection (136). 
Furthermore, serum antibodies against LPS can be found in D+ HUS patients whereas this is 
rarely being detected in patients with only VTEC infection (137,138). These data suggest that 
LPS have a role in the pathogenesis of D+ HUS. Although serum antibodies against LPS can be 
detected in D+ HUS patients, LPS itself has never been detected. 
Because PMN transport VT through the systemic circulation of D+ HUS patients and 
have a CD14-binding domain, we investigated whether LPS might be present on PMN of HUS 
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patients. Furthermore, the presence of LPS on PMN of parents and siblings of D+ HUS patients 
was studied. In addition, the effects of LPS and VT on PMN in whole blood of healthy 
volunteers was evaluated. Our data suggests that the presence of LPS has a decisive role for the 
development of full-blown HUS. 
Materials & Methods 
Reagents and antibodies 
Hanks Balanced Salt solution without phenol red (HBSS) was obtained from Life 
Technologies, Paisley, Scotland. Human serum albumin was obtained from Behringwerke, 
Marburg, Germany). Luminol, phorbol 12-myristate 13-acetate and horseradisch peroxidase 
(hrp) were from Sigma, St Louis, MO, USA. VT-2 was ordered from Kordia (Toxin Technol.), 
Leiden, The Netherlands. Monoclonal antibody against the 2-keto-3-deoxyoctonic acid, that is 
a part of the inner core of LPS (KdO, clone 20) was purchased from HyCult biotechnology Bv, 
Uden, The Netherlands. Monoclonal antibodies against CD66b (fluorescein isothiocyanate 
(FITC)-labeled), CD63 (-phycoerythrin conjugated (PE)-labeled) were ordered from 
Immunotec, Marseille, France. Antibodies against L-selectin, and CDllb/ CD18 complex (both 
FITC-labeled) were purchased from Dako A/S, Denmark as also the secondary antibody goat-
anti-mouse FITC. 
Patients and control subjects 
Ethylenediaminetetraacetate-treated (EDTA) blood was collected from 9 patients with D+ HUS 
immediately after submission, 18 household members of HUS patients on the day of admission 
of the HUS patient, and 5 healthy volunteers. All HUS patients exhibited a prodromal phase of 
bloody diarrhea and presented with thrombocytopenia, hemolytic anemia, and renal failure. 
Blood samples were used for the isolation of PMN as described previously (113). 
Contaminating erythrocytes were removed through lysis with ammoniumchloride. PMN were 
washed twice with PBS. Total number of cells was counted and 1 xlO6 cells were used for 
determination of the presence of LPS. PMN of patients and control subjects were incubated in 
PBS with 10% fetal calf serum with a monoclonal antibody against the KdO of endotoxin for 1 
h, on ice. Subsequently, cells were washed three times with PBS, followed by incubation with 
goat-anti-mouse IgM-FITC. Cells were analyzed using flow-activating cell sorting (FACS). 
FACS analysis made it possible to quantify the percentage of positive cells. 
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Superoxide production 
PMN of eight different healthy donors were isolated as described above. PMN were incubated 
with VT-2 0.1 nM, VT-2 10 nM, LPS 1 μΜ alone, or LPS 1 μΜ in combination with VT-2 0.1 
and 10 nM for 10 min, 1 h, and 4h, respectively. Immediately, after the incubation period, 
luminol-enhanced chemilumniscence of proteose-peptone-elecided PMN was measured on a 
Victor 1420 counter (Wallac, Turku, Finland) at 37 0C using white 96-well microplates as 
described previously (139). Each well-contained 2 χ IO5 PMN, 50 μΜ luminol, 4.5 U/ml 
horseradish peroxidase and 50 ng/mL PMA in 200 μί. of HBSS without phenol red, 
supplemented with 0.25% human albumin. Phorbol 12-myristate 13-acetate (PMA) was used as 
a positive control. 
Detection of activation markers on PMN 
100 μ ι Whole blood of four healthy volunteers was incubated with either LPS 1 μg/ml, VT 0.1 
nM, VT 10 nM alone or LPS (1 μg/mL) in combination with VT 0.1 nM or VT 10 nM for 2 h 
at room temperature. Subsequently, erythrocytes were lysed using ammoniumchloride. The 
solution was centrifiiged at 200g for 5 minutes at room temperature. PMN were identified by 
flow cytometry (Coulter® Epics® XL-MCL) using their morphological criteria and using 
CD13-PE as specific marker for PMN. Monoclonal antibodies against CD63 (-phycoerythrin 
conjugated) and CD66b (-FITC) were used as degranulation markers of PMN and monoclonal 
antibodies against L-selectin and CDl lb/CD 18 (= Mac-1 = anti-ICAM-1) were used to study 
the expression of adhesion molecules. Antigen expression was measured as mean fluorescence 
intensity of 5000 cells by flow cytometry. Data acquisition and analysis were performed using 
XL-2 software (Coulter). 
Statistical analysis 
The Mann-Whitney U test was used to assess the significance of differences between mean 
baseline values of the HUS patients versus controls. Wilcoxen signed rank test was used to test 
significance of within-group differences. Differences were considered significant at Ρ <0.05. 
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Results 
Detection of LPS bound to PMN in HUS 
F ACS analysis of PMN isolated from D+ HUS patients showed that seven out of nine HUS 
patients were positive for the presence of LPS bound to PMN. All HUS patients were positive 
for the binding of VT-2 to PMN (Table 1). 
Table 1. Detection of VT-2 and LPS-bound to PMN of D+ HUS patients 
Diarrhea 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Anti-0157 
antibodies 
Negative* 
Positive 
Positive 
Positive 
Negative 
Positive 
Negative 
Positive 
Positive 
% VT-2 
positive 
92 
76 
47 
69 
79 
46 
21 
95 
52 
% LPS 
positive 
79 
13 
0 
0 
43 
42 
77 
25 
34 
In patient 1 antibodies against E. coli Ol 15 and 0145 were found. 
Five out of 17 household members investigated in this study were positive for the presence of 
LPS whereas 15 were positive for the presence of VT bound to PMN (Table 2). Only three of 
them, all three children, had serum antibodies against E. coli 0157. No LPS or VT-2 was 
detected in any of the healthy controls. 
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Table 2 Detection of LPS and VT-2 in household members of D+ HUS patients 
Patient no Household Diarrhea Presence of Anti-OlS? %PMNVT-2 % PMN LPS 
Members VTEC infection antibodies positive positive 
feces 
Mother 
Mother 
Father 
Brother 
Sister 
Mother 
Father 
Brother 
Sister 
N D 
Mother 
Father 
Father 
Mother 
Mother * 
Father 
Sister 
Mother 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
No 
No 
No 
No 
No 
Yes 
Yes 
No 
ND 
Negative 
Negative 
Positive 0157 
Positive 0157 
Negative 
Negative 
Negative 
Positive 0157 
Negative 
Negative 
N D 
Negative 
Negative 
Negative 
Positive 0157 
N.D 
Negative 
Negative 
Negative 
Weak posit 
Weak posit 
Negative 
Negative 
Negative 
Positive 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
67% 
86% 
90% 
47% 
76% 
24% 
50% 
0% 
41% 
0% 
16% 
20% 
12% 
60% 
60% 
40% 
22% 
0% 
0% 
0% 
0% 
0% 
0% 
3% 
0% 
0% 
0% 
5% 
10% 
0% 
25% 
35% 
0% 
0 % 
N.D. = not determined 
* Fragmented erythrocytes were detected in the blood smear of the mother of patient 8 
Figure 1 shows the results of the detection of LPS in a healthy control, and patient 1. The 
control was negative for the presence of LPS (Figure 1A) whereas in-patient 1 more than 75% 
of the PMN were positive for the presence of LPS (Figure IB). At the same time, more than 
90% binding of VT-2 to PMN was found. No positive staining for LPS was observed for 
patient 3 and 4 whereas in both patients VT-2 bound to PMN was found (47 and 69%, 
respectively) and serum antibodies against E. coll 0157 were present. Unfortunately, it was not 
possible to follow LPS binding in course of the disease in HUS patients because of logistic 
reasons. 
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Figure 1: Detection of lipopolysaccharide (LPS) and verocytotoxin (VT-2) in D+ HUS patient 
(patient 1, respectively) 
Superoxide production 
Spontaneous superoxide production as measured by chemilumniscence activity was very low. 
Upon stimulation with PMA, as has been well documented, a peak in chemilumniscence 
activity was observed that was maximal between 5 and 10 minutes after adding the stimulus 
(data not shown). Incubation of the PMN of eight different healthy donors with VT-2 as 
stimulus did not show any difference with the control situation whereas LPS induced a small 
increase in superoxide production as described previously (110) (data not shown). PMN, 
previously incubated with VT-2 0.1 nM, VT-2 10 nM, LPS 1 μΜ alone, or LPS 1 μΜ in 
combination with VT-2 0.1 and 10 nM for 10 min, 1 h, and 4h respectively showed no 
significant difference in superoxide production as compared with control PMN. No significant 
differences in superoxide production was observed in response to PMA in cells previously 
incubated with LPS 1 μΜ alone, or LPS 1 μΜ in combination with VT-2 0.1 and 10 nM, 
compared to control situation (data not shown). 
Activation of PMN 
Degranulation markers: Incubation of PMN with different concentrations VT-2 did not cause 
any changes in the expression of CD66b on PMN (Figure 2A). However, a significant increase 
in the expression of CD66b was found when PMN were incubated with LPS (1 μ&'ηΛ). 
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Figure 2A. Expression of CD66b, a degranulation marker on the surface of PMN. 
LPS caused an upreguiation of the expression of CD66b whereas VT-2 did not have any effect. 
Ρ < 0.05 is considered to be significant (*). 
Figure 2B. Expression of CD63 another degranulation marker on the surface of PMN. LPS caused an 
increase of CD63 expression although this increase was less extensive compared to that of CD66b. 
Again VT-2 did not influence this expression. Ρ < 0.05 is considered to be significant (*). 
67 
Similar results were obtained by incubation with LPS + VT0.1 nM or LPS + VT 10 nM. In 
addition, the expression of CD63 increased significantly after the incubation with LPS alone 
(Figure 2B). Incubation of PMN with LPS and VT together showed a similar pattern to the 
incubation with LPS alone. Again, VT itself had no effect. 
Adhesion-molecules: The expression of CDllb/CD18 complex and L-selectin on PMN were 
studied with FACS analysis to evaluate whether VT, LPS or both could induce changes in 
expression of these adhesion molecules. Figure 4 shows the results of these experiments. As 
described previously, LPS (1 μg/mL) induced the expression of CDl lb/CD18 complex (Figure 
4A) and at the same time reduced the expression of L-selectin compared to non-stimulated 
PMN (Figure 4B). VT was not able to induce any significant changes in this expression. 
Incubation of PMN with LPS and VT together showed a similar expression pattern compared to 
incubation with LPS alone. Apparently, VT had no additional effect. 
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Figure 4A Expression of CDl lb/CD18 complex and L-selectin. CDl lb/CD18 complex is upregulated 
after incubation with LPS. VT did not influence this expression. 
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Figure 4B L-selectin expression decreased after incubation with LPS (Figure 4B) and again VT-2 had 
no effect. Ρ < 0.05 is considered to be significant (*). 
Discussion 
Recent studies indicate that PMN play a critical role in the pathogenesis of HUS by 
transporting VT from the intestine to target organs (113,114). In this study we investigated 
whether LPS is also bound to PMN in D+ HUS patients and determined the role of VT and 
LPS in activation of PMN. All D+ HUS patients investigated were positive for the binding of 
VT to PMN in the acute phase of the disease. 
The presence of LPS has been demonstrated before only in patients with HUS due to 
shigellosis using the Limulus assay (141). The presence of LPS in the circulation of HUS 
patients due to VTEC infection could not be detected using the same assay (142). The presence 
of LPS bound to CD 14 positive cells like PMN and monocytes might explain the negative 
result obtained with this assay. The results of this study show that LPS was bound to PMN in 
seven out of nine D+ HUS patients with proven VTEC infection. This is the first time, as far as 
we know, that LPS in the circulation of D+ HUS patients has been found. Two patients in our 
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study were negative for the presence of LPS bound to PMN although they were both positive 
for the presence of serum antibodies against E. coli 0157. 
An explanation for this may be the transfer of LPS to other cells and plasma 
components or internalization of LPS into PMN (143). Interestingly, only five of the 17 
household members investigated were positive for the presence of LPS bound to PMN. Two of 
the household members positive for the presence of LPS had less than 5% positive cells and in 
a third household member 10 % of PMN were positive for LPS binding. The other two 
household members (of patient 8 respectively) had higher amounts of LPS bound to PMN (25 
and 35%, respectively). However, no antibodies against E. coli 0157 were found suggesting 
that although LPS was present bound to PMN, the amount of LPS present in the circulation was 
not enough to induce an immunological response by producing antibodies. In three household 
members, all three children, antibodies against E. coli 0157 were found. Apparently, enough 
LPS had entered the circulation to induce an immunological response although the presence of 
LPS bound to PMN could not be demonstrated in these three children. In addition, these three 
children did not develop HUS suggesting that not only the amount of LPS attached to the PMN 
but probably also the amount of VT bound to the PMN determines what is happening. 
It has been suggested several times that PMN play a pivotal role in the pathogenesis of 
D+ HUS. The number of PMN on admission is a predictive factor for the outcome of the 
disease (11). In addition, ultrastructural studies on PMN of D+ HUS patients revealed a 
reduction of granules in some patients. Furthermore, elevated levels of al-antytrypsin 
complexed elastase are found at presentation indicating activation of PMN (79,80). The 
mechanism leading to the activation of PMN in HUS is not fully understood. The finding of 
both VT and LPS bound to PMN in D+ HUS patients may be an explanation. For this reason 
we investigated whether VT or LPS or maybe both are capable to activate PMN in vitro. 
Interestingly, only LPS was able to induce the expression of markers for activation on 
PMN namely CD66b and CD63, whereas VT had no effect. Furthermore, LPS reduced the 
expression of L-selectin and at the same time caused an increase of the CDll/CD18-complex 
(= anti-ICAM). Again, VT did not influence the expression levels of either one. Similar 
expression patterns compared to LPS alone were observed when PMN were incubated with 
LPS and VT together. Apparently, VT had no additional effect. In addition, LPS caused a 
slight increase in superoxide production whereas VT had no effect (data not shown). These data 
seem to be in contrast with a report of King et al. who demonstrated that VT could induce 
superoxide production in PMN but did not find any changes in the expression of CD1 lb/CD18 
as a consequence of incubation with VT or LPS (110). However, the induction of CD1 lb/CD18 
on the membrane of PMN after incubation with LPS has been described several times before 
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(144) Furthermore, it has been reported that LPS can induce the expression of CD66b and 
reduces the expression of L-selection (145) as also observed in our study The finding that VT 
alone did not lead to up-regulation of adhesion molecules or induced superoxide production 
suggests that the present of LPS is necessary to activate PMN and not VT Only very small 
amounts of LPS can already lead to activation of PMN Therefore, the superoxide production 
induced by Stxl in the assay of King et al might be caused by the presence of very small 
amounts of LPS although they had pretreated toxin to remove LPS (110) 
Our study demonstrates that the presence of LPS in the circulation is probably an 
essential factor in the development of HUS Only five household members (= 29 %) of the 17 
investigated were positive for the presence of LPS bound to PMN whereas 7 out of 9 (= 78 %) 
HUS patients had LPS bound to PMN In addition, the finding of serum IgM -antibodies 
against LPS in serum of D+ HUS patients and only in a few cases of non-symptomatic VTEC 
infected patients suggests that there might be a difference in amount or distribution of LPS in 
the circulation 
After entering the circulation, approximately 80-90% of LPS will interact with 
lipoproteins in plasma leading to inactivation of LPS Only a minor part of the LPS is cell-
associated (152) However, large amounts of LPS m the circulation will lead to relative more 
LPS bound to CD14 positive cells (130) Monocytes and PMN are the two main targets for LPS 
in the circulation In this study we investigated whether LPS could be detected bound to PMN 
but it has to be considered that LPS can also be present bound to monocytes in the circulation 
Previous studies have shown that monocytes stimulated with LPS can bind VT leading to the 
production of inflammatory mediators The detection of LPS bound to PMN in D+ HUS 
patients indicates that LPS plays a role in HUS and opens therefore possibilities for treatment 
of patients Treatment with recombinant bactencidal/permeabihty-increasing proteins might be 
such a possibility In a randomized, double blind tnal in children with severe meningococcal 
sepsis it has been suggested that this recombinant is beneficial by decreasing the amount of 
complication (154) However, more research is necessary before this can be indeed used in 
patients with HUS 
In conclusion, this study demonstrates for the first time, to our knowledge, the presence 
of LPS bound to PMN in the circulation of D+ HUS patients Furthermore, in vitro experiments 
have shown that not VT but LPS bound to PMN is necessary to activate these cells Previous 
studies have shown that not only the presence of VT determines whether someone develops 
HUS or not Although this study does not provide direct evidence for the role of LPS, we 
suggest that the entry of high amounts of VT together with LPS has a decisive role for the 
development of ftill-blown HUS 
71 
72 
CHAPTER 6 
VEROCYTOTOXIN-1 INFLUENCES BASAL NITRIC OXIDE PRODUCTION OF 
HUMAN GLOMERULAR ENDOTHELIAL AND MESANGIAL CELLS BUT HAS NO 
EFFECT ON BASAL ENDOTHELIN-1 SYNTHESIS 
D. Maroeska W.M. te Loo, Leo A.H. Monnens, Thea J.A.M. van der Velden, Lambertus P.W.J, 
van den Heuvel, Victor W.M. van Hinsbergh 
Submitted 
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ABSTRACT 
Acute renal failure hallmarks the pathogenesis of hemolytic uremic syndrome (D+HUS). 
Endothelial damage of glomeruli and/or arterioles of the kidney play a crucial role in the 
pathogenesis of HUS. Endothelial damage will lead to a disturbance of factors, like endothelin 
(ET-1) and nitric oxide (NO) that normally are secreted to maintain vascular tone and an 
antithrombotic surface. It has been suggested that mesangial cells also play a role in the 
pathogenesis of HUS. Mesangial cells also produce NO but they do not make ET-1. 
In this study, we investigated the influence of VT-1 on nitric oxide production of 
mesangial cells. Furthermore, the influence of VT-1 on NO and ET-1 synthesis of human 
glomerular microvascular endothelial cells (GMVEC) was evaluated. 
NO production of mesangial cells was measured using the classical Griess-method 
(detection limit 3 μπιοΐ/ί) whereas NO production of endothelial cells was measured using a 
highly sensitive technique (detection limit 30 nmol/L). Indirect immunofluorescence, Western-
blot analysis and L-citrulline assay were used to confirm the results found by these methods. 
The effects of VT-1 on ET-1 production of GMVEC were studied using a radio- immunoassay 
for ET detection. In addition, prepro-ET-l transcript levels were analyzed using reverse 
polymerase chain reaction (r-PCR). 
NO synthesis by human mesangial cells is in the micromolar range and that of GMVEC 
in the picomolar range. VT-1 reduced NO production of non-stimulated and TNFa-pretreated 
human mesangial cells and to a lesser extent of non-stimulated GMVEC. A maximal reduction 
of NO production of human mesangial cells was found after an incubation of 10 finol/L VT-1 
whereas a concentration of five nmol/L VT-1 was necessary to find a significant reduction of 
NO production by GMVEC. Interestingly, NO synthesis of GMVEC previously stimulated 
with TNFa decreased as did the expression of endothelial NOS (eNOS). Pretreated GMVEC 
incubated with VT-1 had a NO synthesis that was comparable to controls. Western blot 
analysis and L-citrulline assay of human mesangial cell showed that VT-1 decreased the 
expression of inducible NOS (iNOS) in a dose-dependent manner, confirming the results found 
by the Griess-method. No effects of VT-1 on ET-1 synthesis were observed in non-stimulated 
GMVEC. In addition, no changes were observed on prepre-ET-1 transcript levels. However, 
TNF pretreated GMVEC showed a dose-depended reduction in ET-1 synthesis after incubation 
with VT-1. 
Although we are aware of the limitations of our results found in vitro, we postulate that 
the reduction of NO synthesis caused by VT-1 might play an important role in the acute renal 
failure and thrombotic microangiopathy seen in patients with D+ HUS. 
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INTRODUCTION 
The hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in 
children (2,155) Endothelial damage of glomeruli and/or arterioles of the kidney hallmark the 
pathogenesis of HUS Histopathological studies of the kidney of HUS patients revealed swollen 
and detached endothelial cells and fibnn deposits in the glomerulus (3,82) The epidemic form 
of HUS, in most cases characterized by a prodromal phase of (bloody) diarrhea, is strongly 
associated with an infection by a verocytotoxin (also termed Shiga-hke toxin) producing 
Eschenchiae coli (E coli), especially serotype 0157 H7 (10) In vitro studies performed with 
human umbilical vein endothelial cells and glomerular endothelial cells (GMVEC) have shown 
that verocytotoxin (VT) can bind to globotnaosylceramide (Gb3) found on the surface of these 
cells after stimulation with inflammatory mediators (55,56) After binding, verocytotoxin is 
internalized The active part of the toxin undergoes partial proteolysis and disulfide bond 
reduction in the target cell, generating an active intracellular enzyme This enzyme can cause 
inhibition of overall protein synthesis through the enzymatic inactivation of the elongation 
factor dependent binding of aminoacyl transfer RNA molecules to the 60S nbosomal unit 
leading to cell death (60,61) The binding of VT to human mesangial cells has also been 
described and leads to inhibition of mitogenesis and protem synthesis without affecting cell 
viability (86) It is still unknown whether VT-1 affects endothelm and /or mtnc oxide (NO) 
production in the human kidney 
Endothelm is an important vasoconstrictor Three different isoforms of endothelm have 
been described, endothelm-1, 2 and 3 Endothelm-1 (ET-1) is the only one produced by 
endothelial cells (154) Endothelial cells are able to synthesize the pro-hormone big-endothelm 
and express endothelm-converting enzymes to generate ET-1 This conversion is necessary to 
obtain full vascular activity (155) ET-1 functions pnmanly in an autoenne or paracrine way as 
also mtnc oxide (NO) functions NO was for the first time desenbed as an endothelium denved 
relaxing factor (156) that caused an acetylcholine-dependent relaxation of vascular smooth 
muscle cells Further investigations showed that EDRF-mediated vascular relaxation was 
associated with increased levels of cyclic guanosine monophosphate, resembling the action of 
mtrovasodilators It is now generally accepted that the substance previously called EDRF is 
mtnc oxide (NO) Elevated levels of NO can cause vasodilatation, but also inhibit platelet 
aggregation and adhesion, inhibits activation and adhesion of leukocytes and inhibits 
proliferation of the underlying vascular smooth muscle (157-159) Besides this, NO can react 
with oxide and form peroxymtnte, which in low concentrations will have the same effect as NO 
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but in high concentrations will be cytotoxic. NO is formed by the enzymatic conversion of L-
arginine to L-citrulline by nitric oxide synthases (NOS). At least three different isofonns of 
NOS have been identified so far (160,161), namely neuronal NOS (nNOS or NOS-1), inducible 
NOS (iNOS orNOS-2) and endothelial NOS (eNOS orNOS-3). 
The purpose of this study was to investigate whether VT-1 affects NO and ET-1 
production by glomerular endothelial cells. Furthermore, the effects of VT-1 on NO production 
by human mesangial cells was evaluated knowing that NO counteracts vasoconstriction, 
platelet aggregation and the interaction of leukocytes with the vessel wall (162). We used an 
improved technique for the detection of NO synthesis of human GMVEC and demonstrate that 
VT-1 reduces NO production of but fails to modify ET-1 synthesis. 
MATERIAL & METHODS 
Purified VT-1 was kindly donated by Dr. MA Karmali (Center for Vaccine Development, 
University of Maryland School of Medicine, USA). The endotoxin content of VT-1 preparation 
was less than 0.05 EU/ml by Limulus amebocyte lysate assay. EBM-medium containing hEGF, 
bovine brain extract, hydrocortisone, gentamicin sulfate and amphotericin Β were purchased 
from Bio Whittaker (Walkersville, MD). Radioimmunoassay kit for quantitative determination 
of endothelin levels was from Nichols Institute Diagnostics (Wijchen, The Netherlands). 6-
keto-prostaglandin Fla [125I] was purchased from Amersham (Buckinghamshire, England). 
Sulfanic acid, Ν (l-naphthyl)-ethylenediamine, sodium nitrate, aprotinin from bovine lung, 
Nonidet P-40, sodium orthovanadate, aminoguanidine were purchased from Sigma (St. Louis, 
MO). NG-monomethyl-L-arginine (L-NMMA) was from Calbiochem (La Jolla, CA). Nitrate 
reductase from Aspergillus spp., Flavin-adenin-dinucleotid (FAD), L-lactate dehydrogenase (L-
LDH) from rabbit muscle and nicotinamide adenine dinucleotide phosphate (NADPH) were 
obtained from Roche Diagnostics, (The Netherlands). Polyclonal antibodies against iNOS 
(NOS2) and eNOS (NOS3) were purchased from Santa Cruz Biotechnology (CA). A 
monoclonal antibody against iNOS was obtained from Transduction Laboratories (Lexington). 
Streptavidin conjugated with FITC was from Dako (Denmark). Nitrite/Nitrate fluorimetrie 
assay kit was obtained from Cayman Chemicals (Alexis Corporation, Switzerland). ECL 
Western blotting analysis system was purchased from Amersham, England. L-Citrulline assay 
was performed using the NOSdetect™ assay kit of the Alexis corporation (Switzerland). All 
other reagents used were of analytic grade or described previously (55,56). 
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Human mesangial cells 
Human mesangial cells were cultured in complete medium as described previously (86). 
Briefly, glomeruli from the cortex of normal human kidney tissue were isolated by gradual 
sieving procedure. Glomeruli were plated on gelatin-coated wells and attached in a few days. 
Outgrowth of predominantly epithelial cells and a limited number of endothelial cells were 
noted. Within 10 to 30 days after the glomeruli were seeded, outgrowth of mesangial cells was 
observed. Mesangial cells were selectively collected by scrapping them of the tissue culture 
plate using the tip of a plastic pipette and then expanded on gelatin-coated wells. To purify the 
mesangial cell populations further, an immunomagnetic separation technique was used (86). 
The cultured mesangial cells showed no immunoreactivity to anti-PECAM-1 antibody or the 
anti-cytokeratin 8 antibody excluding the presence of endothelial or epithelial cells. Cultured 
human mesangial cells were used between passages 5 and 10. 
Human glomerular microvascular endothelial cells 
The isolation and purification of glomerular microvascular endothelial cells (GMVEC) was 
performed as described previously (56). Cells were cultured in complete medium (containing 
M199, 10% human serum, 10% newborn calf serum, 100 IU/ mL penicillin/0.1 mg/mL 
streptomycin, 2 mmol/L L-glutamine, 5 U/mL heparin and 150 pg/mL crude preparation of 
endothelial cell growth factor). The purity of GMVEC cultures was assessed using 
morphological and immunological criteria. Indirect immunofluorescence revealed the presence 
of von Willebrand factor and other endothelial cell specific antigens (56). No positive staining 
was observed with anticytokeratin 8 or the α-smooth-muscle actin monoclonal antibodies 
excluding contamination of the GMVEC with epithelial- and mesangial cells, respectively. 
GMVEC were used between passages 6 and 10. 
Indirect immunofluorescence studies ofeNOS and iNOS 
Indirect immunofluorescence studies were performed to demonstrate the presence of eNOS in 
GMVEC and iNOS in human mesangial cells. Cells were cultured on glass cover slips until 
they had reached confluence. GMVEC and mesangial cells were incubated with VT-1, TNFa 
or both, and compared to cells that were cultured in medium. Cells were fixed using 80% 
acetone for ten minutes at room temperature. Subsequently, cells were washed three times with 
phosphate buffer saline (PBS) and incubated in PBS containing 10% fetal calf serum for twenty 
minutes to suppress non-specific binding of IgG. GMVEC and mesangial cells were washed 
again three times with PBS followed by incubation for 60 minutes with a polyclonal antibody 
against eNOS and iNOS (1:1000), respectively. Subsequently, cells were washed and incubated 
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for 45 minutes with biotin conjugated anti-goat IgG antibody, followed by incubation with 
streptavidin conjugated with FITC. Cells were washed extensively with PBS and the presence 
of eNOS or iNOS was studied using a Zeiss microscope (Aksioscope) with standard equipment. 
As control a-actin was used, a housekeeping protein to exclude the possibility that effects 
observed was due to protein synthesis inhibition. 
Western blot analysis for eNOS and iNOS 
GMVEC and human mesangial cells were cultured in six-well plates. Five days after reaching 
confluence, non-stimulated and TNFa (10ng/mL)-prestimulated cells were incubated with 
various concentrations of VT-1 for 24 hours. After the incubation, cells were washed with PBS. 
Subsequently, RIPA-buffer, containing PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 
0.1% SDS, 10 mg/mL PMSF, aprotinin and lOOmM sodium orthovanadate, was added to the 
cells and the cells were detached from the cell culture plates using a scraper. Cells were passed 
through a 21-gauge needle and transferred to microcentrifuge tubes. 10 μΐ of 10 mg/mL PMSF 
stock solution was added to the lysate followed by incubation for 60 minutes on ice. 
Subsequently, the cell lysates were centrifuged at 15000-x g for 20 minutes at 4° C. The 
supernatant fluid was used to perform Western blot analysis. Equal amounts of lysate proteins 
were separated by 5% SDS-PAGE and subsequently transferred to a nitrocellulose membrane. 
The blots were incubated with either a polyclonal antibody against eNOS or a monoclonal 
antibody against iNOS and washed afterwards. Immunoreactive bands were visualized using 
enhanced chemilumniscence. The amount of actin presence in the extracts was determined with 
a-actin to exclude the possibility that changes in eNOS or iNOS expression was a consequence 
of changes in protein synthesis activity. 
To quantify the relative amount of eNOS antigen, the spots were scanned and the 
product of intensity and surface area was determined. Serial dilutions of an eNOS-containing 
preparation were used to make a calibration curve. Only spots from the same blot were 
compared. 
Measuring NO production by human mesangial cells 
NO production of human mesangial cells was measured using the Griess method (163). 
Mesangial cells were cultured in 24-wells to perform experiments. Complete medium, in which 
cells were cultured until they reached confluence, was replaced by EBM-medium, lacking 
phenol red and fetal bovine serum. Non-stimulated and TNFa-pretreated (24 h; 10 ng/mL) 
mesangial cells were incubated with VT-1 in concentrations ranging between 10 frnol/L till 10 
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nmol/L for 24 hours at 370C. Subsequently, culture medium (total 250 μι) was collected and 
incubated with nitrate reductase from Aspergillus spp. in combination with NADPH and FAD 
for 30 minutes at 370C to convert nitrate to nitrite. By adding 2 μ ι lactate dehydrogenase (final 
concentration 10 μg/reaction) and 8 μ ι of pyruvate dehydrogenase (final concentration 10 
mmol/L) the reaction was stopped. Subsequently, 100 \\L of the samples and of standard 
mixtures of nitrate and nitrite were mixed with an equal volume of Griess-reagents (0.01% 
sulfanilamide, 0.01% N- (1-naphthyl) ethylenediamine, 2.5% phosphoric acid) (163). 
Absorbency was measured in an ELISA plate reader at 540 nm and final NO-concentration was 
determined from standard nitrite/nitrate curves. Aminoguanidine (AMG), an irreversible 
inhibitor of iNOS, and L-NMMA were used to determine specificity of NO-measurements by 
the Griess-method. 
L-citrulline assay 
The enzymatic conversion of L-arginine to L-citrulline in cultured human mesangial cells was 
determined using a commercial NOSdetect™ assay kit. Briefly, human mesangial cells were 
cultured on six-well gelatin-coated plates. Mesangial cells were exposed either to VT-1 (0.1 
nmol/L) or to TNFcc (10 ng/mL) alone or previously stimulated with TNFa followed by 
incubation with VT-1 (0.1 nmol/L) for 24 hours at 370C. Subsequently, cells were washed with 
PBS and harvested with PBS/1 mmol/L EDTA followed by centrifiigation in a microcentrifuge 
at full speed for 2 minutes. Supernatant of the cells was removed and the pellet was 
resuspended in homogenization buffer (250mmol/L Tris-HCl, pH 7.4, 10 mmol/L EDTA, 10 
mmol/L ethyleneglycol-bis (ß-aminoethylether)-N, Ν, Ν', N'-tetra-acetic acid (EGTA)) and 
centrifiiged again for 5 minutes at filli speed in a microcentrifuge. The supernatant was 
separated from the homogenate and the resulting protein sample was adjusted to a 
concentration of 5 μg/μL. Subsequently, 10 μ ι of each sample was incubated with a reaction 
mixture (50 mmol/L Tris-HCl, pH 7.4, 6 μιηοΐ/ί tetrahydrobiopterin, 2 μιηοΐ/ί FAD, 
10 mol/L NADPH, arginine (1 μΟί/μί, H2O) for 10 minutes on room temperature. The reaction 
was stopped by adding 50 mmol/L N-2-hydroxyethylpiperazin-N'-2-ethanesulfonic acid 
(HEPES), pH 5.5 and 5 mmol/L EDTA. One hundred μΐ. of resin was added to each sample 
and the samples were transferred to spin cups. Spin cups were placed into cup holders and 
centrifuged at full speed for 30 seconds. The eluate was transferred to scintillation vials and 
radioactivity was measured. As a positive control for the reaction rat cerebellum extract was 
used. 
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Measuring NO production by GMVEC 
NO production by GMVEC was determined by measuring the NO2- using a highly sensitive 
nitrate/nitrite fluorimetrie assay kit (Caymann). Briefly, cells were cultured in 24-wells using 
complete medium. Five days after reaching confluence cells were used for experiments and 
complete medium was replaced by EBM medium lacking fetal bovine serum and phenol red to 
exclude the possibility of interfering in the measurement of NO production. Non-stimulated 
and TNFa-pretreated (24 h; 10 ng/mL) GMVEC were exposed to VT-1 in a concentration of 
one pmol/L - 5 nmol/L for 24 hours. An improved technique, a nitrate/nitrite fluorimetrie assay, 
kit was used to detect NO production. In this assay nitrate is first converted to nitrite by nitrate 
reductase as also in the Griess-method (163). However, this assay differs from the Griess 
method in that 2,3-diaminonaphtalene is added followed by incubation with NaOH, which 
converts nitrite into a fluorescent compound (l(H)-naphthotriazole). Measurement of this 
component at an excitation wavelength of 365 nm and an emission of 450 nm in a fluorometer 
was used to determine NO2 formation in culture medium. Using this assay NO2 concentrations 
as low as 30 nmol/L could be detected which is not possible using the conventional Griess 
method. To substantiate that NO-measurements were specific, similar experiments were 
performed using L-NMMA, a reversible inhibitor of the NO production. 
Determination of Endothelin-1 production 
Non-stimulated and TNFa-pretreated (24 h: 10 ng/mL) GMVEC were exposed to VT-1 in a 
concentration of 0.1 nmol/L - 10 nmol/L for 24 hours or to PMNs (1 xlO6cells) loaded with VT 
10 nmol/L and PMNs (1 xlO6 cells) alone. After exposure, supernatant was removed and used 
to determine the amount of endothelin-l produced by the cells. Samples were acidified and 
extracted on CI8 columns (Nichols Institute Diagnostics) for endothelin-l determination. After 
extraction, samples were dried using nitrogen gas at 370C. After 45 minutes, 0.5 mL 100% 
ethanol was added, and drying was continued until the smell of acetic acid had disappeared. 
Subsequently, extracts were resuspended in 0.5 mL assay buffer (lyophilized borate buffer, pH 
8.4). Subsequently, each sample was incubated in duplicate with 100 μ ι 125I-Endothelin and 
100 μ ι anti-endothelin for 18 h at 40C. After the incubation period, anti-rabbit (donkey) coated 
cellulose was added and mixed thoroughly. After 30 minutes, 1 mL deionized water was added 
and samples were centrifuged for 15 minutes at 2000-x g. Supernatant was removed and 
radioactivity was determined in a gamma scintillation counter for each sample. Endothelin 
standard curves were prepared at the same time of the assay and made it possible to determine 
the exact amount of endothelin present in each sample. Interassay variation of this assay is 
6.8%. 
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Quantification ofmRNA levels ofprepro-Endothelin-1 
GMVEC were cultured in six well plates until they reached confluence. Non-stimulated and 
TNFa-pretreated GMVEC were exposed to VT-1 in a concentration of 0.1 nmol/L - 5 nmol/L 
for 24 hours. Subsequently, total RNA was extracted after the incubation period followed by 
reverse transcriptase reaction (RT) to form cDNA. RT reaction was performed with 200 U 
Superscript II reverse transcriptase and random hexamer primers for 1 h at 42° C. Amplification 
of cDNA was performed by polymerase chain reaction (PCR) with specific primers for 
preproEndothelin-l (155). 
Forward primer preproEndothelin-l TCTACTTCTGCCACCTGGACAT and reverse primer 
CTCGGTTGTGGGTCACATAA (Genebank accession no Y00749). The PCR program 
consisted of 38 cycli of 60 seconds 950C, 610C and 720C. The cycles were preceded by an 
initial denaturation step at 95° C and were followed by a final extension at 72<>C. The PCR 
products were visualized by ultraviolet light on a 1.5% (w/v) agarose gel electrophoresis and 
ethidium bromide staining. The quantity for mRNA spotted for each sample was normalized 
using the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT). 
Inhibition of protein synthesis 
To investigate whether changes in NO and ET-1 generation were a consequence of inhibition of 
overall protein synthesis, protein synthesis of GMVEC and mesangial cells was determined by 
assaying the incorporation of 3H-leucine in newly synthesized proteins as described previously 
(56). 
Statistics 
All data represented are expressed as mean plus SEM. Significance of increase or decrease of 
NO production compared to controls was analyzed using Wilcoxen signed rank test. The 
statistical level of significance was defined as Ρ < 0.05. 
Results 
eNOS and iNOS in endothelial and mesangial cells 
To investigate the presence of eNOS and iNOS in GMVEC and human mesangial cells 
immunofluorescence studies were performed. Expression of eNOS antigen was consistently 
found in GMVEC (Figure 1A). There was no cross-reactivity with the antibody against iNOS. 
Expression of iNOS antigen was detectable in mesangial cells (Figure IB). It was present in 
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non-stimulated cells (Fig. IB) and increased after stimulation with TNFa (see below). eNOS 
antigen was not detected in human mesangial cells. 
NO production by human mesangial cells 
Nitric oxide production of human mesangial cells was measured by the Griess method (163). 
The aminoguanidine- inhibitable NO production, reflecting iNOS-derived NO, was six umol/L 
on the average (Figure 2A). In addition, Griess reactivity equivalent to five umol/L NO was 
found, which could not be inhibited by aminoguanidine and may reflect a non-NO-related 
reactivity. After a 24 h incubation of the cells with various concentrations of VT-1, a 
significant reduction of NO production was observed in non-stimulated mesangial cells (Figure 
2A). A similar reduction was obtained by aminoguanidine indicating that the VT-1 
reduced iNOS-dependent NO production. A maximal inhibition of NO production was already 
obtained at a concentration of 10 ftnol/L VT-1. When mesangial cells were pre-stimulated by 
TNFa (10 ng/ml), NO production increased (Figure 2C), which was completely due to an 
increase in aminoguanidine-inhibitable NO (iNOS). 
Incubation of TNFa-pretreated cells with VT-1 caused a dose-dependent decrease of NO 
production, which was significant at 10 fmol/L and maximal at one pmol/L. The high 
sensitivity of iNOS-depedent NO production was unexpected, because the amount of VT 
needed to inhibit protein synthesis was several orders of magnitude higher, both under basal 
and TNFa-stimulated cells (Figure 2B,D). Similar results were obtained when the reversible 
inhibitor L-NMMA (7 μιηοΐ/ί) was used instead of aminoguanidine. The results obtained by 
the Griess-method were confirmed by measuring the enzymatic conversion of L-arginine to L-
citrulline. A decrease of 78% of iNOS activity was found after the addition of VT-1 (0.1 
nmol/L) to non-stimulated mesangial cells, while in TNFa-treated mesangial cells the 
reduction was even more than 95%. 
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Figure 1 Indirect immunofluorescence of eNOS in GMVEC (A) and iNOS in human mesangial cells 
(B). No staining was observed when iNOS and eNOS were used as first antibody on endothelial cells 
and mesangial cells, respectively. Magnification used χ 350. 
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Figure 2: NO-production of human mesangial cells of four different donors. Non-stimulated mesangial 
cells were incubated with VT-1 in different concentrations ranging from 10 fmol/L to 10 nmol/L. A 
concentration VT-1 10 fmol/L was sufficient to induce maximal reduction of NO production and was 
similar as the reduction seen in cells incubated with aminoguanidine (AMG). Cells incubated with VT-1 
and aminoguanidine together showed a similar reduction as AMG or VT-1 alone (A). Protein synthesis 
was not inhibited (B). C: Mesangial cells previously stimulated with TNFa 10 ng/mL showed an 
increased NO production compared to basal NO production. Incubation of pretreated mesangial cells 
with VT-1 showed a dose-dependent reduction of NO production (•) to a level obtained with 
aminoguanidine (A). D: Protein synthesis of mesangial cells was not inhibited after an incubation with 
VT-1 in the range of 10 finol- lpmol/L. Statistical significance was calculated using unpaired Student's 
t-test. Values below 0.05 were regarded to be significant ( * P<0.05 and ** P< 0.001). 
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Effect of VT-1 on iNOS antigen levels of human mesangial cells 
To investigate whether the effect of VT-1 on iNOS activity was due to a reduced expression of 
iNOS protein or inactivation of iNOS, the cellular protein content was assayed. Western blot 
analysis of mesangial cells showed a characteristic band of 130 kD for iNOS. (Figure 3 A). No 
reactivity with an antibody for eNOS was observed in the mesangial cell extracts (data not 
shown). The expression of iNOS antigen increased after stimulation with TNF but showed a 
strong reduction when mesangial cells were subsequently incubated with VT-1 (Figure 3B+C). 
A Β C 
Figure 3 western blot analyses of iNOS in mesangial cells. A. Basal iNOS expression in mesangial 
cells. B. TNFa (10ng/mL) caused an induction of iNOS. C. When TNFa pretreated cells were 
incubated with VT-1 (0.1 nmol/L) a strong reduced expression of iNOS was observed. 
NO production by human GMVEC 
Nitric oxide production by human GMVEC is in the picomolar to nanomolar range and was 
determined using a highly sensitive nitrite/nitrate fluorimetrie assay kit (detection limit 30 
nmol/L). Incubation of non-stimulated GMVEC with VT-1 for 24 hours caused a 
concentration-dependent decrease in NO production (Figure 4A). Protein synthesis was not 
inhibited after 24 h incubation of non-stimulated GMVEC with VT-1 at different 
concentrations (Figure 4B). In highly confluent GMVEC inhibition of protein synthesis by VT 
was only seen in TNFa-stimulated cells (Figure 4D), which is due to the fact that pre­
incubation with TNFa increases the number of VT-receptors in GMVEC and enhances their 
sensitivity for VT-1 (Figure 4D)(43). While TNFa (10ng/mL) by itself reduced NO production 
over a 24 h period by 40% (Fig. 4A,C), incubation of TNFa-pretreated GMVEC with VT-1 
increased NO production to the level of control cells (Figure 4C). This finding was consistently 
found in four different preparations of human mesangial cells obtained from five different 
donors. The restoration of NO production of TNFa-pretreated cells to control levels 
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Figure 4: The influence of VT-1 on NO production of human GMVEC was measured in cells 
of five different donors. A. Non-stimulated GMVEC were incubated with VT-1. A significant 
decrease of NO production was observed when VT-1 was added at a concentration of 5 nmol/L, 
whereas the decrease in NO production caused by VT-1 0.1 nmol/L and 1 pmol/L was not 
significant (P= 0,06 and P= 0,05, respectively). B. No inhibition of protein synthesis was 
measured at the same time. C. TNFct-pretreated GMVEC showed a decrease in NO production. 
However, TNFa pretreated GMVEC incubated with VT-1 showed an increase of NO-
production to control levels of non-stimulated cells. D. At the same time, VT-1 caused a dose-
dependent inhibition of protein synthesis. * P< 0.05 
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by the subsequent incubation with VT-1 occurred despite the fact that the protein synthesis was 
reduced (Fig. 4C,D). The presence of L-NMMA (0.7 μηιοΐ/ΐ.) in the culture medium 
caused a reduction of 30 % ± 6% (= SEM) in NO production in non-stimulated GMVEC and 
38%± 10% (= SEM) in TNFa-pretreated GMVEC indicating that NO production was indeed 
eNOS-dependent. 
Effect of VT-1 on eNOS levels of human GMVEC 
Western blot analysis performed with human GMVEC showed a specific band of 130 kD for 
eNOS (Figure 5A). No band was detected when GMVEC were incubated with a monoclonal 
antibody against iNOS. The expression of eNOS was not visibly affected after incubation with 
VT-1 (Figure 5B). Incubation with TNFa (10 ng/mL) for 24 hours caused a reduced expression 
of eNOS of about 50% (Figure 5C). Subsequently, if TNFa pretreated cells were incubated 
with VT-1 expression of eNOS was similar to control cells (Figure 5D). 
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Figure 5 Western blot analysis of eNOS in human GMVEC of a representative donor. 
A. Basal expression of eNOS in GMVEC. B. Non-stimulated GMVEC incubated with VT-1 (5 nmol/L). 
C. TNFa-pretreated GMVEC. D. TNFa- pretreated GMVEC incubated with VT-1 (5 nmol/L). 
ET-1 production of human GMVEC 
Incubation of non-stimulated GMVEC with VT-1 for 24 hours had no effect on ET-1 
production by non-stimulated human GMVEC (Figure 6A). However, in TNFa-pretreated 
GMVEC a dose-dependent inhibition of ET-1 synthesis caused by VT-1 was observed (Figure 
6B). Quantification of mRNA levels of prepro-Endothelin-1, the precursor of ET-1, showed no 
significant changes in mRNA levels in non-stimulated GMVEC because of VT-1 
incubation (data not shown). VT-1 5 nM caused a slight reduction in mRNA expression of 
prepro-ET-1 in TNFa-prestimulated GMVEC (data not shown). Therefore, it is likely that the 
reduction of ET-1 synthesis observed is a consequence of protein synthesis inhibition. 
87 
2000 
control VT 0.1 VT 10 
2000 
TNF TNF+VT0.1 TNF+VT10 
Figure 6. The influence of VT-1 on endothelin-1 production by non-stimulated GMVEC (A) and 
TNFa pretreated GMVEC (B). VT-1 had no effect on ET-1 production of non-stimulated cells. 
However, VT-1 reduced ET-1 synthesis significantly in TNFa pretreated cells. 
DISCUSSION 
In this study, we determined the effect of VT-1 on NO and ET-1 production by GMVEC and 
determined the role of VT-1 on NO production by human mesangial cells. The major finding 
was the ability of VT-1 to reduce in vitro basal NO production of human mesangial cells and 
to a lesser extent of GMVEC. The reduction of NO production by VT-1 found in human 
mesangial cells is in the micromolar range and that of GMVEC, in the nanomolar range. 
Besides this, a concentration of 10 fmol/L was sufficient to cause maximal reduction of non-
stimulated mesangial cells whereas only a concentration of 5 nmol/L caused a significant 
reduction in NO synthesis by human GMVEC. For this reason, we postulate that the decrease 
of NO production of human mesangial cells, caused by VT-1, has more impact than the 
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decrease observed in basal NO-formation of GMVEC. TNFa pretreated GMVEC showed an 
increase of NO production after incubation with VT-1 in different concentrations despite an 
inhibition of protein synthesis. VT-1 caused in TNFa pretreated mesangial cells a decrease in 
NO synthesis comparable to the inhibition of aminoguanidine. VT-1 had no effect on ET-1 
production or on prepre-ET-l mRNA levels of non-stimulated GMVEC and caused a dose-
dependent decrease of ET-1 production in TNFa- pretreated GMVEC. 
Histopathological studies performed on autopsy material of the kidney of patients with 
D+HUS have shown that there is an increased influx of leukocytes and monocytes compared to 
controls (84). The reduction of NO synthesis as observed in vitro might contribute to increased 
presence of platelets and leukocytes as observed in vivo (162,16,165). Besides, mesangial cells 
are a major determinant in the regulation of glomerular filtration (90). The inhibition of NO 
synthesis by VT-1 might therefore be one of the factors contributing to the acute renal failure as 
seen in HUS. 
The possibility that a VT-1 induced reduction of NO production by human mesangial is 
also partly dependent on inhibition of protein synthesis caused by VT cannot be completely 
excluded. However, protein synthesis of mesangial cells was not inhibited after incubation with 
VT-1 in the range of 10 fmol/L - 1 pmol/L, but at the same time a maximal reduction of NO 
production was found, comparable to the inhibition of aminoguanidine. This, in combination 
with the results found on non-stimulated GMVEC is suggestive for the conclusion that the 
influence of VT-1 on protein synthesis and NO formation are two at least partly independent 
processes. 
Basal NO production of endothelial cells is normally in the range of picomolar or 
nanomolar and is therefore not detectable in medium originating from GMVEC culture using 
the Griess method. Therefore, a highly sensitive nitrite/nitrate fluorimetrie assay, a 100-fold 
more sensitive than the Griess method, was used. Surprisingly, VT-1 caused a decrease of basal 
NO production in non-stimulated GMVEC without affecting protein synthesis suggesting that 
VT-1 can activate endothelial cells directly. TNFa- pretreated GMVEC also showed a decrease 
of NO synthesis. This is partly explained by a decrease in eNOS antigen (as demonstrated by 
Western blot analysis). An explanation might be that TNFa induces the synthesis of an enzyme 
that inhibits the production or capacity of eNOS and in this way reduces NO production. 
Interestingly, incubation of the cells with TNFa and VT-1 simultaneously caused a NO 
production that is comparable to control cells. Incubation with VT-1 can cause an inhibition of 
protein synthesis and might inhibit the production of this enzyme that leads to a normal 
capacity of eNOS and normal NO production again. 
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Incubation of TNFa pretreated GMVEC with VT-1 caused a dose-dependent inhibition 
in ET-1 production whereas VT-1 had no effect on ET-1 synthesis in non-stimulated cells. The 
finding that VT-1 failed to modify the amount of ET-1 produced in non-stimulated cells 
indicates that ET-1 produced by GMVEC probably not has a role in the development of renal 
failure observed in HUS. Previous investigation performed by Bitzan and colleagues showed 
that VT was able to induce the expression of preproET-1 mRNA in quiescent bovine aorta 
endothelial cells without having an effect on protein synthesis (166). Their results and the 
results we found on GMVEC implicate that activation of endothelial cells by VT, without the 
presence of inflammatory mediators, may have an important role in the pathogenesis of HUS. 
However, in our study no changes in the expression of prepro-ET-l mRNA in non-stimulated 
GMVEC were found. Bitzan and colleagues also investigated the influence of verocytotoxin on 
nitric oxide production in bovine aorta endothelial cells but did not observe any significant 
changes (166). However, it cannot be excluded that bovine aorta endothelial cells react 
differently after exposure to VT as compared to GMVEC. 
In patients with recurrent thrombotic microangiopathy, a disease with similar clinical 
features compared to HUS, it has been suggested that increased NO formation can be a 
mediator of injury of the endothelium (167). Serum of patients with thrombotic 
microangiopathy induced NO synthesis in cultured endothelial cells more than serum of healthy 
individuals. Moreover, the formation of large amounts of NO has been implicated in cell and 
organ damage as observed in patients with endotoxemic shock (168,169). On the other hand, 
NO measurements performed in the urine of a child with D+ HUS in course of the disease 
showed an increased excretion of NO metabolites where at the same time an improvement of 
renal function was observed (170). They suggested that NO production was decreased in the 
beginning of the disease and that therapy with NO analogs might have beneficial effects. A 
similar suggestion was made by Jaradat et al. (171). He proposed that L-arginine should be 
given to patients with the epidemic form of HUS and to patients with thrombotic 
thrombocytopenic purpera in high amounts through parental nutrition. L-arginine would 
generate high amounts of nitric oxide, leading to a decrease of platelet aggregation and an 
increase of vasodilatation. Based on our in vitro data we suggest that this might be a good 
approach in the treatment of patients with epidemic HUS although we believe that experiments 
with an animal model of HUS have to substantiate this hypothesis. 
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Figure 6. Schematic representation of the juxtaglomerular apparatus. A= afferent arteriole E=efferent 
artende MD= macula densa G= glomerulus. iNOS is expressed in mesangial cells. NO produced by 
these cells can directly act on the arterioles. Because of the presence of haem and oxide in the 
circulation NO produced in the mesangial cells will not reach completely the peripheral capillaries of 
the glomerulus. Local NO production by eNOS in de glomerular endothelial cells prevents adhesion of 
leukocytes and platelets. nNOS is formed in the macula densa and modulate the renin secretion in the 
juxtaglomerular apparatus. It may also effect the renal secretion (175). 
Previous investigations performed by our group have shown that activated monocytes 
are able to produce inflammatory cytokines such as TNFa after binding VT-1 (76). TNFa can 
lead to upregulation of Gb3, the classical receptor of VT (55,56). Subsequently, VT can bind to 
this receptor followed by internalization of the toxin causing inhibition of protein synthesis and 
serious damage of the endothelium. By damaging the glomerular endothelium, circulating 
nucleotides and vasoconstrictors as well as VT may gain access to the mesangial cells and 
promote vasoconstriction of the afferent arterioles of the glomerulus (see Figure 7). 
Vasoconstriction will lead to increased presence of leukocytes and platelets and a decreased 
renal blood flow (175). Interestingly, the kidney is the only organ in the human body that 
contains mesangial cells and therefore may be the only organ that will show vasoconstriction 
because of VT action. This might partly explain why the kidney is the main organ involved in 
the pathogenesis of HUS. Besides this, it has been reported that the developing renal 
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vasculature responds to stimulation and inhibition of NO synthesis in a different way from the 
adult renal vasculature (173). Solhaug et al. showed that in the 3-week-old developing piglet 
infusion with 3 μg/kg L-NAME caused a 3-times higher decrease of renal blood flow than 
compared to the adult (174). We hypothesize that VT might cause a stronger inhibition of NO 
synthesis in children than in adults. This, in combination with the fact that arterioles in 
childhood are smaller than in adulthood might partially explain why children develop HUS. 
However, it is also possible that activated monocytes will reach the glomerular 
endothelial cells after the endothelial monolayer has already been damaged. TNFa then might 
have beneficial effects by stimulating iNOS in mesangial cells leading to enhanced NO 
production and inhibition of platelet aggregation. Furthermore, the presence of TNFa and VT 
at the same time causes a reduction in ET-1 production by human GMVEC in vitro. More 
experiments will be needed to leam more about the influence of NO and ET-1 in HUS. 
In conclusion, we observed a strong reduction in vitro of basal NO production in human 
mesangial cells and to a lesser extent of GMVEC because of incubation with VT-1. No effect 
of VT-1 on ET-1 synthesis in non-stimulated cells was observed. Although we are aware of the 
restriction of our results found in vitro, we postulate that a reduction of NO synthesis, and not 
changes in ET-1 production, caused by VT might play an important role in the acute renal 
failure and thrombotic microangiopathy seen in patients with D+ HUS. 
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CHAPTER 7 
RELEVANCE OF POLYMORPHISMS IN THE TUMOR NECROSIS FACTOR α AND 
PLASMINOGEN ACTIVATOR INHIBITOR-1 GENES IN THE HEMOLYTIC 
UREMIC SYNDROME. 
D. Maroeska W.M. te Loo, Marije M. Löwik, Leo A.H. Monnens, Thea J.A.M. van der Velden, 
Victor W.M. van Hinsbergh, Lambertus P.W.J, van den Heuvel 
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ABSTRACT 
The hemolytic uremic syndrome (HUS) is charactenzed by a tnad of symptoms namely 
hemolytic anemia, thrombocytopenia and acute renal failure Hereditary factors may determine 
the occurrence and/or seventy of the disease In this study PAI-I and TNFa levels were 
measured in former HUS patients and compared to healthy controls Besides this, the 4G/5G 
polymorphism m the PAI-I gene and two polymorphisms in the TNFa gene at position -
308(G/A) and -863(C/A) were evaluated and compared to non-symptomatic VTEC infected 
patients and controls 
Levels of PAI-I and TNFa were in the normal range in both former HUS patients and in 
controls Interestingly however, levels of PAI-I in HUS patients, that recovered several years 
ago of the disease, were significantly higher compared to age-matched healthy controls 
(P<0 05) For this reason we investigated the 4G/5G polymorphism in the PAI-I gene, which is 
associated with higher PAI-I levels, in HUS patients, patients with non-symptomatic VTEC 
infection, and healthy controls No significant difference in frequency of this polymorphism 
was found in patients versus healthy controls and between non-symptomatic VTEC infected 
patients and healthy controls However, the frequency of the 4G/5G polymorphism was 
significantly higher in non-symptomatic VTEC infected patients than in D+ HUS patients 
suggesting that this polymorphism has not directly a role in the development of HUS In 
addition, no relationship was found between the presence of the 4G/5G polymorphism and 
seventy of the disease according the classification of Gianantomo Also the polymorphism in 
the TNFa gene at position -863 (C/A) and at position -308(G/A) were not associated with the 
seventy of the disease according the classification of Gianantomo although a relationship 
between serum creatinine and the polymorphism at position -863 was found These results 
indicate that the 4G/5G polymorphism in the PAI-I gene and the two polymorphisms in the 
TNF gene probably do not have a role in the pathogenesis of HUS 
INTRODUCTION 
The hemolytic uremic syndrome is one of the leading causes of acute renal failure m childhood 
and is mostly caused by an infection with a verocytotoxin (= Shiga toxin) producing 
Escherichae coll (VTEC), especially serotype 0157 H7 (4,118,120) Endothelial damage of 
glomeruli and in lesser extent kidney artenoles caused by the interaction of verocytotoxin (VT) 
with its classical receptor (globotnaosylceramide or Gb3) is believed to play a central role in 
the pathogenesis of D+ HUS (10,53) Histopathological studies of kidney matenal of HUS 
patients reveal a charactenstic thrombotic microangiopathy with swollen and detached 
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monoclonal antibody against splicing factor (Sigma) used at a dilution of 1/200 and visualized 
by a goat anti-mouse alkaline phosphatase antibody. Fast blue was used as a chromogen. 
RESULTS 
Renal biopsy material of seven HUS-patients seemed to show a significant amount of apoptotic 
cells (about 30%) after staining with TUNEL-technique alone (figure 1A). However, staining 
with RNA splicing factor showed that most of the cells positive with the TUNEL technique 
were also positive for RNA splicing activity, indicating that these cells were not in the 
execution phase of the apoptotic process. (Figure IB). Number of apoptotic cells was counted 
in five different glomeruli and surrounding tubuli in each patient and total number of apoptotic 
cells are shown in table 2. Co-labeling showed that just 2.5% of the cells (1.5 % located in 
tubules) stained with the TUNEL technique were indeed apoptotic (Figure 1C-F) . However, 
even after co-labeling the sections (TUNEL and SC-35), renal biopsy material of HUS patients 
showed a significant increase (Wilcoxen test: ρ < 0.05) in apoptotic cells in glomeruli and 
tubuli compared to controls (Table 2). Interestingly, the amount of apoptotic cells detected in 
tubuli of HUS patients was significantly higher (30% of total apoptotic cells) than those 
detected in the glomeruli. 
Furthermore, a much stronger positive staining for RNA splicing factor in the tubular epithelial 
cells was found in patients with HUS compared to controls (Figure 1) indicating that there was 
a higher transcription activity in HUS patients. Clinical characteristics of patients are shown in 
table 1. All patients had a prodromal phase of (bloody) diarrhea. Interestingly, those patients 
that were treated with dialysis (pts 3-6) had more apoptotic cells than patients that received no 
dialysis suggesting that there might be a relationship between severity of the disease and 
amount of apoptotic cells detected. Finding of apoptotic cells suggest that apoptosis plays a role 
in the pathogenesis of HUS. 
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Table 2 Number of apoptotic cells detected in five different glomeruli and surrounding tubuli in each 
biopsy of HUS-patients and controls. 
Patient no. 
6 
7 
MLS 
MLS 
TBM 
TBM 
TBM 
TBM 
TBM 
glomeruli (5) 
0 
1 
1 
2 
2 
0 
Ü 
0 
0 
0 
0 
« 
0 
0 
tubuli 
3 
0 
7 
4 
6 
7 
1 
0 
0 
Ü 
0 
0 
1 
0 
total: 
3 
1 
S 
6 
S 
7 
1 
0 
0 
0 
0 
0 
1 
0 
For statistical analysis Wilcoxen test was used. There was a significant increase of apoptotic cells in 
patients with HUS compared to controls (p< 0.05). 80% of apoptotic cells observed in HUS-patients 
were localized in the tubuli and only 20% in glomeruli. MLS, minimal lesions nephrotic syndrome; 
TBM, thin basement membrane. 
DISCUSSION 
In this study we used an improved and stringent TUNEL technique to detect apoptotic cells in 
renal biopsies. We investigated renal biopsy material of seven D+ HUS-patients and found an 
increased number of apoptotic cells in glomeruli and tubuli compared to control patients with 
minimal lesions nephrotic syndrome or thin basement syndrome. Endothelial damage of 
primarily glomeruli is a characteristic feature of HUS. Although a lot of the pathogenesis of 
HUS is still unclear, it has been postulated that VT plays an important role in the damage of 
endothelial cells of glomeruli and to a lesser extent renal arterioles (2,18). In several studies a 
role of verocytotoxin in inducing apoptosis has been suggested (19,20). 
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Figure 1: Detection of apoptosis in renal biopsies in IH HUS patients versus controls. 
A) Labeling with TTJNEL technique and SC-35. Nuclei that show high levels of RNA synthesis/splicing 
are stained in blue which will mask the non-specific (brown) signal of the TUNEL technique. Only one 
cell is really apoptotic (indicated with an arrow). B) The same section of figure A is shown, however the 
matenal was washed out and labeled again with SC-35 alone (brown this time): A tubulus and a part of 
a glomerulus are shown. Numerous nuclei of the tubulus and the glomerulus are labeled (brown-labeled 
nuclei). The cell positive for apoptosis in figure A after staining with the TUNEL technique and labeling 
with SC-35, shows in figure Β no positive staining at all indicating that this cell has no RNA 
synthesis/splicing activity and is really apoptotic. All the other cells have high RNA synthesis/splicing 
activity and are therefore not apoptotic. C) Double labeling of TUNEL and SC-35. A glomerulus of a 
HUS patient contains two TUNEL positive nuclei that are negative for SC-35, which indicates the 
presence of apoptosis in the glomerulus. D) Double labeling of TUNEL and SC-35. A glomerulus of a 
control patient is shown without apoptosis. The nuclei show signs of RNA synthesis/splicing. E) Double 
labeling of TUNEL and SC-35. A tubulus of a HUS patient that contains TUNEL positive nucleus that 
is negative for SC-35, which indicates apoptosis in the tubular epithelial cells of this HUS patient. F) 
Double labeling of TUNEL and SC-35. A tubulus of a control patient is demonstrated without 
apoptosis. 
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In vitro experiments have shown that VT binds to the Gb3 receptor found after stimulation on 
endothelial cells, enters the cell and can cause inhibition of overall protein synthesis (3,4). In 
vitro studies performed with Vero-, Burkitt's lymphoma and renal tubular epithelial cells have 
shown that VT can induce apoptosis (85,217-220). Experiments performed in our own group 
demonstrated that VT can also induce apoptosis in human glomerular endothelial cells in vitro 
by a mechanism that involves caspase 3 (211). Mitra et al described that plasma of patients 
with thrombotic thrombocytopenic purpera, a disease that is closely related to HUS, can induce 
apoptosis in restricted lineages of human microvascular endothelial cells (221). Furthermore, it 
has been described that endothelial cells undergoing apoptosis become procoagulant and 
proadhesive for platelets (222). The finding of apoptotic cells in HUS patients in vivo using a 
double labeling for RNA-syntheses splicing factor (SC-35) together with the TUNEL-technique 
has not been described before. In a recent study, the presence of apoptosis was studied in 
biopsy material of one child and in postmortem tissue of two children with D+ HUS (84). 
Apoptotic cells were detected in tubular structures and in lesser extent in glomeruli of the 
kidney. TUNEL-technique was used to identify apoptotic cells. However, it has been reported 
that different factors such as RNA synthesis/splicing and small calcium containing vesicles can 
interfere with TUNEL-labeling (212,216). In this study of biopsy material of seven HUS 
patients we demonstrate that there is indeed non-specific labeling of non-apoptotic cells in 
biopsy material by the TUNEL-reaction. Therefore we used a co-labeling for RNA synthesis 
splicing factor and incubated the material of patients and controls with citric acid to remove 
calcium-containing vesicles. RNA transcription and splicing requires intact DNA indicating 
that cells positive for both TUNEL and RNA-splicing factor probably are not apoptotic. 
Sections of renal biopsy material of HUS patients stained with TUNEL showed a high fraction 
of nuclei that were labeled (30%) mainly in tubuli and in lesser extent glomeruli. Correction for 
RNA splicing factor made it possible to differentiate between TUNEL false positive cells and 
to identify true apoptotic cells. Especially, non-apoptotic nuclei showing signs of active gene 
transcription can be labeled non-specific by the TUNEL technique. Renal epithelial cells show 
high levels of RNA synthesis and therefore are prone for this non-specific labeling in the 
TUNEL technique. However, we still found an increased number of apoptotic cells in HUS 
patients compared to controls indicating that apoptosis probably plays a role in HUS. It is even 
possible that there is an underestimation of the amount of apoptosis, because all biopsy material 
we used was taken in the second week of the disease or even later and patients might be already 
recovering at that time. Normally, apoptotic cells are removed by macrophages in just a few 
hours (208,223). 
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In addition of finding apoptosis, we observed an increased RNA splicing activity in 
biopsy material of HUS patients compared to controls. This indicates that cells were active and 
transcribing genes that might be related or completely unrelated to the apoptotic process. 
Because the induction of apoptosis normally does not require new protein synthesis it is more 
reasonable to think that high RNA synthesis and splicing activity is not related to the apoptotic 
process. It is even possible that the high RNA synthesis and splicing activity is related to a 
phase of repair and re-establishment (224). Furthermore, we found that most apoptotic cells 
were seen in those patients that were anurie or that received peritoneal dialysis suggesting that 
there is a relationship between seriousness of the disease and amount of apoptotic cells. 
In conclusion, we demonstrated the presence of apoptotic cells in glomeruli and tubuli 
of renal biopsy material of HUS patients. The finding of apoptotic cells suggest that apoptosis 
plays a role in HUS. Probably more apoptosis will be seen at an early point of time in the 
course of the disease. 
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CHAPTER 9 
ELEVATED LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN 
SERUM OF PATIENTS WITH D+ HEMOLYTIC UREMIC SYNDROME. 
D. Maroeska W.M. te Loo, Nienke J. Bosma, Victor W.M. van Hinsbergh, Paul N. Span, Rob 
M.W. de Waal, Ruud Clarijs, Cos GJ Sweep, Leo A.H. Monnens, Lambertus P.W.J, van den 
Heuvel 
Submitted 
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ABSTRACT 
The epidemie form of hemolytic uremic syndrome (D+ HUS) is the most common cause of 
acute renal failure in children. The pathogenesis of this syndrome is characterized by 
endothelial damage of glomeruli and tubules all within the kidney. In several other diseases in 
which glomerular endothelial damage occurs, elevated serum levels of vascular endothelial 
growth factor (VEGF) have been described. VEGF is involved in angiogenesis, 
permeabilization of blood vessel endothelium and can have a role in wound repair. In this study 
we evaluated VEGF levels in serum of 40 D+ HUS patients in the acute phase and in course of 
the disease. VEGF levels were measured using a double sandwich ELISA technique with a 
detection limit of 12 pg/mL. Indirect immunohistochemistry was performed for the detection of 
VEGF in renal biopsy material of three HUS-patients. Significantly elevated VEGF levels were 
found in HUS patients compared to controls in both serum (P<0.001) and plasma (P<0.05). A 
significant relationship was found between VEGF levels and severity of the disease according 
to the classification of Gianantonio et al. (p< 0.05). Levels of VEGF in blood increased during 
the second and third week after HUS was diagnosed. Immunohistochemistry of renal biopsy 
material showed increased levels of the receptors for VEGF in the glomeruli and a 
disappearance of staining of VEGF in tubuli of patients compared to controls. During the 
course of HUS plasma VEGF levels increase depending on the severity of the disease. This is 
probably associated with the repair process. In the kidney glomerulus of HUS patients the 
VEGF receptors Flt-1 and KDR are elevated. 
INTRODUCTION 
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability 
factor, is related to platelet-derived growth factor and is a member of a growing family of 
closely related growth factors. VEGF is an endothelial cell mitogen, which can promote 
angiogenesis as well as permeabilization of blood vessels (225). It has been shown to modulate 
hemostatic properties of monocytes and macrophages by inducing tissue factor expression and 
exerting a chemotactic action on monocytes (226). VEGF plays a role in several physiological 
and pathological processes, including embryogenesis, diabetic complications, tumor growth, 
wound healing and tissue remodeling (227). It is encoded by a single gene, localized on 
chromosome 6p21.3, and exists in five different isoforms of 121, 145, 165,189 and 206 amino 
acids due to alternative mRNA splicing. These isoforms differ in biological properties such as 
their ability to bind to cell-surface heparan sulphate proteoglycans and neuropilin-l. The most 
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abundantly expressed splice vanant is VEGF165 It is associated with a vanety of cells such as 
platelets, leukocytes and mesangial cells (225,228,229) The biological function of VEGF is 
mainly mediated by interaction with two tyrosine kinase receptors Flt-1 (fins-like tyrosine 
kinase), which is expressed on endothelial cells, monocytes and renal mesangial cells, and 
KDR/Flk-1 (kinase domain-containing receptor/fetal liver kinase), which is present on 
endothelial cells and several hematopoietic precursor cells (225, 230) Hemolytic uremic 
syndrome (D+HUS) is the most common cause of acute renal failure in childhood and its 
pathogenesis is characterized by endothelial damage of glomeruli and arterioles of the kidney 
(4,92) The syndrome is associated with an infection with a verocytotoxin producing 
Escherichia coli (E coli)(\Q) Verocytotoxin is believed to play an important role in the 
endothelial damage observed in D+ HUS (56) Elevated serum VEGF levels have been found 
in several other diseases, in which glomerular endothelial damage plays a role (231,232) To 
elucidate whether VEGF is involved in the pathogenesis and/or recovery phase of D+ HUS, 
VEGF levels in serum and plasma of D+ HUS patients were measured and compared to the 
levels in controls Furthermore, the relationship between VEGF levels and clinical parameters 
on the day of admission and in course of the disease were investigated Finally, the presence of 
VEGF 165 and the expression of Flt-1 and KDR, the main receptors for VEGF, were studied in 
renal biopsy material of three HUS patients and compared to controls 
MATERIALS & METHODS 
Demographic and clinical data of HUS patients 
Blood samples of 40 patients presenting with D+ HUS (mneteen boys and twenty-one girls, age 
ranging between 4 months and 10 years) were collected during the time penod 1985 till 1999 
and evaluated in this study The criteria for HUS were defined as hemolytic anemia with 
fragmented erythrocytes, thrombocytopenia and acute renal failure All patients investigated 
presented with a prodromal phase of (bloody) diarrhea Fulfilling the criteria for HUS, the 
number of platelets, red blood cells and renal function were significantly decreased on 
admission Table 1 shows the clinical characteristics of D+ HUS patients presented in this 
study The seventy of renal failure was classified according to Gianantomo et al (5) Thirteen 
children had a mild form of renal dysfunction, whereas the moderate and severe form was 
observed in eighteen and nine children respectively Control samples of children were collected 
during the time penod 1989 till 1998 
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Total number of HUS patients 
(n=40) 
Age (mean ± SE (yrs)) 3.6 ± 2.6 
Gender (male/female; no.) 19/21 
Peripheral blood cells on admission (mean ± SD) 
Hb(nimol/L) 5.5 + 1.5 
WBC (x 109/L) 17.9 ± 8.8 
Plt(xl09/L) 81.5 ±89.3 
Renal function on admission (mean ± SD) 
ureum (mmol/L) 32.5 ± 18.2 
creatinine (μπιοΙ/L) 340 ± 259 
Anuria during the prodromal phase (yes/no; no.) 5/38 
Duration anuria (mean ± SD (days); n=20) 5.4 ±4.1 
Duration oliguria (mean ± SD (days); n=32) 6.1 ± 4.7 
Duration of dialysis (mean ± SD (days); n=28) 9.0 ± 6.7 
Extra renal complications (no.) 
cerebrum 5 
pancreas 1 
Creatinine after 2 years (mean ± SD; n=30) 48.8 ± 9.2 
Table 1 : Clinical and demographic characteristics of D+ HUS patients investigated in this 
study. 
Detection of VEGF in serum and plasma using a double sandwich ELISA 
Serum and citrate plasma samples of D+ HUS patients were collected starting on the day of 
admission followed by day seven and fourteen and evaluated for the presence of VEGF121+165· 
To exclude the possibility that decreased renal function is a cause of changed levels of VEGF, 
material of eleven patients with end-stage renal failure receiving continuous ambulatory 
peritoneal dialysis (CAPD), were collected and studied. This group consisted of seven boys and 
four girls, age ranging between 1.5 and 16.5 years. To determine normal VEGF levels, serum 
samples of 39 control children were investigated (age ranging between 6 months and 11 years). 
VEGF levels in plasma of 15 D+ HUS patients were measured to assess the contribution of 
VEGF release by platelets in serum during clotting (233,234). 
VEGF was detected using a double sandwich ELISA that detects VEGF 155 and VEGF121, as 
described earlier (235). Sensitivity of this assay was 12 pg/ml. Intra-assay variation was 6 % 
and inter-assay variation was 12%. 
Histopathological studies 
Kidney specimens of three different D+ HUS patients were obtained from renal biopsies taken 
in the acute phase of the disease on days 9, 14 and 15, respectively, after HUS was diagnosed. 
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These renal biopsies were a kind gift of Dr MC Gubler (Hospital Necker-Enfants Malades, 
Paris, France). Biopsy material had been stored at -80oC. All three children presented with 
diarrhea-associated HUS. The diagnosis HUS was established by combining clinical data and 
light microscopy of biopsy material. The presence of VEGF was studied in these biopsies and 
as control, biopsy material of three patients with thin basement syndrome (TBS) was used 
(stored at -80oC). VEGF was demonstrated histochemically on cryosections (4 μπι) that were 
fixed in acetone at room temperature for ten minutes. The sections were incubated with the 
primary antibody (rabbit polyclonal anti-VEGF, dilution 1:25; Santa Cruz Biotechnology, CA, 
Santa Cruz, USA) for one hour in phosphate-buffered saline (PBS) at room temperature. 
Subsequently, sections were washed thoroughly with PBS followed by incubation with 
biotinylated affinity-purified anti-rabbit IgG antibody for 30 minutes (dilution 1:200: Vector 
Laboratories Inc., Burlinghame CA, USA). The sections were washed with PBS and incubated 
with peroxidase-labeled biotin avidin complex (Vector Laboratories Inc.). 
Two successive sections of each biopsy specimen were also incubated with mouse anti-Fit-1 
(Sigma, the Netherlands; dilution 1:100) and mouse anti-KDR (Sigma, the Netherlands; 
dilution 1:100) at 4° C overnight to determine the presence of VEGF receptors in glomeruli and 
tubules. After this incubation and all following steps, sections were rinsed with PBS. 
Subsequently, sections were incubated with biotinylated affinity-purified anti-mouse IgG 
(Vectastain, Vector Laboratories Inc.; dilution 1:200) for 30 minutes at room temperature 
followed by incubation for the Flt-1 and KDR staining with peroxidase-labeled biotin avidin 
complex (Vectastain, Vector Laboratories). After this, sections were incubated for 10 minutes 
with biotinylated tyramine (dilution 1:400) followed by incubation with ABC-peroxidase 
solution as described previously (238). All stainings were developed by a 10 minute incubation 
with 0.4 mg/mL amino-9-ethyl-carbazole solution (Aldrich, Steinheim, Germany). In control 
sections primary antibodies were omitted. All stainings were counterstained for 45 seconds 
with Harris' haematoxylin (Merck, Darmstadt, Germany) at room temperature. The stained 
sections were mounted in Imsol-mount medium. 
Determination of Platelet Factor - 4 (PF- 4) 
Citrated plasma samples of 11 HUS children and 10 healthy age-matched controls were used 
for the evaluation of PF-4. PF-4 is a marker for platelet activation that is not influenced by 
renal function. PF-4 levels were determined using a standard commercial ELISA-assay from 
Roche Diagnostics (Almere, The Netherlands). 
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Statistical analysis 
All determinations were performed in duplicate. ANOVA was used to analyze statistical 
significance of differences found for VEGF levels between the control group and HUS-patients 
and HUS patients and CAPD patients. The correlation between VEGF levels and several 
clinical characteristics of HUS patients, including platelet count, hemoglobin, serum creatinine, 
and white blood cell count were calculated using Spearman's rank test. Multi-variance analysis 
was performed including all these factors. Statistical level of significance was defined as P< 
0.05. All values are expressed as mean ± SEM. 
RESULTS 
VEGF- levels in serum and plasma ofD+ HUS patients 
Levels of VEGF were measured in serum and plasma of patients with D+ HUS and compared 
to VEGF levels found in healthy controls. 
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Day· after diagnosis HUS 
Figure 1 VEGF levels in serum during the course of the disease. VEGF levels increased during the 
second and third week after patients were diagnosed having HUS. VEGF levels were calculated from 
three or more data obtained of different HUS patients at each time penod except for the two last time 
points in the mild form of HUS (n=2 and 1, respectively). The graph shows the results of patients with 
the mild form ( · ; n=13), moderate form of HUS (•; n= 18) the severe form (A ; n= 9) according the 
classification of Gianantomo (13). 
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Upon administration to the hospital, serum VEGF levels of almost all D+ HUS patients were 
comparable to those of controls (0.34 ± 0.04 ng/mL versus 0.29 ±0.13 ng/mL). They increased 
during the second and third week after the onset of hemolytic uremic syndrome (Figure 1). 
Highest VEGF levels were found in those patients with the most severe form of HUS according 
to the classification of Gianantonio et al. (5). Figure 2 shows the results of highest values found 
for VEGF in serum of patients in the second or third week of the disease 
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Figure 1 Box-whisker plots of VEGF levels in HUS-patients versus CAPD-patients and healthy 
controls. The box-whisker plots show lowest values and highest values measured and medium of the 
values (black line). VEGF levels in HUS patients were significantly elevated compared to controls 
(p<0.001) and patients receiving CAPD (p<0.05). No significant difference was found between CAPD 
patients and controls. 
and healthy controls. In D+ HUS patients significantly elevated VEGF levels were observed 
whereas only small amounts of VEGF were found in controls (0.55 ± 0.38 ng/mL versus 0.29 ± 
0.13 ng/mL, P<0.001). Serum VEGF levels were measured in patients with end-stage renal 
failure to exclude that VEGF levels were changed due to renal failure. D+ HUS patients 
showed significantly higher VEGF levels in serum than patients with end-stage renal failure 
receiving CAPD (0.55 ±0.38 ng/mL versus 0.33 ± 0.09 ng/mL, P<0.05). VEGF levels in 
plasma of D+HUS patients were also significantly elevated when compared to control plasmas 
(0.15 ±0.01 ng/mL versus 0.10 ± 0.02 ng/mL, PO.05). 
Statistical analysis using Spearman's rank correlation test was used to determine whether raised 
VEGF levels were correlated with severity of the disease. Clinical parameters such as serum 
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creatinine, white blood cell count and platelet count, hemoglobin and duration of the anurie 
phase were included. A significant positive correlation was found between highest VEGF 
levels found in D+ HUS patients and number of white blood cells on the day of admission (data 
not shown, PO.05). Multivariate analysis, including platelet count, white blood cell count and 
serum creatinine levels as indicators for severity of the disease, showed that there was a 
negative correlation in course of time between VEGF levels and these factors (PO.05). 
Furthermore, a significant positive relationship was found between severity of the 
disease according the classification of Gianantonio et al. (5) and VEGF levels (P <0.05), 
indicating that the highest VEGF levels were found in those patients with the most severe form 
of HUS (Figure 2). Platelets are a main source of VEGF in blood and for this reason we 
investigated the relationship between number of platelets and VEGF but also platelet factor 4 
(PF-4) and VEGF levels in plasma. In both cases no significant relationship was found (P= 0.46 
and P=0.56, respectively). PF-4 levels were significantly (negative) correlated with number of 
circulating platelets as expected (PO.05). 
Presence of VEGF-A and VEGF receptors in renal biopsy material of HUS patients 
To investigate whether an increase in VEGF-A production in the kidney was associated with 
the increased plasma VEGF-A level, the presence of VEGF-A in renal biopsy material of D+ 
HUS children and controls was immunohistochemically investigated using a polyclonal 
antibody against VEGF. In concert with previous reports (18; 19), control kidney specimens 
showed predominantly VEGF staining in tubules and to a lesser extent expression of VEGF-A 
in the glomeruli, probably expressed by podocytes (Figure 3A). Unexpectedly, the presence of 
VEGF in D+ HUS patients in both glomeruli and tubules was markedly reduced as compared to 
control sections (Figure 3B). To evaluate whether the reduced presence of VEGF was 
accompanied by a change in the expression of VEGF-A receptors, the expression of VEGF-
receptors, Flt-1 and KDR were visualized. In control specimens both Flt-1 and KDR were 
observed in the tubular area (Figure 3 C+E) and almost no staining for Flt-1 or KDR was found 
within the glomerulus. Biopsy samples of D+ HUS patients showed a strong expression of both 
Flt-1 and KDR in glomeruli whereas limited expression was observed in tubular area (Figure 
3D+F). 
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Figure 3 Immunohistochemistry of frozen sections of HUS-patients taken in the second or third week 
of the disease versus control (thin basement syndrome). Figure A VEGF expression in controls is 
predominantly seen in tubules and in lesser extent in the glomerulus. The cells that express VEGF in the 
glomerulus are most probably podocytes. The amount of VEGF present in glomeruli and tubuli in D+ 
HUS patients was strongly reduced (Figure B). In serial sections, the receptors for VEGF-A, Flt-1 (C, 
D) and KDR (E, F), of control and D+ HUS biopsy material were visualized. The expression of both 
receptors was enhanced in D+ HUS patients compared to controls. Magnification 400x. 
DISCUSSION 
In the present study we demonstrate that in patients with D+ HUS levels of VEGF in serum and 
plasma were significantly elevated during the second and third week of the disease when 
compared to healthy controls and compared to patients with end-stage renal failure (PO.001 
and P<0.05 respectively). VEGF levels were not significantly elevated on the day of admission 
compared to controls. Furthermore, a significant relationship between VEGF levels and 
severity of the disease according the classification of Gianantonio (5) was found. 
At the time D+ HUS patients were improving, VEGF levels in serum increased. This is 
suggestive for the conclusion that VEGF plays a role in the second phase of the disease, namely 
recovery. It has been described that VEGF can inhibit apoptosis of endothelial cells (21) and 
can mediate endothelial cell proliferation, neovascularization and eventually can induce the 
formation of fenestrae (239-242) Besides, increased levels of VEGF might induce an increase 
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in NO-production leading to vasodilatation and inhibition of leukocyte and platelet 
endothelium interactions. This may prevent the (further) formation of thrombi (239); all 
processes that can be important for repairing the damage of glomeruli and arterioles of the 
kidney as seen in HUS. The importance of VEGF in renal diseases in which thrombotic 
microangiopathy like in HUS plays a role was recently studied in an experimental model (243). 
The thrombotic microangiopathy was induced in rats by the administration of anti-glomerular 
endothelial cell IgG. Twenty-four hours later, half of the rats received VEGF. Renal function 
was evaluated and compared to control animals that received a placebo. Rats treated with 
VEGF had more glomeruli with intact endothelium and less glomerular ischemia compared to 
controls. Furthermore, the administration of VEGF was associated with an improved renal 
function indicating that VEGF might indeed have a role in repair and recovery in these animals. 
It is believed that endothelial damage of mainly the glomeruli hallmarks the pathogenesis of 
D+ HUS. In exactly these areas increased expression of KDR and Flt-1 was found. Other 
investigators found an increase in VEGF receptors and VEGF after vascular injury (244). 
Furthermore, an increased expression of VEGF receptors might be found after a period of 
hypoxia (245,246). The thrombotic microangiopathy in the kidney of D+ HUS patients will 
cause a period of hypoxia. The increased glomerular expression of KDR and Flt-1 is suggestive 
for the conclusion that more VEGF will be bound there and that for this reason more VEGF 
will be found in these regions than in control biopsies. However, to our surprise the amount of 
VEGF was reduced in both glomeruli and tubules of D+ HUS patients, despite the elevated 
levels of VEGF found in serum and plasma. It is important to realize that kidney biopsies were 
taken on day 9, 14 and 15. VEGF levels started to increase between day 14 and 21. For this 
reason, it may be possible that at a later time point of the disease, increased presence of VEGF 
can be found corresponding to the increased expression of the VEGF receptors Flt-1 and KDR. 
Unfortunately, no material ofthat time period was present. 
In other glomerular diseases, like diffuse endocapillary proliferative glomerulonephritis, 
crescentic glomerulonephritis, and lupus erythematosus decreased expression of VEGF has also 
been found within the glomerulus (247). Furthermore, in patients with crescentic 
glomerulonephritis elevated serum levels of VEGF are found at the same time (248). Our data 
do not provide evidence that an increased VEGF production in the kidney occurs and 
contributes to the elevated VEGF levels. Furthermore, VEGF levels in patients with end stage 
renal failure (CAPD-patients) were not elevated compared to healthy controls indicating that 
renal function is not related to VEGF levels. A possible source for the increased VEGF levels 
found in D+ HUS patients may be platelets. Microthrombi are found in the kidney of D+ HUS 
patients and in vitro studies have shown that platelets can release VEGF during aggregation 
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(233,234). Multivariate analysis showed a relationship with platelet count however no direct 
relationship was found between VEGF levels in serum or plasma and number of circulating 
platelets or with platelet factor 4 suggesting that there is another source that plays a role. White 
blood cells may represent such a source. In inflammatory bowel disease, it has been described 
that peripheral blood mononuclear cells were one of the sources for increased levels of VEGF 
(249,250). Furthermore, in vitro studies have shown that activated neutrophils express VEGF 
and that they can release VEGF (230,251,252). Elevated levels of IL-8 and elastase are found 
in HUS patients indicating that neutrophils of HUS patients are indeed activated (79,80). 
However, these data should be interpreted with some precaution. Because in hemorrhagic 
colitis elevated number of white blood cells have been found, even in the absence of renal 
failure, it has to be considered that the increased number of white blood cells found in HUS is 
no more than a reflection of intestinal infection. It has been described that inflamed tissue in 
bowel disease can cause the release of VEGF (251). All patients suffering of HUS in this study 
went trough a prodromal phase of (bloody) diarrhea. Therefore it would be reasonable to 
suggest that the intestine might be the main origin of elevated VEGF levels in D+ HUS and that 
the relationship found between VEGF levels and number of white blood cells is just a reflection 
of the intestinal infection seen in these patients. However, no direct evidence for this was 
obtained during this study. 
In conclusion, VEGF levels in serum and plasma are significantly increased in the 
second and third week of the disease in D+ HUS patients. In addition, D+HUS is associated 
with reduced presence of VEGF and increased VEGF receptor localization in the kidney. A 
good candidate for the increased VEGF production might be the inflamed intestine. Our data 
suggest that VEGF have a role in the recovery phase of the disease, probably by repairing 
endothelial damage. 
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CHAPTER 10 
SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
The hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in 
childhood in Europe. The pathogenesis of this syndrome is hallmarked by endothelial damage 
of predominantly the glomerular capillaries (2-4,9). An infection with a verocytotoxin 
producing Escherichia coli (VTEC) plays a prominent role in the etiology of HUS (10,118). It 
is generally thought that verocytotoxin (VT), after entering the circulation is transported 
through the circulation by an unknown mechanism. Subsequently, VT will bind to endothelial 
cells that express VT binding receptors, followed by endothelial cell damage and death. The 
endothelial damage is believed to be the primary events leading to a thrombotic 
microangiopathy and the development of acute renal failure (44). The reason why the damage 
preferentially is seen in the kidney is still not clear. 
The purpose of this thesis was to identify the transport mechanism of VT through the 
systemic circulation and to gain more insight into the complex mechanism of the relationship 
between an infection with VTEC and the development of acute renal failure. Particularly the 
role of vasodilators and vasoconstrictors that normally regulate the perftision of the kidney 
were investigated. 
In chapter 1, an overview of the current knowledge about the hemolytic uremic 
syndrome is given. An infection with a VT producing E. coli plays a central role in the etiology 
of most cases of HUS and therefore the interaction of VT with his functional receptor and the 
mode of cytotoxic action are discussed in this chapter. Furthermore, the possible interactions of 
VT with different cells in the systemic circulation and with human endothelial and mesangial 
cells are considered. 
The study presented in chapter 2, shows that in vitro VT is rapidly and completely 
bound to polymorphonuclear leukocytes (PMN) and not to other components of the blood. This 
binding occurs to a neutral glycolipid present on PMN with a Kd for VT-binding that is a 100-
fold less than that of the classical VT-receptor globotriaosylceramide (Gb3). Furthermore, thin 
layer chromatography of extracted neutral glycolipids on PMN showed two small bands with 
an Rf value just below the Gb4. Further studies will focus on the exact nature of this receptor. 
In line with the difference in affinity for VT, PMN that had bound VT were able to transfer the 
toxin to cultured glomerular endothelial cells. Furthermore, after transfer of the toxin protein 
synthesis inhibition and finally cell death occurred. The data obtained in this study strongly 
suggests that PMN transport VT from the intestine to the endothelium in target organs. 
However, several other suggestions considering the transfer of VT from the intestine to the 
kidney have been made earlier. Bitzan and colleagues (54) showed that VT was able to bind to 
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erythrocytes in vitro depending on the P-blood group glycohpids present on erythrocytes The 
Pk-antigen, and to a lesser extent the Pi antigen were able to bind VT, but not the P2-antigen 
Based on their results, we investigated whether VT bound to isolated human erythrocytes of 
eight healthy donors with different Ρ blood group phenotypes No significant binding was 
observed m these donors The fact that no binding of VT to human erythrocytes was observed 
when incubated in whole blood is strongly suggestive for the conclusion that erythrocytes do 
not play a pivotal role in transfer of the toxin Little binding of VT to human monocytes has 
also been described (76,77) This binding increased significantly after stimulation by 
hpopolysacchande In our study in whole blood, however, no significant binding was observed 
For this reason, it is reasonable to suggest that human monocytes do not play a role in transport 
of VT from the intestine to the kidney 
Cooling et al (74) reported the binding of VT (= SLT) to two different glycohpids on 
platelets obtained by apheresis, besides Gb3, a novel glycosphingolipid different from either 
Gb3 or the PI phenotype was capable of binding of VT On the contrary, Yagi et al (75) 
indicated that isolated leukocyte-depleted human platelets have no receptor for VT They 
suggested that enhanced platelet aggregation observed after incubation with VT-1 (= SLT-1) is 
depended on cytokine production by the presence of other cells In our study, no binding to 
platelets in whole blood environment or when isolated was found, and therefore we conclude 
that the relative contribution of platelets in transporting VT through the systemic circulation 
appears to be limited as compared to PMN That PMN play a seminal role in the pathogenesis 
of HUS has been suggested several times PMN are elevated in the acute phase of the disease 
and the number of PMN present in the acute phase of the disease is predictive for the outcome 
of the disease (79,105) Furthermore, renal autopsy material of HUS patients showed an 
increased presence of PMN in the glomeruli (82) In addition, Forsyth and colleagues (81) 
showed that PMN isolated from D+ HUS patients in the acute phase of the disease can damage 
cultured endothelial cells, probably through the release of intracellular components like 
elastase, or by the formation of superoxide (80, 109,110) Interestingly, in our in vitro study, 
PMN previously loaded with VT showed to be cytotoxic to non-stimulated glomerular 
endothelial cells whereas PMN alone had no effect Although several ways of transport of VT 
have been suggested, VT itself has never been detected in the systemic circulation A study 
performed with rabbits showed that after injection the VT-1 was detectable in serum obtained 
from rabbits but also that there was a short serum half-life of VT-1 (2 minutes) (70) It was 
concluded that VT is probably rapidly cleared from the systemic circulation and for this reason 
not detectable in D+ HUS patients A more reasonable explanation for this short serum half-life 
would be the rapid binding of VT to PMN, as we observed in vitro In 85% of all cases with D+ 
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HUS in Western Europe, infections with VT-2 producing E. coli are found (21), therefore, we 
investigated whether VT-2 bound to PMN could be detected in the systemic circulation of D+ 
HUS patients. In chapter 3, we demonstrate for the first time as far as we know the presence of 
VT-2 in the systemic circulation of patients during the acute phase of HUS. VT-2 was bound to 
PMN in the systemic circulation of nine out of ten patients in the acute phase of the disease. 
PMN isolated from 11 healthy volunteers and six patients with different infectious diseases 
were used as negative control samples. One patient with atypical HUS repeatedly exhibited no 
positive staining in the acute phase of the disease. Furthermore, we were able to study time 
course of VT-binding to PMN in five of the ten patients. The binding decreased in four patients 
within a week but the last patient studied showed no decrease at all and died in the second week 
of the disease. The finding of VT bound to PMN in the systemic circulation of D+ HUS 
patients forms the missing link between the intestinal infection and the development of renal 
failure as seen in HUS. Furthermore, this finding opens new approaches for treatment in the 
future. We believe that VT passes the intestinal-blood barrier during the acute phase of the 
disease and subsequently binds to PMN and in this way is transported to target organs. Acheson 
and colleagues showed that when PMN transmigrate across intestinal epithelial cells an 
associated movement of VT is seen in the opposite direction. Interfering in the VT-passage of 
the intestinal-blood barrier might prevent further transfer of VT by PMN and subsequently 
damage to target organs. Synsorb Pk might be such a substance that can interfere. In vitro 
studies have shown that Synsorb Pk, which is a synthetic analog of the Gb3 receptor, can bind 
VT and can neutralize VT when mixed in vitro with VT-positive stools from children with D+ 
HUS (116,117). Administration of Synsorb Pk, to patients with D+ HUS, but also to the 
siblings and parents of the patients might therefore be beneficial. Another possibility might be 
treatment with monoclonal antibodies against VT. By giving monoclonal antibodies, passing of 
the bound VT to the endothelium might be prevented. VT will stay on the PMN that are finally 
removed from the circulation. Experiments with antibodies against Stx-2 in piglets and rabbits 
seemed to be protective depending on the time and dose given (254-257). In addition, a study 
performed with cloned Stx-2 B-subunit in pigs seemed to prevent the binding of the toxin to 
target cells and in this way prevented the development of edema disease (258). In vitro 
experiments performed with a humanized monoclonal antibody against VT-2 developed by a 
Japanese group look hopeful. However, these antibodies are not available for clinical treatment 
yet. Therefore, other additional therapy might be required in severe cases of HUS. We propose, 
that on the basis of the finding that VT is bound to PMN in the systemic circulation in the acute 
phase of the disease in D+ HUS patients, leukopheresis could be considered to prevent further 
transfer of the toxin or protecting target organs for more damage in severe cases. 
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Because mostly young children develop HUS, we hypothesized that the easier entry of 
VT into the circulation in young children might be essential for the development of hemolytic 
uremic syndrome In chapter 4, it was evaluated whether VT was present in the systemic 
circulation of household members of D+ HUS patients to investigate whether this theory is 
correct Stool and serological analysis was performed to determine the strain of the VTEC 
involved To our surprise, more than 80% of the household members were positive for VT 
binding whereas only 10% was positive for VTEC infection in stool and/or serological analysis 
The number of PMN positive for VT-binding was similar to that found in D+ HUS patients 
However, because D+ HUS patients have an increased number of leukocytes and household 
members have not, relatively more VT will be present in the systemic circulation of D+ HUS 
patients Furthermore, it is also possible that daily measurements of VT bound to the surface of 
PMN will show a difference between young children and adults Improvement of the technique 
to quantify VT bound to PMN will be necessary to determine the exact amounts of VT entering 
and present in the systemic circulation This study shows that the total number of household 
members of D+ HUS patients being infected is underestimated based on the examination of 
stool and serological analysis alone Furthermore, this study suggests that the entry of the toxin 
into the circulation is an important but not the only factor that determines whether someone 
develops HUS or not One of these additional factors might be hpopolysacchande (LPS) LPS, 
or bacterial endotoxin, is a component of the outer cell membrane of gram-negative bactena 
(259) The host response to LPS depends on the amount of LPS-binding proteins, degree of 
cellular responsiveness to LPS and the presence of the active part of LPS (260) In patients who 
develop HUS, serum antibodies against LPS can be found whereas in household members this 
is rarely detected Therefore, it is possible that less LPS is entering the circulation of household 
members than in D+ HUS patients and that the amount of LPS entering the circulation 
determines whether someone develops HUS Although serum antibodies against LPS are 
detected in the circulation of D+ HUS patients, LPS itself has never been found in D+ HUS 
patients In chapter 5, we demonstrate for the first time the presence of LPS bound to PMN in 
the beginning of the acute phase of the disease in D+ HUS patients Furthermore, we 
demonstrated that the binding of LPS, and not of VT leads to the activation of PMN 
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Figure 1. The interaction of lipopolysaccharide with different structures in the circulation. 
LPS can bind to the lipopolysaccharide binding protein (LBP) and can in this way be 
transported to lipoproteins, to CD14-bearing cells like monocytes and polymorphonuclear 
leukocytes (PMN) or to soluble CD 14. The formation of Soluble CD14/LPS/LBP binding 
complex can subsequently lead to activation of cells that do not express CD14 themselves, like 
endothelial cells. 
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Activation of PMN by LPS led to up-regulation of the CD11/CD18 or anti-ICAM-1 complex 
and at the same time a reduced expression of L-selectin as described by other investigators 
(262) VT was able to induce in vitro ICAM-1 expression on endothelial cells The increased 
expression of the CD11/CD18 complex and the simultaneous up-regulation of ICAM-1 on 
endothelial cells might lead to increased adhesion of PMN to the endothelium Interestingly, it 
has been described that PMN isolated from HUS patients adhere more avidly to the 
endothelium than PMN isolated from healthy controls Furthermore, Zoja and colleagues 
reported that VT-1 could cause increased adhesion of PMN to the endothelium under flow 
conditions, by up-regulating adhesive proteins (78) Besides the up-regulation of CD11/CD18 
complex, also an increased expression of CD66 and CD63 was observed indicating the release 
of the contents of azurophilic granulae (263) Incubations in whole blood performed with VT 
and LPS in different concentrations showed a release of elastase, corresponding with the 
increased expression of CD63 on PMN In line with these results, is the finding of elevated 
elastase levels in patients with D+ HUS (80) Future investigations in patients with HUS have 
to show whether the expression of adhesion-molecules on PMN is indeed increased and 
whether other activation markers will be present Apparently, LPS plays an important role in 
activation of PMN and probably activates other target cells such as monocytes and endothelial 
cells Elevated levels of hpopolysacchande binding protein (LBP) in patients with D+ HUS 
have been found compared to healthy controls and to patients with only VTEC infection (141) 
LBP is an acute phase protein and hepatically synthesized Furthermore, LBP is the main LPS 
binding protein that is responsible for transporting LPS to lipoproteins, to CD14-beanng cells, 
which include monocytes and PMN but also to soluble CD14 (152) Transport of LPS to 
lipoproteins will lead to inactivation of LPS (Figure 1) It has even been suggested that high 
levels of lipoproteins, like high-density lipoprotein (HDL), might work protective against LPS 
challenges The formation of LPS-LBP-soluble CD 14 complexes can lead subsequently to the 
activation of endothelial cells that do not express CD 14 themselves In the study presented in 
chapter 5, we only investigated the presence of LPS bound to PMN and it cannot be excluded 
that LPS bound to lipoproteins and to soluble CD 14 are also present in blood plasma dunng the 
acute phase of the disease Therefore, it would be of interest to study in the future whether LPS 
bound to soluble CD 14 and/or lipoproteins can be detected in D+ HUS patients and patients 
that only have VTEC infection Maybe differences in distribution patterns of LPS or total 
amount of LPS presence in the circulation of HUS patients and those with only VTEC infection 
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will form a key role in the explanation why some develop HUS and others not. Apparently, VT 
itself is not cytotoxic to PMN, resembling the monocytes (76). 
Under basal conditions, VT does not affect protein synthesis in endothelial cells. In 
vitro studies performed with human endothelial cells (56) showed that these cells have to be 
stimulated with inflammatory cytokines or LPS to increase susceptibility for VT. However, it 
might be possible that VT induces in basal conditions, factors that are involved in perfusion. In 
normal circumstances, equilibrium is seen between different factors such as endothelin-1 (ΕΤ­
Ι) and NO. Nitric oxide is a potent vasodilatator and prevents adhesion and aggregation of 
platelets to the endothelium whereas ET-1 acts as a vasoconstricting factor (264,265). Injury or 
activation of the endothelium changes its regulatory functions leading to an imbalance between 
the relaxing and constricting factors and loss of anti-thrombotic properties. In chapter 6, the 
influence of VT on NO and ET-1 production of human glomerular endothelial cells was 
investigated. Furthermore, the effect of VT on NO production of human mesangial cells was 
studied in vitro. Human mesangial cells express in non-stimulated conditions the functional 
receptor of VT, Gb3, whereas glomerular endothelial cells have to be stimulated (86). For this 
reason, non-stimulated and stimulated cells were investigated in this study. VT-1 reduced basal 
NO production in vitro of human mesangial cells and to a lesser extent of GMVEC. The 
reduction of NO production by VT-1 found in human mesangial cells is in the micromolar 
range and that of GMVEC, in the nanomolar range. A concentration of 10 fmol/L was 
sufficient to cause maximal reduction of non-stimulated mesangial cells whereas a 
concentration of five nmol/L was necessary to cause a significant reduction of NO production 
by non-stimulated human GMVEC. This observation and the fact that endothelial cells make at 
least 1000-fold less NO, at least in vitro, makes it likely that the decrease of NO production of 
human mesangial cells, caused by VT-1, has more impact than the decrease observed in basal 
NO-formation of GMVEC. VT did not influence the production of ET-1 in non-stimulated 
GMVEC suggesting that this substance does not play a role in the initial phase of the disease. 
These data seem to be in contrast with observations of Bitzan and colleagues (166). They 
studied the effect of VT on NO and ET-1 production by bovine aortic endothelial cells. No 
significant changes in NO synthesis were observed but VT appeared to increase ET-1 
production and preproET-l mRNA transcript levels without affecting protein synthesis in 
quiescent bovine aortic endothelial cells. In our study, VT had no effect on ET-1 or on 
preproET-l mRNA level in non-stimulated cells. However, it has to be considered that bovine 
aorta endothelial cells may react differently after exposure to VT as compared to GMVEC. The 
only change in ET-1 production found in this study was a decrease in ET-1 production when 
GMVEC were previously stimulated with TNFa. 
136 
It is of interest to notice that the kidney is the only organ in the human body that 
contains mesangial cells and therefore may be the only organ that will show vasoconstriction 
because of VT action. This may partly explain why the kidney is the main organ involved in the 
pathogenesis of HUS. It has to be considered that the data obtained in this study only represent 
what happens in vitro, in static conditions. Although it is anticipated that the data obtained in 
this study are in general representative for what happens in vivo in HUS patients, it cannot be 
excluded that the flowing blood system may influence such data. It might therefore be of 
interest for future studies to investigate the effect of VT under physiological flow conditions. 
Inflammatory mediators are considered to play an important role in the pathogenesis of 
HUS. For example, in vitro studies have shown that VT is not cytotoxic to confluent 
glomerular endothelial and human umbilical vein endothelial cells and requires pre-exposure to 
inflammatory cytokines to induce cytotoxicity (55,56). In addition, elevated levels of TNFa 
and IL-6 have been found in urine and plasma of patients with D+ HUS as also MCP-1 and IL-
8 (205). It has been suggested that monocytes may be an important source of these mediators 
(76,77). Furthermore, Harel and colleagues reported that VT (= SLT), injected into transgenic 
mice that bear a chloramphenicol acetyltransferase reporter (CAT) gene coupled to a TNFa 
promotor, was able to induce CAT activity in the kidney indicating an increased local TNFa 
synthesis (177). If inflammatory mediators indeed play an important role, then it might be 
possible that polymorphisms in one of these genes could influence the outcome of the disease. 
Plasminogen activator inhibitor I (PAI-I) is also believed to play a role in the 
pathogenesis of HUS (188). PAI-I is a major regulatory protein of the fibrinolytic system and 
can rapidly inactivate tissue type and urokinase-type plasminogen activator (t-PA and u-
PA)(49). Elevated PAI-I levels have been found in patients with D+ HUS and some studies 
suggest that there is an association with a worse outcome in D+ HUS (186-188). Polymorphism 
in the PAI-I gene could to lead to an increased or decreased PAI-I production and in this way 
influence the course of the disease in HUS (267). Therefore, polymorphisms of these two genes 
were studied in chapter 7. The role of the polymorphisms at position-308 (G/A) and -863 
(C/A) in the tumor necrosis factor α gene and of the 4G/5G polymorphism in the PAI-I in 
relationship to the severity of the disease was investigated. In addition, levels of PAI-I and 
TNFa in plasma were measured in former HUS patients and compared to healthy controls. 
Levels of PAI-I and TNFa were in the normal range in both former HUS patients and in 
controls. Interestingly however, levels of PAI-I in HUS patients, who recovered several years 
ago, were significantly higher compared to age-matched healthy controls. It was evaluated 
whether the presence of 4G/5G polymorphism in the PAI-I gene could be an explanation for 
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this difference However, no significant difference in frequency of this polymorphism was 
found in patients versus controls The presence of other polymorphisms in this gene might form 
an explanation Another possibility might be the presence of a polymorphism in the 
angiontensin-converting enzyme (198) It has been descnbed that elevated levels of 
angiontensin II can lead to increased PAI-I synthesis Therefore, a polymorphism in this gene 
resulting in elevated angiontensin II levels might contribute to the elevated PAI-I levels 
observed in former HUS patients No relationship was found between seventy of the disease 
and the presence of the polymorphism according the classification of Gianantomo (5) It would 
be intnguing to study in the future the role of other polymorphisms and to evaluate whether 
these polymorphisms can help in understanding why some children develop a severe form of 
HUS and others only have diarrhea 
As mentioned before, the pnmary site of damage in HUS is the endothelium of the 
kidney The endothelial damage is probably caused by two distinct mechanisms First, by the 
inhibition of protein synthesis in the cell and second by the induction of a process called 
programmed cell death or apoptosis (206) Several in vitro studies have pointed out that VT can 
induce apoptosis in endothelial cells, renal tubular epithelial cells, and other cell types 
(85,89,218,219) It seems that apoptosis induced by VT, is caspase-3 and -8 dependent after 
cross-linking the Gb3 receptor (268) There are only a few in vivo data present suggesting that 
apoptosis might indeed play a role in HUS Therefore, we studied in chapter 8 the presence of 
apoptosis in renal biopsy matenal of seven D+ HUS patients and seven controls (mimmal 
change disease or thin basement syndrome) and evaluated whether the presence of apoptotic 
cells was related to the seventy of the disease To investigate the presence of apoptosis a 
stnngent terminal deoxynucleotidyl nick-end labeling (TUNEL) technique was used Recently, 
it was shown that non-apoptotic cells that show signs of active gene transcnption could be 
labeled nonspecifically by the TUNEL technique (216) In a true apoptotic cell, the nuclear 
DNA is cleaved into fragments and processes like DNA repair and simultaneously the RNA 
transcnption/sphcing activity disappears Therefore, the TUNEL technique was combined with 
a staining of RNA-synthesis and splicing factor, SC-35 True apoptotic cells are TUNEL 
positive but RNA splicing negative, whereas non-apoptotic TUNEL positive cells will be 
positive for the RNA splicing factor Using this combined method, an increased number of 
apoptic cells were observed in glomeruli and tubules of patients with D+ HUS compared to 
controls Most apoptotic cells were detected in tubules (80%) of the HUS patients and not in 
the glomeruli (20%) Furthermore, an increased staining for RNA splicing factor was observed 
in the tubular epithelial cells of D+ HUS patients compared to controls, indicating higher 
transcnption activity of these cells Therefore, these cells are prone for non-specific labeling 
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with the TUNEL technique. Indeed non-specifical labeling of these cells were observed 
indicating that one should be careful interpreting results obtained by TUNEL technique alone. 
The finding of apoptosis in tubules and glomeruli of the D+ HUS patients is in line with the 
results reported by Karpman et al (84). She studied apoptosis in autopsy material of two 
children and in biopsy material of one child with D+ HUS. The amount of apoptotic cells 
observed in this study was much higher than in ours. However, apoptosis was studied using the 
TUNEL technique alone. Delay in fixation of the autopsy material, proteinase Κ pretreatment, 
the presence of calcium-containing vesicles and increased RNA-splicing activity, all could have 
caused non specific labeling in this study and therefore an overestimation of apoptotic cells 
might be expected (212,216). Alternatively, the occurrence of apoptosis in biopsy material of 
the seven D+ HUS patients in our study might be underestimated. Biopsies studied were taken 
in the second or third week of the disease and it is possible that patients were already 
recovering at that time. It is possible that the high RNA synthesis and splicing activity found in 
the tubular epithelial cells are related to a phase of repair and re-establishment. However, 
studying biopsy material of HUS patients in an earlier phase of the disease is not possible 
because the risk of hemorrhage due to thrombocytopenia is too high. 
It is of interest to note that most patients with D+ HUS recover spontaneously and that 
only supportive therapy, consisting of peritoneal dialysis or hemodialysis, correction of 
electrolyte imbalance and treatment of hypertension when necessary, is given. The fact that 
patients recover spontaneously suggests that there are also factors playing a role in repairing the 
damaged tissues. One of these substances might be vascular endothelial growth factor (VEGF). 
VEGF is related to platelet-derived growth factor and is a member of a growing family of 
closely related growth factors (230). VEGF can promote angiogenesis and can stabilize 
endothelial cells. It also increases endothelial permeability (230). Elevated serum VEGF levels 
have been found in several diseases, in which glomerular endothelial damage has a role (248, 
269). The role of VEGF in HUS was studied to determine whether VEGF has a function in 
HUS. For this reason VEGF levels in serum and plasma of patients with D+ HUS were 
evaluated and the results are presented in chapter 9. VEGF levels in serum and plasma were 
significantly increased during the second and third week of the disease. At that time, D+ HUS 
patients were already improving suggesting that VEGF plays a role in the second phase of the 
disease, namely repair and recovery. Interestingly, VEGF levels found in D+ HUS patients 
correlated with severity of the disease according to the classification of Gianantonio (5). To 
investigate whether the increased plasma VEGF level was associated with an increase in VEGF 
production in the kidney, the presence of VEGF in renal biopsy material of D+ HUS children 
and controls was investigated. Unexpectedly, the presence of VEGF in D+ HUS patients in 
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both glomeruli and tubules was markedly reduced as compared to control sections. In addition, 
no significantly elevated VEGF levels were observed in patients with chronic renal failure 
compared to controls indicating that decreased renal function is not related to VEGF levels. 
The biological function of VEGF is mainly mediated by interaction with two tyrosine kinase 
receptors: Flt-1 (fms-like tyrosine kinase) and KDR/Flk-1 (kinase domain-containing receptor/ 
fetal liver kinase) (230,270,271). For this reason we evaluated whether the reduced presence of 
VEGF was accompanied by a change in the expression of VEGF receptors. A strong expression 
of both Flt-1 and KDR in glomeruli was observed in D+ HUS patients whereas limited 
expression was observed in tubular area. On the contrary, VEGF staining in control sections 
was observed in the tubular area and almost no staining was found in the glomeruli. The 
reduced staining of VEGF in the kidney was surprising considering the elevated levels of serum 
VEGF levels. However, it have to be considered that biopsies were taken in the second or 
beginning of the third week. At that time, VEGF levels started to increase. Therefore, it may be 
possible that biopsies that are taken in a later time period will show increased presence of 
VEGF. Unfortunately, no kidney material of this period was available. Another possibility that 
has to be considered is, that VEGF may be localized intracellularly, beyond the reach of the 
antibody. It has been described that VEGF bound to his receptors can be internalized via a 
classical receptor-mediated endocytosis pathway and accumulates in the endosomal or nuclear 
compartment (271,272). Finally, we can not exclude that VEGF measured in D+ HUS patients 
may be bound partly to the soluble receptor of VEGF and for this reason can not bind to 
receptors expressed on the damaged endothelium. 
In other glomerular diseases, such as diffuse endocapillary proliferative glomerulonephritis and 
lupus erythematosus decreased expression of VEGF has been found within the glomerulus 
(247). Furthermore, in patients with crescentic glomerulonephritis elevated serum levels of 
VEGF have been found. Recently, the role of VEGF in renal diseases in which thrombotic 
microangiopathy plays a role similar as in HUS, was studied in an experimental model (243). A 
thrombotic microangiopathy was induced by the administration of anti-glomerular endothelial 
cell IgG in rats. Rats, that were given VEGF had more glomeruli with intact endothelium and 
less glomerular ischemia compared to controls. The administration of VEGF was associated 
with an improved renal function. It has been described that VEGF can inhibit apoptosis of 
endothelial cells and can mediate endothelial cell proliferation, neovascularization and 
eventually can induce the formation of fenestrae (241,242). In addition, increased levels of 
VEGF might induce an increase in NO-production leading to vasodilatation and inhibition of 
leukocyte and platelet endothelium interactions (239). This may prevent the (further) formation 
of thrombi in the kidney. The elevated levels of VEGF found in HUS patients were related to 
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the number of white blood cells, which may suggest that these cells might be a source for the 
VEGF. However, the finding that VEGF levels increased at the time white blood cells were 
normalizing suggests that this is not probable. Future investigation might lead to the 
identification of the source releasing VEGF. The development of an animal model would give 
probably more insight in this aspect of the pathogenesis of HUS. Although several attempts 
have been made, no good animal model for the pathogenesis of HUS is available although VT 
susceptibility in different animals has been described. For example, infection with VT2e causes 
edema disease in young pigs showing symptoms of non-hemorrhagic diarrhea and systemic 
vascular damage (273). However, no renal damage is seen. In addition, mice injected with VT 
show tubular damage but no glomerular damage is seen (274,275). Recent data of Fernandez et 
al. show that the (Java) monkey is probably the only animal that might serve as model for the 
hemolytic uremic syndrome as seen in HUS. PMN of the monkey are capable of binding VT 
and transferring the toxin to GMVEC. Furthermore, staining with the B-subunit of VT 
demonstrated the presence of the VT receptor Gb3 in both glomeruli and tubules of this animal. 
Development of this monkey animal model will give more insight into the pathogenesis of 
HUS and probably gives opportunities to investigate possible treatment. 
CONCLUSION 
The data presented in this thesis form the missing link between the intestinal infection and the 
development of renal failure seen in HUS. For the first time, as far as we know, the presence of 
VT and LPS in the systemic circulation of D+ HUS patients was demonstrated. Both, VT and 
LPS were bound to PMN. LPS bound to PMN, but not VT, led to up-regulation of adhesion-
molecules and degranulation of PMN. The finding of VT bound to PMN in household members 
of D+ HUS patients indicates that not only the entry of VT into the circulation determines 
whether HUS will develop. Additional factors, like LPS and genetic differences, probably 
determine what the consequences of the VTEC infection will be. Probably, LPS is not bound 
only to PMN but also to human monocytes in HUS leading to the activation of these cells. A 
schematic representation of the possible mechanism leading to HUS and subsequently recovery 
is shown in Figure 2. VT was able to decrease NO production of mesangial cells and to a lesser 
extent of GMVEC in vitro. No effect of VT was observed considering ET-1 synthesis under 
basal conditions suggesting that ET-1 does not play a role in the initial phase of the disease. 
The reduced NO production observed in vitro may be an explanation for the acute renal failure 
and the thrombotic microangiopathy as seen in vivo in HUS. Stimulation of GMVEV and 
subsequently incubation with VT led to reduced ET-1 production in endothelial cells and 
increased NO production of mesangial cells. 
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Figure 2 Proposed mechanism of the pathogenesis of D+ HUS. Verocytotoxin producing E. coli 
(VTEC) binds to the epithelial cells of the intestine. After binding, VT and LPS enter the systemic 
circulation and will bind to PMN (Ι +Π). Activation of PMN will occur as a consequence of LPS 
binding (ΓΠ). LPS will induce the expression of adhesion molecules on PMN (CD1 lb/CD18 complex 
but also on endothelial cells (P-selectin and ICAM-1). PMN will adhere firmly to the endothelium 
inducing the release of elastase, cathepsins and superoxide (IV). 
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Furthermore, cytokines like TNFa will be released inducing the expression of 
globotriaosylceramide (Gb3). Transfer of VT will occur leading to reduced production of nitric 
oxide, inhibition protein synthesis and subsequently cell death (V). LPS stimulated monocytes 
will enter the damaged area, bind VT, and will produce large amounts of cytokines. This will 
lead to increased NO synthesis of mesangial cells and reduced endothelin-1 production in 
endothelial cells (VI). 
It is of interest to notice, that the kidney is the only organ in the human body that 
contains mesangial cells. Therefore, reduction of NO production may occur only in this organ 
during the development of HUS because of the presence of VT. This would at least partly 
explain why the kidney is the major organ involved in HUS. 
Whereas this thesis has provided new insights into the development of HUS, it is not 
completely clear why mainly young infants are affected and secondly why the kidney is the 
main target. It may be that the entry of LPS together with VT will form partially the 
explanation why especially younger children are affected. However, this would lead 
immediately to a new question; why is there a difference in the entry of LPS and VT between 
children and adults? This has to be investigated in the future. 
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The in vitro data obtained in this thesis showing that VT can reduce NO synthesis of 
mesangial cells may explain why the kidney is the main organ involved in HUS, however, 
more studies will be needed to prove this is indeed the case. To gain more insight into these 
questions, future research should be performed as indicated in the general discussion. Two 
aspects are especially of interest to focus on: First, the amount of LPS entering the circulation 
and its distribution pattern in patients with HUS and those with only VTEC infection and 
secondly, to study the effects of VT in a circulating system. 
In addition, data presented in this thesis shows that both VT and LPS are transported by 
PMN in the systemic circulation of D+ HUS patients. The finding of this opens possibilities for 
treatment of these patients. Preventing the transfer of the toxin to target cells and inactivation of 
LPS still present in the circulation are especially of interest. Future research should also focus 
on this aspect. At the moment, prevention of VTEC infection is the best we can do. Treatment 
of HUS patients and household members with Synsorb-Pk might be beneficial. However, in a 
randomized double blind, placebo controlled trial, no significant reduction in the incidence of 
HUS was seen (28). On the other hand, it might be possible that Synsorb-Pk was given too late 
and for this reason no significant effect was observed. After admission to the hospital, 
symptomatic treatment can be offered to the HUS patients. Stabilizing electrolyte balance, 
treatment of the acute renal failure with dialysis are only supportive therapies. Maybe in the 
near future, based on the studies presented in this thesis, it will be possible to interfere between 
toxin binding to PMN and the transfer of the toxin and in this way preventing the development 
of the more severe form of HUS. Perhaps that also the inactivation of LPS present in the 
circulation of D+ HUS patients forms a therapeutic possibility. What can be done at the 
moment, is educating parents and in particular young children to prepare food well and taking 
hygienic precautions as much as possible to reduce the incidence of HUS. 
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NEDERLANDSE SAMENVA TTING 
Hoofdstuk 1. Het hemolytisch uremisch syndroom (HUS), is een syndroom dat met name op 
de kinderleeftijd vaak wordt gezien. Het ziektebeeld kenmerkt zich door het optreden van 
bloedarmoede (hemolytische anemie), een tekort aan bloedplaatjes (thrombocytopenie) en het 
plotseling verminderen van de nierfiinctie (acute nierinsufficiëntie). HUS is de meest 
voorkomende oorzaak van acute nierinsufficiëntie op de kinderleeftijd in Europa. De 
Pathogenese van het ziektebeeld kenmerkt zich door beschadiging van endotheelcellen die de 
binnenkant van in de nier gelegen bolvormige vaatkluwentjes (glomeruli) bekleden. In ernstige 
gevallen wordt niet alleen endotheelschade gezien in de nier maar kunnen ook andere organen, 
zoals de alvleesklier en hersenen aangedaan zijn. Er zijn twee subtypes te onderscheiden, te 
weten de typische of epidemische vorm van HUS en een atypische vorm. In tegenstelling tot de 
atypische vorm, kenmerkt de typische of epidemische vorm van HUS zich door een prodromale 
fase van acute, vaak bloederige diarree en wordt daarom ook wel D+ (diarree geassocieerde) 
HUS genoemd. D+ HUS wordt in de meerderheid van de gevallen veroorzaakt door een 
infectie met een verocytotoxine producerende Escherichia coli (VTEC). 
De belangrijkste bron van besmetting is veelal de consumptie van besmet rundvlees. Wanneer 
het vlees onvoldoende verhit wordt, kunnen de bacteriën overleven en zich vermenigvuldigen. 
De verocytotoxines (VT) zijn opgebouwd uit twee delen: Een gedeelte dat biologisch activiteit 
kan ontplooien (A-subunit) en een gedeelte dat ervoor zorgt dat het toxine kan binden aan 
doelwit cellen (B-subunits). Binding van VT aan doelwit cellen kan plaatsvinden als er een 
specifieke receptor voor VT aanwezig is. De meest beschreven receptor voor VT is 
globotriaosylceramide (Gb3). Deze receptor bevindt zich met name op endotheelcellen. 
Wanneer VT door middel van de B-subunits gebonden is aan de receptor op het celoppervlak 
van de doelwit cellen, kan intemalisatie plaats vinden door middel van endocytosis. In de cel 
kan het toxine de eiwitsynthese op ribosomaal niveau remmen, hetgeen uiteindelijk tot celdood 
kan leiden. Behalve remming van de eiwitsynthese kan VT in bepaalde celtypes ook apoptosis 
(geprogrammeerde celdood) induceren. 
Het complexe mechanisme dat uiteindelijk leidt tot acuut nierfalen in met name kinderen wordt 
nog steeds niet volledig begrepen. In het algemeen wordt aangenomen dat VT de bloedbaan 
binnen treedt, getransporteerd wordt door de systemische circulatie door een vooralsnog 
onbekend mechanisme, en vervolgens bindt aan endotheelcellen die de Gb3 receptor tot 
expressie brengen. Verschillende in vitro studies hebben uitgewezen dat gekweekte 
endotheelcellen afkomstig uit navelstrengen en uit de glomeruli van de nier, onder normale 
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omstandigheden niet gevoelig zijn voor de schadelijke effecten van VT. Door stimulatie van de 
cellen met ontstekingsmediatoren, zoals tumor necrosis factor alfa (TNFa), is het mogelijk om 
het aantal receptoren op deze cellen op te reguleren waarna een toxisch effect kan worden 
waargenomen. 
Doelstelling van dit promotieonderzoek was het identificeren van het transport mechanisme 
van VT door de systemische circulatie en het verkrijgen van meer inzicht in factoren die een 
mogelijke rol spelen in het ontstaan van de acute nierinsufficiëntie in HUS. Factoren die ons 
inziens met name hierbij een rol zouden kunnen spelen zijn het vaatverwijdende (vasodilatator) 
stofje stikstofinono-oxide en het vaatvemauwende (vasoconstrictor) endotheline-1. 
Verandering in de productie van één of beide stofjes door het glomerulaire endotheel onder 
invloed van VT zou een verklaring kunnen zijn voor het ontstaan van het nierfalen in HUS. 
Hoofdstuk 2. Verschillende studies hebben aangetoond dat een VTEC infectie een belangrijke 
rol speelt bij het ontstaan van HUS, het is echter nog nooit iemand gelukt om de aanwezigheid 
van VT in de systemische circulatie van patiënten met D+ HUS aan te tonen. In deze studie 
hebben we daarom onderzocht welke fractie van het bloed verantwoordelijk was voor de 
binding en overdracht van VT aan doelwit cellen. Hieruit bleek dat VT in vol bloed, in een 
korte tijd volledig bond aan granulocyten. Er werd geen binding aan andere componenten van 
het bloed waargenomen. Door middel van Scatchard plot analyse werd duidelijk dat de binding 
van VT aan granulocyten teweeg werd gebracht door de aanwezigheid van één type receptor 
voor VT met een affiniteit die een factor 100 lager is dan die van de klassieke receptor voor 
VT, de Gb3 receptor. Met behulp van dunne laag chromatografie kon bovendien worden 
aangetoond dat het gaat om een neutraal glycolipid bestaande uit twee banden met een ander 
migratie patroon vergeleken met de Gb3 receptor op endotheel. Vanwege het verschil in 
affiniteit tussen de receptor aanwezig op granulocyten en die op endotheel, bleek het VT van de 
granulocyt overgedragen te kunnen worden aan het endotheel. Na overdracht van VT trad een 
biologisch effect op in de vorm van eiwitsynthese remming en celdood. 
Hoofdstuk 3. Zoals al eerder vermeld is VT zelf nog nooit gedetecteerd in de circulatie van 
HUS patiënten. In een studie waarbij konijnen geïnjecteerd werden met radioactief gelabeld 
VT, kon VT voor een zeer korte tijd in het serum gemeten worden. De halfwaardetijd van het 
toxine was ongeveer 2 minuten in het serum. Hieruit werd de conclusie getrokken dat VT snel 
geklaard wordt uit de systemische circulatie en daarom niet detecteerbaar is in HUS patiënten. 
De binding van VT aan granulocyten van D+ HUS patiënten zou misschien een betere 
verklaring kunnen zijn. Analyse van granulocyten geïsoleerd uit bloed van D+ HUS patiënten 
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in de acute fase van het ziektebeeld, liet zien dat VT inderdaad gebonden aan granulocyten 
aanwezig was. Er was bovendien een sterke associatie tussen de aanwezigheid van VT 
gebonden aan granulocyten en tegelijkertijd de aanwezigheid van diarree. Een afname van het 
totaal aantal granulocyten positief voor de aanwezigheid van VT correleerde met een 
verbetering van het klinische beeld. Eén patiënt in deze studie liet geen afname zien en 
overleed binnen een week na binnenkomst in het ziekenhuis. De aanwezigheid van VT 
gebonden aan granulocyten in de systemische circulatie van HUS patiënten bevestigd de 
hypothese dat granulocyten waarschijnlijk verantwoordelijk zijn voor transport en overdracht 
van VT vanuit de darm naar doelwit organen. 
Hoofdstuk 4. Het is nog steeds niet begrijpbaar waarom met name op de kinderleeftijd de 
typische vorm van HUS wordt gezien. Op basis van de bevinding van VT in de systemische 
circulatie van D+ HUS patiënten ontwierpen we daarom de hypothese dat de passage van de 
darmwand en vervolgens het bereiken van de circulatie een essentiële stap was voor het 
ontwikkelen van een HUS. Verassend genoeg bleek dit echter niet te kloppen. Meer dan 80% 
van de familieleden van HUS patiënten bleek positief te zijn voor de aanwezigheid van VT 
gebonden aan granulocyten tijdens de acute fase van het ziektebeeld. In slechts 23% van de 
gevallen kon de infectie ook in de feces of serologisch worden vastgesteld. De detectie van VT 
gebonden aan granulocyten maakt het mogelijk om op een snelle en gemakkelijke manier vast 
te stellen of er inderdaad een infectie is en geeft meer inzicht in het aantal personen 
daadwerkelijk geïnfecteerd met VTEC. De aanwezigheid van VT in de circulatie van 
familieleden geeft bovendien aan dat niet alleen de passage van de darmwand en vervolgens het 
transport van VT door de circulatie bepalend of iemand een hemolytisch uremisch syndroom 
ontwikkeld. Het is echter niet uitgesloten dat de hoeveelheid toxine die uiteindelijk de 
systemische circulatie bereikt en getransporteerd kan worden naar doelwit cellen wel een rol 
speelt. 
Hoofdstuk 5 Lipopolysaccharide (LPS), ook wel endotoxine genoemd, is afkomstig van gram-
negatieve bacteriën zoals ook van de E. coli. Door de interactie van het afweersysteem met LPS 
worden een aantal processen geactiveerd die allen leiden tot bescherming tegen gram-negatieve 
bacteriën. Zo wordt bijvoorbeeld het stollingssysteem geactiveerd maar ook monocyten en 
granulocyten. Als er echter teveel LPS in de circulatie terechtkomt kan dit nadelige gevolgen 
hebben. In hoge concentraties kan LPS leiden tot een lage bloeddruk (hypotensie), 
beschadiging van verschillende organen zoals nieren en longen en het ontstaan van 
bloedstolseltjes (thrombi). In HUS patiënten worden antilichamen tegen LPS, met name 
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serotype 0157, gevonden. Het endotoxine zelf is echter nog nooit gedetecteerd. In deze studie 
hebben we zover we weten, voor het eerst de aanwezigheid van LPS gebonden aan 
granulocyten in de circulatie van HUS patiënten kunnen aantonen. Aangezien zowel LPS als 
VT gebonden is aan granulocyten in de acute fase van HUS, hebben we onderzocht welke van 
deze twee, of misschien wel beiden leiden tot de activatie van de granulocyten. Hierbij bleek 
dat LPS opregulatie van verschillende adhesiefactoren zoals het CD11/Cdl8 complex (= anti-
ICAM-1) en CD66 gaf maar VT zelf geen enkel effect daarop had. LPS, maar ook VT, bleek 
bovendien in staat te zijn om elastase release van granulocyten te induceren. Deze resultaten 
suggereren dat LPS in combinatie met VT een belangrijke rol spelen in het ontstaan van HUS. 
Hoofstuk 6 Stikstofinono-oxide, afgekort NO (nitric oxide), is een belangrijke vasodilatator. 
Tegelijkertijd voorkomt NO de adhesie van plaatjes en leukocyten aan het endotheel. 
Endotheline-1 (ET-1) heeft juist een tegenovergestelde werking, het zorgt voor samenknijpen 
van de vaten (vasoconstrictie). Beide substanties kunnen gemaakt worden door endotheelcellen 
en oefenen hun werking uit op de daaronder liggende spiercellen. Onder de glomerulaire 
endotheelcellen in de nier liggen geen normale gladde spiercellen maar mesangiale cellen. 
Deze mesangiale cellen spelen een belangrijke rol bij het in stand houden van de glomerulaire 
hemodynamiek en kunnen ook NO produceren maar niet ET-1. VT bleek in staat te zijn om in 
basale omstandigheden de NO productie van zowel mesangiale cellen als van glomerulaire 
endotheelcellen te remmen. De afname van de NO synthese door mesangiale cellen was een 
factor 1000 hoger dan dat van de glomerulaire endotheelcellen. Dit suggereert dat 
veranderingen in de NO synthese door de mesangiale cellen meer impact zal hebben in de 
ontwikkeling van HUS dan dat door de glomerulaire endotheelcellen. Onder basale, niet 
gestimuleerde omstandigheden werd geen enkel effect van VT-1 op de ET-1 productie 
waargenomen. In het geval van gestimuleerde endotheelcellen bleek de ET-1 productie naar 
beneden te gaan. Gebaseerd op deze gegevens is het dan ook waarschijnlijk dat in de begin fase 
van het ziektebeeld met name veranderingen in de NO-productie een belangrijke rol zullen 
spelen. 
Hoofstuk 7 Tijdens deze studie werden twee polymorphisms in het TNFa gen onderzocht 
namelijk op positie -308 (G/A) en op positie -863 (C/A) en het 4G/5G polymorphisme in het 
plasminogen activator inhibitor I gen (ΡAI-I) in voormalige HUS patiënten aangezien beide 
factoren een belangrijke rol spelen in de Pathogenese van HUS. Er werd geen verschil gezien 
tussen frequentie van het voorkomen van deze polymorphisms in HUS patiënten, patiënten die 
alleen de VTEC infectie hadden en controles. Er werd bovendien geen relatie gevonden tussen 
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de ernst van het ziektebeeld volgens de classificatie van Gianantonio en de aanwezigheid van 
het polymorphisme hetgeen suggereert dat deze polymorphisms geen invloed hebben op het 
beloop van het ziektebeeld. Opvallend genoeg bleken HUS patiënten enkele jaren na het 
doormaken van het ziektebeeld verhoogde PAI-I spiegels te hebben vergeleken met gezonde 
controles. Geen relatie kon worden aangetoond met het 4G/5G polymorphisme hetgeen 
suggereert dat andere polymorphisms in dit gen of mogelijk andere genen een rol spelen. 
Toekomstig onderzoek zal dit moeten uitwijzea 
Hoofdstuk 8 Verschillende in vitro studies hebben aangetoond dat VT niet alleen de 
eiwitsynthese kan remmen maar ook apoptosis kan induceren in verschillende celtypen. In deze 
studie werd nierbiopsie materiaal van 7 HUS patiënten in de tweede of derde week van het 
ziektebeeld en 7 controles (patiënten met dunne basaal membraan of minimal change nefrotisch 
syndroom) onderzocht op de aanwezigheid van apoptosis door middel een verbeterde TUNEL 
techniek waarbij een extra kleuring voor RNA synthese activiteit werd uitgevoerd. Nierbiopsie 
materiaal van HUS patiënten lieten een sterk toegenomen RNA synthese activiteit van de tubuli 
zien. Met name in deze cellen werd ook aspecifieke aankleuring van de TUNEL techniek 
waargenomen hetgeen bevestigend dat men voorzichtig moet zijn met het interpreteren van 
resultaten verkregen met TUNEL techniek alleen. De TUNEL techniek in combinatie met de 
kleuring voor RNA synthese activiteit toonde aan dat zowel in glomeruli als tubuli van HUS 
patiënten verhoogde aantallen apoptotische cellen aanwezig waren vergeleken met controles. 
De hoge RNA synthese activiteit die wordt waargenomen zou mogelijk een reflectie kunnen 
zijn van cellen die bezig zijn met reparatie van de schade die tijdens het ziektebeeld is 
opgetreden. 
Hoofdstuk 9 Het merendeel van de HUS patiënten herstelt zelf na het doormaken van een 
HUS. Vaak is alleen ondersteunende therapie in de vorm van dialyse en correctie van het 
elektrolyten evenwicht noodzakelijk. Dit impliceert dat er bepaalde factoren zijn die de 
herstelfase van het ziektebeeld mogelijk beïnvloeden of zelfs bevorderen. Vascular endothelial 
growth factor (VEGF) zou een van deze factoren kunnen zijn. Analyse van serum en plasma 
van HUS patiënten liet een toename van VEGF spiegels zien in de tweede en derde week van 
het ziektebeeld. Op dat moment was de klinische toestand van de patiënt al weer aan het 
verbeteren. Om te onderzoeken of de verhoogde VEGF waarden gevonden in plasma en serum 
afkomstig waren van een toegenomen VEGF productie in de nier werd nierbiopsie materiaal uit 
de tweede of begin derde week van het ziektebeeld van drie patiënten met HUS onderzocht. 
Hieruit bleek dat er geen verhoogde maar juist een verlaagde VEGF expressie in zowel 
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glomeruli als tubuli van de HUS patiënten was ten opzichte van controles. De expressie van de 
receptoren voor VEGF, Flt-1 en KDR, was tegelijkertijd toegenomen. Aangezien VEGF pas in 
het eind van de tweede week cq derde week stijgt is het zeer aannemelijk dat in een latere fase 
van het ziektebeeld wel verhoogde VEGF expressie kan worden waargenomen in de nier. 
Helaas was geen materiaal uit een latere periode van het ziektebeeld beschikbaar. 
Conclusie: 
De bevinding van VT gebonden aan granulocyten in de circulatie van HUS patiënten biedt 
perspectieven voor behandeling. Het verhinderen van de overdracht van VT aan doelwit cellen 
zou de emst van het ziektebeeld ten goede kunnen beïnvloeden Als immers VT niet meer wordt 
overgedragen aan doelwit cellen kan er ook niet meer schade ontstaan. Een van de 
mogelijkheden om te interferen zou het toepassen van leukoferese kunnen zijn. Nadeel is echter 
dat patiënten deze methode erg ingrijpend is. Een beter alternatief zou een behandeling zijn met 
gehumaniseerde monoklonale antilichamen gericht tegen het toxine. Helaas is deze 
mogelijkheid momenteel nog in de experimentele fase en daardoor nog niet toepasbaar voor D+ 
HUS patiënten. De aanwezigheid van LPS in de circulatie van HUS patiënten zou hierin ook 
belangrijk kunnen zijn. Als immers LPS een belangrijke rol speelt in het ontstaan van het 
ziektebeeld dan zou inactivering van LPS bijvoorbeeld door antilichamen of door toediening 
van recombinant eiwit dat LPS inactiveert (BPI) beschermend kunnen werken. Toekomstig 
onderzoek zou zich hierop moeten richten. De bevinding dat VT in staat is om de productie van 
NO en ET-1 te beïnvloeden geeft meer inzicht in de thrombotische microangiopathy en het 
ontstaan van nierfalen in HUS. Echter bij toekomstig onderzoek moet ook de rol van andere 
factoren zoals thromboxaan en prostacycline in overweging worden genomen. 
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DANKWOORD 
Na vier jaar ploeteren is nu dan eindelijk het moment gekomen om diegenen die direct of 
indirect hebben meegedragen bij de totstandkoming van dit proefschrift te kunnen bedanken. 
Voordat ik hiermee begin wil ik alvast mijn excuses aanbieden aan eenieder die niet hier 
genoemd wordt en wel genoemd had moeten worden. Op de eerste plaats wil ik alle ouders en 
HUS patientjes bedanken voor de medewerking die zij hebben verleend. Zonder hun hulp zou 
dit onderzoek niet mogelijk zijn geweest. 
Promotor Prof. Dr. LAH Monnens. Prof. Monnens, nooit zal ik vergeten dat u me tijdens mijn 
co-schappen opbelde en vroeg om te komen praten over het onderzoek. Een uur lang werd er 
gepraat over de problematiek rond asielzoekers. Een uur waarin ik mij afvroeg waarom ik nu 
moest komen. In de laatste vijf minuten van ons gesprek vroeg u mij of ik interesse had in een 
promotieonderzoek over het hemolytisch uremisch syndroom. De beslissing was snel gemaakt. 
De afgelopen vier jaar zijn voorbij gevlogen. In deze vier jaar waren uw brede 
wetenschappelijke, maatschappelijke en sociale kennis van grote waarde voor mij. De energie 
en het enthousiasme waarmee u vertelde over nieuwe ontwikkelingen in de wetenschap, de 
verhalen over de eerste kinderen met HUS die in de kliniek gezien werden en de gesprekken 
over andere maatschappelijke problemen maakten dat ik continu gemotiveerd bleef om meer te 
leren en te weten. Kortom, bedankt voor alle wijze lessen en bedankt dat u mijn promotor bent 
geweest. 
Promotor Prof. Dr. VWMvan Hinsbergh. Beste Victor, zonder jouw hulp en inzicht waren veel 
problemen onopgelost gebleven. Elke bespreking weer verbaasde ik mij over jouw 
pragmatische manier van aanpakken waarbij in een korte tijd de kem van het probleem boven 
tafel kwam. Met jouw nauwgezette adviezen was het probleem vervolgens bijna altijd op te 
lossen. De werkbesprekingen met jou waren altijd bijzonder leerzaam. Enkele experimenten 
heb ik ook bij jou op het lab mogen uitvoeren. De zal nooit vergeten hoe jij bereidwillig bij een 
van de eerste experimenten maar liefst tien buizen bloed afstond. Helaas bleek later dat we er 
slechts twee nodig hadden (sorry !). Victor, ik wil je bedanken voor al die tijd en goede raad die 
je mij de afgelopen vier jaar hebt gegeven. 
Copromotor Dr. LPWJ van den Heuvel. Beste Bert, de afgelopen vier jaar was je mijn 
begeleider op het lab. De had geen enkele lab ervarmg en herinner me nog goed hoe je in het 
begin mijn resultaten bekeek en bij twijfel (m.n. bij de eerste ELISA's) toch Thea een keer 
wilde laten pipetteren. Langzamerhand begon echter ook jij er overtuigd van te raken dat ook 
iemand die geneeskunde heeft gestudeerd op een lab kan leren werken. Je merkte ook al snel 
dat ik niet op mijn mondje gevallen was maar wist hier altijd goed mee om te gaan en vooral 
kalm te blijven. De denk dat we de afgelopen vier jaar goed hebben samengewerkt. Bij deze zou 
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ik je speciaal willen bedanken voor die momenten dat je meteen achter me stond en het voor 
me opnam en die keren datje me ondersteunde bij moeilijke beslissingen 
Thea van der Velden. Lieve Thea, wat had ik zonder jou moeten beginnen op het lab' Je was 
mijn maatje in goede tijden maar ook in slechte De hennner me bijvoorbeeld nog het moment 
dat ik te horen kreeg dat al onze endotheelcellen, opgeslagen in de vloeibare stikstof, 
verdwenen waren Na ruim anderhalfjaar onderzoek zag ik het toen even met meer zitten Jou 
optimisme en humor hierover maakten dat ik het wist te relativeren en weer vrolijk verder ging 
Kortom, ik kon eigenlijk met zonder je in dit onderzoek Vandaar dat ik ook wilde dat je 
meeging naar de DNA-cursus en op congres naar Japan (ik zal de kimono's met snel vergeten) 
De hoop dat in de toekomst er nog eens een congres zal zijn waar wij naar toe gaan Lieve Thea, 
ik hoop dat JIJ de afgelopen jaren net zo'n leuke tijd hebt gehad als ik Bedankt' 
Nicole van de Kar, Annet Heuvelink en Petra van Seiten Jullie gingen mij voor in het 
onderzoek naar de Pathogenese van HUS en legden de basis voor verder onderzoek Hierdoor 
was het voor mij mogelijk in jullie voetsporen te treden Jullie enthousiasme en interesse in het 
onderzoek zijn voor mij steeds weer een stimulans geweest 
Marije Lowik, je begon op het lab als HLO-student en vervolgens mocht je blijven als analist 
op het HUS project De tijd dat ik met je heb mogen samenwerken heb ik als zeer positief 
ervaren De autontten naar de patiënten toe waren erg gezellig alhoewel hierdoor het autorijden 
naar de goede plaats soms wat bemoeilijkt werd Manje, ik wil jou heel veel succes en plezier 
wensen in je eigen onderzoek Karin Assink, ook JIJ was als analist werkzaam op het HUS-
project Met jouw inzet wist je menig PCR lopend te krijgen waarvoor mijn bewondering De 
hoop dat jij binnenkort een mutatie in het vWF-cleaving protease gen zult vinden en dat dit 
tevens je eerste artikel zal worden Je hebt het verdiend' 
Mano Vermeer, vele expenmenten met radioactief gelabeld verocytotoxine zijn door jou 
uitgevoerd De mocht op veilige afstand over je schouder meekijken en vaak het je me de 
uitkomst via mail weten Daarnaast gaf je ook nog een persoonlijk tintje aan je mail waarbij je 
me op de hoogte hield over het weer in Leiden 
Nienke Bosma en Rikke Schiphorst wil ik bedanken voor hun inzet en enthousiasme dat ze 
hebben getoond tijdens hun wetenschappelijke stage op het HUS-project 
Frans Zeegers. Ook jij vormde een onmisbare schakel in mijn onderzoek Ten alle tijde stond 
je klaar om een nier of matenaal van patientjes op te halen Zelfs op je vnje dag mocht ik je 
bellen Frans, bedankt voor alles' 
Spierlab en weefselkweek Antoon, Diana, Liesbeth, Chnstien, Anneke, Berendien, Mananne, 
Irma, Frans, Gera en met te vergeten Sandra S en Anita Mijn werkplekje was de afgelopen 
drieënhalf jaar met name bij jullie op het lab In die tijd heb ik van jullie gezelligheid en 
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interesse in mij en mijn onderzoek mogen gemeten Dankzij jullie allemaal is dit zonder meer 
een van de gezelligste werkplekken geweest waar ik tot nu toe ben geweest Bedankt voor de 
fijne tijd' Connie Brouwer Vele scherpe (soms met al te vriendelijke) opmerkingen hebben we 
naar eikaars hoofd gesmeten tot ontsteltenis van andere mensen maar tot vermaak van ons zelf 
Gelukkig wisten wij altijd wat we aan elkaar hadden en zijn we door de jaren heen alleen maar 
steeds betere vriendinnen geworden Meid, ik hoop datje onderzoek goed zal eindigen en datje 
een superpromotie zult hebben Zet hem op' Alle andere onderzoekers op het lab K+N, Iwan, 
Maneke (bedankt voor al die keren datje de cellen ververste), Sandra H, Sandy, Enk J , Rolf, 
Manje, Kann L , Lydia en Maarten wens ik veel succes met hun onderzoek Gaby Fernandez, 
it was great having you on the lab and working together I hope you will be succesfull in the 
future and will find the happiness you are searching for' 
Lab K+N Ik wil graag alle mensen van het lab K+N bedanken voor alle hulp en gezelligheid 
die gegeven werd Het koffiekwartiertje 's ochtends om 8 00 u zorgde er voor dat het begin van 
de dag al goed begon De zal jullie missen 
Margriet Cornelissen, de afgelopen jaren ben ik je steeds meer gaan waarderen Als ik bij jou 
langs kwam konden we lachen om niets en het volgende moment konden we het ook over 
minder leuke dingen hebben Jouw enthousiasme en vrolijkheid zijn aanstekelijk Ongetwijfeld 
is dit ook Marco Borsaio opgevallen (wanneer is ook alweer de trouwdatum9) 
Rikke Schiphorst wil ik succes wensen met de voortgang van het HUS-project Met jouw 
enthousiasme en doorzettingsvermogen kom je er wel Prof Dr C Schroder, Dr J Nauta, en 
Dr J Vande Walle wil ik bedanken voor al hun energie en hulpvaardigheid om maar steeds 
weer matenaal van HUS patientjes naar mij toe te sturen Dr VandeWalle wil ik speciaal 
attenderen om ook de laatste pagina van het boekje te bekijken 
Nu aan het eind van deze lange lijst aangekomen wil ik mijn ouders noemen die altijd voor mij 
hebben klaargestaan Jullie hebben me altijd gestimuleerd om het beste eruit te halen en om met 
op te geven als het tegen zat Zonder jullie steun en liefde had ik hier nu met gestaan Bedankt' 
Ook wil ik mijn familie, mijn broer en mijn vnenden bedanken die steeds weer naar mijn 
verhalen over het onderzoek luisterden en simpelweg mij steunden 
Tot slot wil ik mijn woord nchten tot Jeroen De afgelopen jaren heb je me steeds ondersteund 
en toonde je erg veel belangstelling voor mijn onderzoek Je ging zelfs mee naar het lab als ik 
in het weekend een nier (het kipfiletje') of matenaal van een HUS patientje moest opwerken 
Met jouw liefde, jouw sterke relativenngsvermogen en steun heb ik het gevoel de hele wereld 
aan te kunnen Je bent eenvoudig een moordvent' Bedankt' 
Maroeska 
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STELLINGEN 
Behorend bij het proefechrift 
"De pathogenesis of the hemolytic uremic syndrome: 
the role of the granulocyte " 
• Met betrekking tot de Pathogenese van het hemolytisch uremisch 
syndroom, is het vinden van verocytotoxine gebonden aan 
granulocyten te vergelijken met het binnenhalen van het paard van 
Troje ! (dit proefschrift) 
α Het vinden van verocytotoxine gebonden aan granulocyten in de 
circulatie van HUS patiënten vormt de ontbrekende schakel tussen 
enerzijds de darminfectie en anderzijds het ontstaan van schade in 
onder andere de nier.(dit proefschrift) 
a Diagnose en behandeling van cystinose dient te berusten op de meting 
van cystine in de granulocyte en niet in het totaal aantal leukocyten. 
o Lipopolysaccharide speelt naast verocytotoxine een belangrijke rol in 
de Pathogenese van het hemolytisch uremisch syndroom (dit 
proefschrift). 
α De gevonden remming van de NO synthese van mesangiale cellen in 
vitro, veroorzaakt door incubatie met verocytotoxine, vormt mogelijk 
een belangrijk deel van de verklaring waarom met name in de nier 
vasoconstrictie en microthrombi ontstaan. De nier is immers het enige 
orgaan in het menselijke lichaam dat mesangiale cellen bevat. 
(dit proefschrift) 
α Het feit dat er nog geen genetische oorzaak gevonden is voor het 
ontstaan van de typische vorm van HUS wil nog niet betekenen dat 
genetische factoren ook geen rol spelen in dit ziektebeeld, (dit 
proefschrift) 
a Our research competitors are easily identified. They never criticise our 
work, neither in reports nor lectures, they simply fail to recognise its 
very existence. (Lancet, augustus 2001) 
α Een positieve waardering dient vaker te worden uitgesproken ! 
• We moeten zelfde verandering zijn, die we in de wereld willen zien. 
(Ghandi) 
a Het is opmerkelijk dat de therapie van een zo ernstig ziektebeeld als de 
Diamond Blackfan anemie zo eenvoudig kan zijn. Helaas betekent 
echter een eenvoudige therapie niet, dat ook de Pathogenese wordt 
begrepen. 
• De mogelijkheid om de minimal residual disease (MRD-) activiteit te 
kunnen meten bij patiënten met acute leukemie zal ongetwijfeld meer 
inzicht geven in welke behandeling het beste en wanneer gegeven kan 
worden. 
α De verklaring van de X-gebonden vorm van hypophosphatemische 
rachitis is vermoedelijk gelegen in de gestoorde afbraak van FGF-23. 
(Bowe et al. Biochem. Biophys. Res. Comm. 2001). 
a Het is merkwaardig dat er wordt gedacht dat artsen door middel van 
financiële vergoeding gestimuleerd kunnen worden om zich in te 
zetten voor werven van weefseldonoren. 
α Iemand die boven aan de ladder staat mag niet vergeten dat hij ooit de 
eerste stap heeft gezet beneden aan de ladder. 
α Terrorism is a consequence of wider political and social change and 
thrives therefore especially in countries enduring state failure. 
{Lancet, October 2001). 
• Today the real test of power is not the capacity to make war but 
capacity to prevent it. {Anne O 'Hara McCormick) 
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